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ABSTRACT 
 I 
ABSTRACT 
The t(12;21) (p13;q22) chromosomal translocation, generating the ETV6/RUNX1 
(E/R) fusion gene, is present in 25% of childhood B-cell precursor acute 
lymphoblastic leukemias. While the E/R gene fusion is considered a critical step for 
the initiation of leukemia, its functional contribution to overt leukemia is less clear. We 
aimed to investigate this issue by suppressing endogenous E/R fusion protein with 
lentivirus-transduced shRNA in the leukemic cell lines REH and AT-2. E/R 
suppression reduced cell proliferation, increased apoptosis and impaired leukemia 
outgrowth in NOD/SCID mice. These effects were accompanied by a concurrent 
inactivation of the PI3K/AKT/mTOR pathway. Consistently, pharmacological 
PI3K/mTOR inhibition diminished the phosphorylation of AKT and RPS6, significantly 
increased the apoptosis rate in E/R-positive leukemias and sensitized REH cells to 
prednisolone. We also performed genome-wide gene expression analyses upon E/R 
silencing in REH and AT-2 cells and identified 777 differentially regulated genes. 
Even though we observed similar numbers of up- and down-regulated genes, striking 
differences emerged when biological processes and pathways were investigated by 
the Database for Annotation, Visualization and Integrated Discovery (DAVID) and 
Gene Set Enrichment Analyses (GSEA). E/R-repressed genes resulted in a 
significant enrichment of the categories "cell activation", "immune response", 
"apoptosis", "signal transduction" and "development and differentiation" while E/R 
induced genes were less significantly associated with specific pathways. Most 
prominently enriched terms for the latter gene set indicated alterations in 
"PI3K/AKT/mTOR signaling" and "hematopoietic stem cells". De-regulation of 
pathways and molecular functions was essentially confirmed by comparison with a 
previously published E/R-specific profile from primary ALL. RT-qPCR was applied to 
validate six differentially expressed genes (PROM1, IFITM1, PECAM1, SPIB, MDM2, 
DDIT4), corroborating modulation of “stem cell properties” and “B-cell differentiation”, 
and supporting the notion that “immune-response”, “cell adhesion” and “DNA damage 
pathways” are affected by the fusion protein. Collectively, our data demonstrate that 
the E/R fusion protein constitutes a major driving force in overt leukemia and 
establish a molecular map of its putative functions.  
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ZUSAMMENFASSUNG 
Die chromosomale Translokation t(12;21) (p13;q22) , welche die Grundlage für die 
Enstehung des ETV6/RUNX1 (E/R) Fusionsgens ist, ist in 25% aller akuten 
lymphoblastischen B-Zell Vorläufer Leukämien im Kindesalter zu finden. Die E/R 
Fusion wird als kritischer Schritt in der Leukämieentstehung betrachtet, ihre 
funktionelle Bedeutung in der klinisch manifesten Leukämie ist hingegen weitgehend 
unbekannt. Um Informationen darüber zu erhalten, setzten wir uns zum Ziel, das 
endogene E/R Fusionsprotein in den leukämischen Zelllinien REH und AT-2 mittels 
lentiviral-transduzierter shRNA  zu unterdrücken. Dadurch wurde eine Reduktion der 
Zellproliferation, Erhöhung der Apoptose und Beeinträchtigung des Auftretens einer 
Leukämie in einem Xenotransplantationmodell mit NOD/SCID Mäusen 
hervorgerufen. Diese Effekte wurden von einer Inaktivierung des PI3K/AKT/mTOR 
Signalweges begleitet. Gleichfalls reduzierte die pharmakologische Inhibierung von 
PI3K/mTOR die Protein Phosphorylierung von AKT und RPS6, und bewirkte eine 
erhöhte Apoptoserate und Prednisolon-Sensitivität in E/R-positiven Leukämien bzw. 
REH Zellen. Genomweit durchgeführte Genexpressionsstudien von E/R 
unterdrückten REH und AT-2 Zellen identifizierten 777 differenziell regulierte Gene. 
Obwohl eine ähnliche Anzahl von induzierten und reprimierten Genen gefunden 
wurde, zeigten sich bei der Untersuchung von biologischen Prozessen und 
Signalwegen mittels „Database for Annotation, Visualization and Integrated 
Discovery“ (DAVID) sowie „Gene Set Enrichment Analyses“ (GSEA) beträchtliche 
Unterschiede. E/R reprimierte Gene resultierten in einer signifikanten Anreicherung 
der Kategorien "Zellaktivierung", "Immunantwort", "Apoptose", "Signaltransduktion" 
und "Entwicklung und Differenzierung". Hingegen konnten E/R induzierte Gene 
weniger signifikant mit bestimmten Signalwegen assoziiert werden. Die am stärksten 
regulierten Begriffe in letzterem Set an Genen, deuten auf eine Veränderung der 
Begriffe "PI3K/AKT/mTOR Signalweg" und "hämatopoetische Stammzellen" hin. 
Weiters wurde die differenzielle Regulation von Signalwegen und molekularen 
Funktionen mit dem Vergleich bereits publizierter E/R spezifischer Profile von 
primären akuten lymphoblastischen Leukämien bestätigt. Schließlich setzten wir RT-
qPCR ein, um die differenzielle Regulation von sechs Gene (PROM1, IFITM1, 
PECAM1, SPIB, MDM2, DDIT4) zu bestätigen, welche die Modulierung von 
“Stammzell Eigenschaften” und “B-Zell Differenzierung” bekräftigten, sowie die 
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Annahme unterstützten, dass die “Immunantwort”, “Zelladhäsion” sowie “DNA 
Damage Signalwege” durch das Fusionsprotein kontrolliert werden. 
Zusammenfassend zeigen unsere Daten, dass das E/R Fusionsprotein eine 
bedeutende Rolle in der malignen Zelle spielt. Zusätzlich konnten wir ein molekulares 
Modell für dessen putative Funktionen etablieren.  
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1. INTRODUCTION 
1.1 Childhood acute lymphoblastic leukemia 
Acute lymphoblastic leukemia (ALL) is the most common cancer in childhood and 
adolescence and is characterized by the expansion and accumulation of lymphoid 
progenitor cells. The peak incidence of ALL in children is between 2 and 5 years and 
represents the principal subtype of pediatric cancer in affluent societies, affecting 1 in 
100.000 people up to the age of 15. Even though steady progress in treatment has 
led to a cure rate of more than 80%, certain subtypes are still associated with dismal 
prognosis and a substantial proportion of patients may suffer from treatment-related 
toxicities or late effects. Hence, innovative new therapeutic approaches to increase 
leukemia-free survival rates and reduce the toxic side-effects of current treatment 
regimens are required (Parkin 1988; Pui, Robison et al. 2008). 
 
1.1.1 Etiology and pathogenesis 
Only a minority of ALL (< 5%) cases are associated with predisposing genetic 
syndromes (Down’s syndrome, Bloom’s syndrome, Ataxia-telangiectasia, and 
Nijmegen breakage syndrome), ionising radiation or exposure to specific 
chemotherapeutic drugs (Pui, Robison et al. 2008). In most cases the precise 
pathogenic events leading to development of ALL remain unknown.  
However, the development of childhood ALL has been shown to be associated with 
industrialisation and modern or affluent societies. Furthermore, clusters of leukemia 
cases have been observed especially in new towns. These observations influenced 
British investigators to develop two parallel leukemia development models based on 
infections. Kinlen’s population-mixing hypothesis explains the presence of clusters of 
childhood ALL cases by an exposure of susceptible, non-immune individuals to 
common but fairly non-pathological infections after population-mixing with carriers 
(Kinlen 2004). In contrast, the delayed-infection hypothesis of Greaves is based on a 
minimal two-hit model (Greaves 2006). It suggests that some susceptible individuals 
with a prenatally acquired pre-leukemic clone had low or no exposure to common 
infections since they lived in an affluent hygienic environment. Subsequent or 
delayed exposure to common infections at an age usually associated with increased 
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proliferation of lymphoid-cells predisposes the immune system to aberrant or 
pathological responses.  
Development of childhood ALL is associated with at least two distinct temporal 
“exposure” windows. The first one takes place in utero, when leukemia is initiated 
through, for instance, chromosomal rearrangements. The second - usually postnatal -
window, is linked to emergence of overt disease through the acquisition of secondary 
genetic changes (Figure 1) (Greaves 2006). Consistent with this concept, the 
initiation of disease by the chromosomal translocation t(12;21) in utero exceeds the 
rate of overt ALL by 100-fold (Mori, Colman et al. 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Two-step model of childhood acute leukemia development (Greaves 2006). Note that 
1% refers to the transition frequency between covert pre-leukemia and overt clinical leukemia. This 
model is not applicable to infant ALL and acute myeloid leukemia where secondary genetic events are 
thought to take place already prenatally. 
 
Chromosomal translocations are initiated by DNA double strand breaks, followed by 
non-homologous end-joining and result in the recombination of normally separate 
genes. Resultant in-frame chimeric or fusion proteins exhibit activated kinase activity 
or lead to novel transcriptional regulation (Look 1997; Rowley 1998). Importantly, 
each distinct chromosomal translocation contributes to leukemic transformation by 
altering key regulatory processes, such as the acquisition of an unlimited capacity for 
self-renewal, inhibition of differentiation, evading growth control and promoting 
resistance to apoptotic stimuli (Figure 2) (Pui, Relling et al. 2004). 
The ultimate target cell for a chromosomal translocation needs to be permissive for 
expression of the chimeric protein and must provide an intracellular-signaling network 
that supports rather than inhibits clonal advantage (Greaves and Wiemels 2003). 
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Since different subsets of childhood leukemia show a distinct cell type or lineage 
phenotype, each chromosome translocation must have arisen either in a cell of the 
respective lineage, or in an uncommitted hematopoietic stem cell (HSC) that affects 
only progenies of one lineage (Reya, Morrison et al. 2001). In general, stem cells are 
mostly non-cycling and, as such are assumed to be protected from damage. 
However, they are an attractive target for chromosomal translocations as their long 
lifespan would allow the acquisition of secondary genetic changes necessary for 
leukemic cell transformation. Consistent with this notion, recent evidence in t(12;21) 
leukemia suggested that the leukemia initiating E/R gene fusion and subsequent 
chimeric protein expression may indeed already take place in an uncommitted 
hematopoietic stem cell (Schindler, Van Buren et al. 2009). Secondary leukemia-
promoting mutations, mediated by V(D)J recombination, therefore, can only take 
place during early B-cell development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Contribution of chimeric proteins to leukemic cell transformation (Pui, Relling et al. 
2004). During leukemogenesis, a hematopoietic stem cell or one of its committed progenitors has to 
elude normal mechanisms of homeostatic control, implicated in regulation of growth-factor signaling, 
differentiation, apoptosis, and self-renewal (panel A). Different chimeric transcription factors can 
commonly impact on the HOX gene–mediated transcriptional cascade linked to leukemic 
transformation. Different sites of action are indicated in red (panel B). 
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1.1.2 Classification of ALL 
Depending on the cell type and developmental stage, childhood ALL can be divided 
into T-cell, mature B-cell, and precursor B-cell phenotypes. Furthermore, gross 
chromosomal changes representing aneuploidies and translocations, or aberrant 
expression of proto-oncogenes, are selectively associated with distinct leukemia 
immunophenotypes (Figure 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Genotypes and their recurrent leukemia-associated frequencies in T- and B-cell 
lineage childhood ALL (Pui, Relling et al. 2004).  
 
Chromosomal translocations frequently result in the formation of chimeric 
transcription factors, capable of conferring altered self-renewal and differentiation to 
hematopoietic cells. The t(12;21)(p13;q22) chromosomal translocation, with an 
incidence of 20-25%, generates the ETV6/RUNX1 (E/R)  fusion gene (Pui, Relling et 
al. 2004). Mixed lineage leukemia (MLL) translocations result in the fusion of the N-
terminal portion of MLL to the C-terminal portion of 1 of more than 40 partners and 
are identified in more than 80% of infant ALL cases, but are rare in older children. 
Furthermore, most therapy-induced leukemias, caused by topoisomerase II inhibitors 
involve MLL translocations. A small group of BCP ALL cases (5%) harbors the t(1;19) 
translocation, generating a fusion gene that encodes the chimeric transcription factor 
E2A/PBX1. The BCR/ABL gene fusion creates a constitutive tyrosine kinase and is 
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generated by the t(9;22) translocation which is found in 3% of BCP ALL cases. 
Finally, approximately 10-15% of childhood ALLs have a T-cell immunophenotype. 
Chromosomal translocations occur rarely in this lineage (Weng, Ferrando et al. 
2004). 
Specific genetic abnormalities may be associated with prognosis. This is exemplified 
by Kaplan Meier plots which show the event-free survival for patients that have been 
enrolled in four consecutive treatment protocols at St Jude Children’s Research 
Hospital from 1991 to 2006 (Figure 4) (Pui, Robison et al. 2008). Hyperdiploid (> 50 
chromosomes), E/R and E2A/PBX1 fusion carrying ALL, have a favourable outcome, 
whereas MLL/AF4 and BCR/ABL fusion positive cases have a dismal prognosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Kaplan-Meier event-free survival curve according to ALL subtypes; modified (Pui, 
Robison et al. 2008). 
 
1.1.3 Concepts of treatment  
Chemotherapy 
Conventional drugs being currently applied to treat ALL inhibit nucleic acid synthesis, 
block protein synthesis by hydrolysing an amino acid or impair mitosis by interfering 
with the mitotic spindle apparatus.  
The remission-induction treatment aims to eradicate more than 99% of the initial 
leukemic cell burden, thereby restoring normal hematopoiesis and a healthy 
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performance status. During this treatment, a glucocorticoid (prednisolone or 
dexamethasone), vincristine, and at least a third drug (asparaginase, anthracycline, 
or both) is administered. By this treatment, clinical remission can be achieved in 96-
99% of childhood ALL cases. The induction course is followed by a remission 
consolidation or intensification treatment and is applied to eradicate drug-resistant 
residual leukemic cells. Furthermore, patients with ALL need continuation treatment 
to prevent or forestall relapse for reasons that currently remain unknown. Therefore, 
all patients receive chemotherapy for a total of 2.0-2.5 years (Pui and Evans 2006). 
 
Stem-cell transplantation  
Allogeneic hematopoietic stem-cell transplantation is considered the most intensive 
form of treatment. It was shown to be beneficial for selected patients with high-risk 
ALL, such as individuals with Philadelphia chromosome-positive disease and MLL-
positive infant ALL with additional poor prognostic factors (Arico, Valsecchi et al. 
2000; Mann, Attarbaschi et al. 2010).  
 
Novel treatment concepts 
Leukemic cells express lineage associated antigens representing attractive targets 
for treatment with monoclonal antibodies (mAb). They can be administered in 
unconjugated forms or conjugated to anti-leukemic drugs, immunotoxins or 
radioactive molecules. Examples are rituximab (Rituxan, Mabthera; Biogen Idec) and 
alemtuzumab (Campath, MabCampath; Genzyme Corporation) which target the cell 
surface molecules CD20 and CD52, respectively (Pui and Jeha 2007).  
In recent years, different methods aimed to identify molecular genetic and epigenetic 
aberrations in leukemic cells that can be exploited for use as novel drug targets. 
Subsequently, the repertoire of different therapies directed against aberrantly 
regulated molecular pathways in cancer cells was expanded. The feasibility of drugs 
targeting components of the cell-cycle, gene transcription, cell motility, apoptosis and 
cell metabolism has been demonstrated. At least, transient responses can be 
obtained by inhibition of certain key enzymes such as tyrosine kinases, DNA 
methyltransferase, histone deacetylase, γ-secretase, serine-threonine kinases, and 
proteasomes.  
One of the most successful small drugs is imatinib mesilate (Gleevec) which has 
proven effective in treating chronic lymphoblastic leukemia (Druker, George et al. 
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2004). In ALL, however, complete remission could not be achieved with Gleevec 
alone. Furthermore, rapid development of drug resistance suggests that curative 
treatment will need alternative concepts (Pui and Jeha 2007). 
 
 
1.2 ETV6/RUNX1-positive B-cell precursor ALL 
The cytogenetically not detectable t(12;21)(p13;q22), resulting in the fusion of the 
ETS variant 6 (ETV6) and runt-related transcription factor 1 (RUNX1) genes (also 
called TEL and AML1, respectively), was first described in 1995 and is present in 
approximately 25% of pediatric BCP ALL cases (Romana, Mauchauffe et al. 1995). In 
general E/R-positive ALL is associated with low risk features and, based on the 
application of anti-metabolites, a good prognosis, with 5-year event-free survival 
estimates of about 85% (Figure 4) (Pui, Robison et al. 2008). 
The phenotype of the E/R-positive leukemic blasts corresponds to early CD19-
positive progenitor B-cells. However, this does not rule out the possibility that the 
cellular targets for the initiating translocation are more primitive CD34-positive stem 
cells. Indeed, experiments in mice and zebrafish demonstrate that E/R oncogenic 
activity requires fusion gene expression from HSC onwards and, in contrast, specific 
expression in the B-cell lineage failed to increase the probability to develop leukemia 
(Andreasson, Schwaller et al. 2001; Sabaawy, Azuma et al. 2006; Schindler, Van 
Buren et al. 2009). 
Data from identical twins shared the same E/R genomic breakpoints, suggesting 
prenatal spread of pre-leukemic cells from one twin to the other and, furthermore, 
retrospective screening of archived neonatal blood spots of ALL patients provided 
convincing evidence that E/R usually arises prenatally as an early or initiating 
mutation (Greaves and Wiemels 2003).   
While E/R provides the first or initiating mutation in leukemia development, it is by 
itself unable to cause overt leukemia. This assumption is supported by the fact that 
the incidence rate of E/R fusions is 100 times the leukemia rate (Mori, Colman et al. 
2002) and that the concordance rate in twins is low (~10%) (Greaves and Wiemels 
2003). Furthermore, the protracted postnatal interval, or latency, before disease 
emergence can be up to a decade or more (Wiemels, Cazzaniga et al. 1999), 
corroborating the notion that additional events need to occur for the clinical 
manifestation of leukemia. There might not be an exclusive second genetic ‘hit’, 
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however, most cases of E/R-positive ALL have the non-rearranged ETV6 allele 
deleted (Raynaud, Cave et al. 1996). Other commonly observed genetic alterations 
include a trisomy of chromosome 21 (Attarbaschi, Mann et al. 2004), disruptions of 
the paired box 5 (PAX5) gene as well as loss of cyclin-dependent kinase inhibitor 2A 
(CDKN2A)/p16 and CDKN2D/p19 (Mullighan, Phillips et al. 2008). 
In vivo experiments revealed that the E/R fusion protein was able to impede the 
differentiation program of B-lymphocytes, leading to an accumulation of early B-cell 
progenitors at the expense of more mature forms. Notably, E/R seems to exert a 
lineage-dependent role, since no block in differentiation other than the B-lineage was 
observed (Tsuzuki, Seto et al. 2004). Interestingly, enforced E/R expression resulted 
in an enlargement of the less differentiated multipotential progenitor cell (cKit+, 
Sca1+, lin-) or hematopoietic stem cell compartment (Fischer, Schwieger et al. 2005; 
Sabaawy, Azuma et al. 2006; Schindler, Van Buren et al. 2009). Whether this very 
primitive compartment is responsible for the maintenance and/or expansion of a pre-
leukemic clone remains to be shown.  
 
1.2.1 The ETV6/RUNX1 fusion  
There are a number of other chromosomal translocations involving the RUNX1 or 
ETV6 genes, being detected in different subtypes of acute leukemias, affecting both 
the myeloid and lymphoid lineage (Rowley 1998). However, E/R is the only gene 
fusion that involves the RUNX1 gene that has been identified in ALL.   
Expression of RUNX1 was shown to be required for the switch from yolk sac to liver 
hematopoiesis in the developing mouse embryo. Experiments in adult animals 
additionally revealed a role for RUNX1 in the regulation of genes during 
hematopoietic differentiation (Dann, Fears et al. 2000). While RUNX1 is capable of 
either activating or repressing its target genes, ETV6 is generally considered to act 
as a transcriptional repressor (Zelent, Greaves et al. 2004). ETV6 knockout mice are 
embryonic lethal, due to defects in yolk sac angiogenesis defects. Mouse chimeras 
with homozygous ETV6 deletions demonstrated that ETV6 is required for homing of 
hematopoietic cells to the bone marrow (Wang, Swat et al. 1998). ETV6 also plays 
an important role in adult hematopoiesis by supporting cell survival and regulating 
megakaryopoiesis (Hock, Meade et al. 2004).  
The E/R protein consists of N-terminal ETV6 sequences and of the almost entire 
RUNX1 sequence (Figure 5). Importantly, E/R is under transcriptional control of the 
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ETV6 promoter while specificity in DNA binding is determined by RUNX1 derived 
sequences (Golub, McLean et al. 1996 Aug 8; Berger 1997).  
RUNX1 is located at chromosome 21q22.12, encoding a protein that consists of two 
large functional domains, the proximal DNA binding and protein interaction domain 
(or runt homology domain) and the distal transactivation domain. Additional functional 
domains are the mSin3A transcriptional regulator interaction domain (SID) and the 
VWRPY motif that is capable of binding groucho corepressors (Figure 5). RUNX1 
represents a transcription factor that exerts its function in the nucleus.  
ETV6 is located at chromosome 12p13.2. Functional domains of the ETV6 protein 
are the C-terminal ETS domain, mediating DNA binding, the central repression 
domain and the amino-terminal pointed domain (PD), required for oligomerization 
(Figure 5) (Zelent, Greaves et al. 2004).  
 
 
 
 
 
 
 
 
 
Figure 5. Schematic presentation of full-length ETV6, RUNX and E/R proteins (Zelent, Greaves 
et al. 2004). Fusion sites between ETV6 and RUNX1 sequences are indicated by arrows. Numbers 
indicate amino acids that border functional domains. 
 
1.2.2 Molecular functions of ETV6/RUNX1 
RUNX1 binds its target genes together with its regulatory subunit core binding factor 
β (CBFβ). It modulates transcription depending on the association with specific 
cofactors. For instance, binding of RUNX1 to mSin3A recruits histone deacetylases 
leading to reduced accessibility of a given promoter to the basal transcriptional 
machinery and transcriptional repression. However, this process can be reversed via 
dissociation of RUNX1 from mSin3A/histone deacetylases and binding to 
p300/histone acetylases (Figure 6) (Zelent, Greaves et al. 2004).      
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Figure 6. Molecular mechanism of wt RUNX1 and E/R (Zelent, Greaves et al. 2004). The 
transcription factor RUNX1 either activates or represses its target genes by recruitment of p300 or 
mSin3A/HDAC, respectively (panel a). By contrast, the abilities of the ETV6 moiety on E/R to dimerize 
and bind N-CoR and mSin3A allows formation of a very stable repressor complex (panel b), rendering 
the chimeric protein resistant to the regulation depicted in panel a. See text for detailed descriptions. 
 
The E/R fusion protein can bind nuclear receptor corepressor 1 (N-CoR1) and 
mSin3A corepressors via its ETV6 oligomerization moiety which allows formation of a 
very stable repressor complex. Given that E/R retains the ability to bind the RUNX1 
target sequences, it has the potential to function as a constitutive histone 
deacetylase dependent repressor of genes normally regulated by RUNX1 (Figure 6). 
Containing the pointed domain of ETV6, the fusion protein may bind to RUNX1 target 
sequences as a homodimer or an oligomer (Zelent, Greaves et al. 2004).  
Consistent with the assumption that the fusion protein represses RUNX1 target 
genes in a histone deacetylase dependent mode, reporter constructs driven by 
regulatory regions of hematopoietic-specific genes were found to be suppressed by 
E/R (Hiebert, Sun et al. 1996). Furthermore, the E/R mediated repression was 
relieved by the histone deacetylase inhibitor trichostatin A (Fenrick, Amann et al. 
1999).  
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Apart from its role in the nucleus, E/R has been suggested to interfere with wt 
RUNX1 and ETV6 function by trapping other proteins in the cytoplasm and forming 
non-functional complexes (Gunji, Waga et al. 2004). However, the experimental 
evidence for such a function is lacking. 
 
 
1.3 Oncogene addiction 
The phenomenon of cancer reversion by oncogene inactivation is collectively defined 
by the term oncogene addiction. It presumes that cancer cells, despite the acquisition 
of cooperating genetic abnormalities, are still dependent on the specific oncogene 
that initiated cellular transformation (Weinstein 2002). Oncogene activation initiates 
and contributes to tumorigenesis because it aberrantly activates physiologic 
programs to overcome growth control and bypasses checkpoint mechanisms 
essential for cellular mortality, self-renewal, and genomic integrity. Accordingly, 
following the shutdown of all safety mechanisms by secondary alterations, the 
inactivation of the initiating oncogene can restore some of these pathways. Possible 
outcomes are an arrest of proliferation, induction of cell differentiation, cellular 
senescence and/or increased apoptosis rates (Figure 7) (Felsher 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Possible outcomes to oncogene inactivation (Felsher 2008). The repression or in-
activation of a single oncogene can either result in complete/partial tumor reversion, tumor death, 
dormancy, differentiation or relapse. 
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It also has been postulated that oncogenes induce cancer because they induce a 
cellular state of enforced oncogenic amnesia, and only upon oncogene inactivation 
the tumor becomes aware of its transgression (Felsher 2008).  
Consistent with this notion, essential roles for oncogenic rat sarcoma (RAS), v-myc 
myelocytomatosis viral oncogene homolog (MYC) and sialidase 1 (NEU) for 
maintenance of viability of different types of malignancies, including solid tumors as 
well as hematopoietic malignancies, could be demonstrated (Chin, Tam et al. 1999; 
Felsher and Bishop 1999; Fisher, Wellen et al. 2001; Jain, Arvanitis et al. 2002; 
Moody, Sarkisian et al. 2002). Later, the effects of targeting chimeric proteins in 
hematopoietic malignancies were evaluated. Strikingly, in acute promyelocytic 
leukemia (APL) PML/RAR, generated by the t(15;17) translocation, was effectively 
degraded by arsenic trioxide, involving a proteasomal dependent mechanism. 
Treatment of patients with arsenic trioxide resulted in high rates of complete 
remission in both, primary and relapsed APL (Zhang TD 2001). Alternatively, 
experiments in acute leukemia demonstrated that targeting of the fusion proteins 
BCR/ABL or MLL/AF4 in ALL and MLL/ENL in AML was effective at eradicating overt 
disease (Thomas, Gessner et al. 2005; Kharas, Janes et al. 2008; Horton, Walf-
Vorderwulbecke et al. 2009).  
Based on previous results indicating that the E/R expressing leukemic cell line REH 
requires expression of the fusion gene for survival, we speculated that t(12;21) 
leukemic cells might also be addicted to E/R (Diakos, Krapf et al. 2007).  
 
 
1.4 The PI3K/AKT/mTOR pathway 
1.4.1 Molecular signaling mechanisms 
The phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR)  
pathway regulates key cellular processes, such as cell survival, growth, proliferation, 
glucose uptake, metabolism and angiogenesis (Manning and Cantley 2007).  
Different receptor tyrosine kinases (RTKs) activate PI3K, either through direct binding 
or following tyrosine phosphorylation of scaffolding adaptors, such as insulin receptor 
substrate 1 (IRS1), which then bind and activate PI3K (Figure 8). PI3K 
phosphorylates phosphatidylinositol-4, 5-bisphosphate (PIP2) and generates 
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phosphatidylinositol-3, 4, 5-trisphosphate (PIP3). This reaction can be reversed by 
the PIP3 phosphatase and tensin homolog (PTEN).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. The PI3K/AKT/mTOR pathway (Manning and Cantley 2007). Different receptor tyrosine 
kinases (RTK) are capable of activating the PI3K/AKT/mTOR signaling cascade, leading to 
characteristic activation of downstream effector molecules. See text for detailed descriptions. 
 
After binding to PIP3, AKT is phosphorylated and activated by pyruvate 
dehydrogenase kinase 1 (PDK1). Inactivation of AKT by de-phosphorylation is 
mediated by the pleckstrin homology domain and leucine rich repeat protein 
phosphatase (PHLPP). The isoforms AKT1, AKT2 and AKT3, encoded by three 
different genes, are ubiquitously expressed but their levels vary depending on the 
tissue type. In general, AKT-mediated protein phosphorylation either leads to 
substrate activation or inhibition. So far, over 100 non-redundant AKT substrates 
have been identified. For instance, tuberous sclerosis 2 (TSC2) that forms a complex 
together with TSC1, is phosphorylated by AKT, which blocks the ability of TSC2 to 
act as a GTPase-activating protein for RAS homolog enriched in brain (RHEB). This 
allows accumulation of RHEB-GTP, leading to activation of mTOR complex 1 
(mTORC1). Furthermore, phosphorylation and inhibition of the proline-rich AKT 
substrate 40 (PRAS40) by AKT relieves PRAS40-mediated inhibition of mTORC1. 
Among the most prominent downstream targets in the mTOR pathway are the 
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eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) and the 
ribosomal protein S6 kinase (S6K), being either repressed or activated by mTORC1 
mediated phosphorylation, respectively. Alternatively, AKT can be activated by 
mTORC2 after its activation by RTK signaling and S6K by cytoplasmic PDK1, 
independently of AKT. 
A negative feedback mechanism to attenuate PI3K/AKT/mTOR signaling represents 
phosphorylation of IRS1 by mTORC1 and S6K leading to its degradation.  
 
1.4.2 Regulation of biological functions 
Cell survival 
As exemplified by the BCL2-associated agonist of cell death (BAD) in Figure 9, AKT 
promotes cell survival through regulation of the function or expression of several B-
cell CLL/lymphoma 2 (BCL2) homology domain 3 (BH3)-only members with a pro-
apoptotic function. Otherwise, their activated forms would inactivate other BCL2 
family members, stimulating cell survival.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Biological functions of 10 representative AKT substrates (Manning and Cantley 2007). 
AKT-mediated phosphorylation can either result in protein activation (arrows) or inhibition (blocking 
arrows), controlling various cellular processes. Notably, a high degree of functional versatility and 
overlap exists amongst different AKT substrates. See text for detailed descriptions. 
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Additionally, AKT inhibits the expression of BH3-only genes indirectly through effects 
of forkhead box-O (FOXO) transcription factors and the E3 ubiquitin ligase mouse 
double minute 2 (MDM2) (Manning and Cantley 2007). Activated MDM2 triggers 
tumor suppressor protein p53 degradation (Mayo and Donner 2001), thereby 
preventing p53 dependent transcription proapoptotic genes that play an important 
role in p53-induced apoptosis (Villunger, Michalak et al. 2003).  Furthermore, AKT 
inactivates glycogen synthase kinase 3 (GSK3) (Cross, Alessi et al. 1995) which 
prevents GSK3 isoforms to activate different substrates with pro-apoptotic roles. AKT 
also decreases the protease activity of procaspase-9 by phosphorylation, or indirectly 
by effects of BCL2 family members (Cardone, Roy et al. 1998).  
Cell-survival effects of AKT can also be initiated by crosstalk with other pathways, 
such as the activation of nuclear factor (NF)κB survival signaling or inhibition of c-Jun 
NH(2)-terminal kinase (JNK)/p38 apoptotic signaling (Nidai Ozes, Mayo et al. 1999; 
Kim, Khursigara et al. 2001). 
 
Cell growth and proliferation  
AKT mediated promotion of cell growth (an increase in cell mass) through activation 
of mTORC1 by nutrients and growth factor signaling represents one of its best 
conserved functions. It is well established that mTORC1 is a critical regulator of 
translation initiation and ribosome biogenesis and plays an evolutionarily conserved 
role in cell growth control (Wullschleger, Loewith et al. 2006). 
Different downstream targets of AKT stimulate proliferation through cell-cycle 
regulation (Figure 9). For instance, AKT mediated phosphorylation of CDKN1B/p27 
and CDKN1A/p21 leads to their cytosolic sequestration, relieving their cell-cycle 
inhibitory effects (Zhou, Liao et al. 2001; Liang, Zubovitz et al. 2002). Furthermore, 
the transcription of CDKN1A/p21 is inhibited by the inhibitory effects of AKT on p53 
signaling (Zhou, Liao et al. 2001). Additionally, the AKT targets GSK3, TSC2 and 
PRAS40 were described to drive cell proliferation, either through stabilization or 
synthesis of different proteins involved in cell-cycle entry. 
AKT activity has been shown to be elevated during the G2/M phase. Strikingly, 
activated AKT was shown to promote progression through mitosis, even in the 
presence of DNA damage by phosphorylation of the DNA damage checkpoint kinase 
homolog 1 (CHK1) (Kandel, Skeen et al. 2002). This stimulates its translocation to 
the cytosol where it is sequestered from the DNA damage-sensing kinases ataxia 
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telangiectasia mutated (ATM) and ataxia telangiectasia Rad3 related (ATR) (Puc, 
Keniry et al. 2005). 
 
Cellular metabolism   
A variety of AKT downstream targets regulate nutrient uptake and metabolism in a 
cell-intrinsic and cell-type-specific manner (Figure 9). The main glucose transporter in 
most cell types is the glucose transporter type 1 (GLUT1) which is primarily regulated 
by differential gene expression. Hypoxia inducible factor 1α (HIF1α)-dependent 
transcription of the GLUT1 gene as well as cap dependent translation of GLUT1 
mRNA is initiated by activated mTORC1 (Taha, Liu et al. 1999). Furthermore, 
glycogen synthesis is stimulated by AKT-mediated phosphorylation and inhibition of 
GSK3, preventing GSK3 from phosphorylating and inhibiting glycogen synthase. 
Consistent with the high glycolytic nature of tumor cells, AKT activation also 
increases the rate of glycolysis (Elstrom, Bauer et al. 2004). 
 
Angiogenesis  
AKT can stimulate angiogenesis through different mechanisms (Figure 9). For 
instance, activation of endothelial nitric oxide synthase (eNOS) through direct 
phosphorylation results in a release of nitric oxide and leads to vasodilation, vascular 
remodeling and angiogenesis (Fukumura and Jain 1998). Additionally, AKT directly 
phosphorylates and activates HIF1α and thereby stimulates the secretion of vascular 
endothelial growth factor (VEGF) and other angiogenic factors (Gordan and Simon 
2007). 
 
Cell migration 
Studies on cell migration using mouse embryonic fibroblasts deficient of specific AKT 
isoforms have suggested opposite effects on fibroblast migration, suggesting that 
different isoforms can have distinct cellular functions (Zhou, Liao et al. 2001).  
 
1.4.3 Aberrant PI3K/AKT/mTOR pathway activation in cancer 
Inappropriate activation of the PI3K/AKT/mTOR signaling pathway as a consequence 
of aberrant activation by cell surface receptors or somatic mutations of downstream 
pathway components can be observed in different forms of cancer.  
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For instance, activating mutations in the RTK fms-related tyrosine kinase 3 (FLT3), 
represent the second most frequent genetic lesions in AML. These mutations lead to 
ligand-independent dimerization of FLT3, following constitutive up-regulation of its 
tyrosine kinase activity and stimulation of downstream signaling pathways, including 
PI3K/AKT/mTOR (Naoe and Kiyoi 2004). Furthermore, activating mutations in the 
extracellular or intracellular domains of the stem cell factor ligand KIT, representing a 
class III receptor tyrosine kinase, were identified in 20-30% of AML patients (Frohling, 
Scholl et al. 2005).  
PI3K is also capable of binding directly to RAS, possibly bypassing the obligate 
engagement with phosphotyrosines (Rodriguez-Viciana 1994). In line with this notion, 
RAS mutations could be associated with constitutive PI3K activation in AML and 
more recently in T-cell ALL (Birkenkamp, Geugien et al. 2004; Gutierrez, Sanda et al. 
2009).  
Somatic mutations that activate the class IA PI3K catalytic subunit p110α, encoded 
by PIK3CA as well as the regulatory subunit p85 of PI3K, encoded by PIK3R1, were 
observed in different solid tumors and in T-cell ALL  (Philp 2001; Palomero, Sulis et 
al. 2007). 
The first described genetic abnormalities downstream of PI3K were deletions of 
PTEN tumor suppressor in solid tumors, followed by T-cell ALL (Li 1997; Gutierrez, 
Sanda et al. 2009). Later, inhibition of PTEN expression, as well as increased 
phosphorylation, leading to an abrogation of its enzymatic activity and increased 
PI3K/AKT/mTOR pathway activity was identified in AML blasts (Xu, Simpson et al. 
2003) (Cheong, Eom et al. 2003) (Vazquez, Grossman et al. 2001). Furthermore, 
dominant-negative mutations in the SH2 domain-containing inositol phosphatase 
(SHIP1) may contribute to AKT activation in AML (Luo, Yoshida et al. 2003). 
Importantly, studies reporting about FLT3 mutations as well as deletions of PTEN 
and phosphorylated PTEN in AML also correlated these with adverse effects on 
prognosis. 
Genetic alterations involving AKT isoforms have been reported in solid tumors and T-
cell ALL (Carpten 2007; Malanga 2008; Gutierrez, Sanda et al. 2009).  
Apart from somatic mutations of PTEN, PIK3CA, PIK3R1 and AKT, some cancers 
have amplifications of AKT1, AKT2 and PIK3CA (Brugge, Hung et al. 2007). 
So far, mutations within the PI3K/AKT/mTOR pathway could not be detected in BCP 
ALL. However, since these cells are highly sensitive for PI3K and mTOR inhibition 
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(Avellino, Romano et al. 2005; Levy, Kahana et al. 2009), pathway activation may 
result from de-regulated expression or activation of certain pathway components in 
the absence of genetic alterations, as shown in AML blasts (Martelli, Nyakern et al. 
2006).  
 
1.4.4 Pharmacological PI3K/AKT/mTOR pathway inhibition  
Since hyperactivation of the PI3K/AKT/mTOR pathway frequently confers drug 
resistance to leukemic cells, small molecule inhibitors targeting components of the 
PI3K/AKT/mTOR pathway such as PI3K, AKT and mTOR present promising targets 
for cancer therapy. These pathways inhibit many tumor suppressor-like proteins such 
as FOXO transcription factors, BAD, GSK3 and the tuberin/hamartin complex. This 
diverse set of proteins negatively regulates cell survival, proliferation and growth. 
Therefore, blocking this pathway could simultaneously inhibit the proliferation of 
tumor cells and sensitize them to apoptosis. Importantly, many components in the 
PI3K/AKT/mTOR pathway are protein kinases which can be targeted by different 
classes of drugs.  
LY294002 was the first synthetic PI3K inhibitor. It efficiently inhibited cell growth in 
vitro and showed a significant in vivo antitumor effect. Consequently, LY294002 was 
widely used to explore the function of PI3K. However, skin-related toxic side effects 
due to the induction of apoptosis and, additionally, poor solubility and low 
bioavailability, prevented the entry of LY294002 into clinical trials (Hu, Zaloudek et al. 
2000). 
In recent years, a large number of PI3K pathway therapeutics have been developed 
and many potential clinical scenarios exist for their application.  
Specific PI3K inhibitors are further differentiated into isoform-specific or pan-PI3K 
inhibitors. The latter inhibit all class IA PI3Ks in a given tumor, however, the 
application of isoform-specific inhibitors probably reduces the risk of side effects even 
if administered in high doses. The major drawback of specific PI3K inhibitors is that, 
they might not effectively repress AKT activation in cancers with mutations or 
amplifications in AKT1 or AKT2 since they do not inhibit mTORC2. 
In these cases, dual PI3K/mTOR inhibitors targeting different p110 isoforms as well 
as mTORC1 and mTORC2 might be more effective. Additionally, they are expected 
to effectively shut down PI3K/AKT/mTOR signaling in cancers with PTEN loss, RTK-
dependent activation of AKT via mTORC2 and might mitigate feedback activation of 
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PI3K, as frequently observed by mTORC1 inhibition (O'Reilly 2006). For instance, the 
synthetic inhibitor PI-103 simultaneously inhibits PI3K and mTOR and was shown to 
confer antitumor activity in vivo, attributed to its ability to target both kinases. 
Importantly, PI-103 did not cause obvious side effects. In vitro, PI-103 inhibited 
growth of glioma cells at submicromolar concentrations and arrested the cell cycle at 
the G1 phase (Fan, Knight et al. 2006). However, pharmacokinetic studies later 
indicated that PI-103 was metabolized to form glucuronide, being rapidly cleared from 
the plasma (Raynaud 2007). Thus, optimization of its pharmacokinetic properties by 
structural modification is currently underway. 
In addition, AKT can be targeted by either ATP mimetics or non-catalytic site 
inhibitors (She 2008). Isoform-specific AKT inhibitors could be useful in cancers 
where AKT1 and AKT2 have distinct functions. 
The fourth class of inhibitors are mTOR catalytic site inhibitors. In contrast to 
rapamycin, they are expected to inhibit both complexes, mTORC1 and mTORC2. 
 
 
1.5 Gene expression profiling in ALL 
Gene expression profiling was introduced in leukemia research a decade ago, 
enabling the simultaneous investigation of the expression of thousands of genes. In 
order to better understand the diversity of genetic aberrations in acute leukemias of 
the myeloid as well as lymphoid lineage, independent pioneer studies demonstrated 
the predictability of cytogenetic and molecular subclasses by differentially expressed 
genes. Moreover, gene expression profiling can identify and define new prognostic 
subclasses within distinct leukemia subgroups. For therapy of patients with acute 
leukemia, gene expression profiling can promote the development of treatment-
specific sensitivity assays and assist in detecting new molecular targets (Bacher, 
Kohlmann et al. 2009). 
 
1.5.1 Molecular signatures of ALL subtypes  
Yeoh et al first demonstrated that prognostically important leukemia subtypes can be 
identified by gene expression profiling (Yeoh, Ross et al. 2002).  
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Later, these findings were confirmed by Ross et al who identified leukemia subtype 
discriminating genes from a larger proportion of the human genome using new 
expression profiling platforms.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Expression profile based classification of distinct leukemia subtypes; modified 
(Ross, Zhou et al. 2003). Gene expression profiles were obtained from leukemic blasts of 132 
diagnostic bone marrow aspirates.  Data was analyzed by an unsupervised 2-dimensional clustering 
algorithm (left panel and top right panel) and principle component analysis (right panel). 
 
These investigators applied a principle component analysis for diagnostic leukemia 
samples, revealing that childhood ALL cases clustered into T-cell lineage ALL and six 
different subtypes of B-cell lineage ALL, corresponding to rearrangements of the MLL 
gene, chromosomal translocations resulting in E2A/PBX1, BCR/ABL and E/R fusions, 
hyperdiploid leukemias with more than 50 chromosomes and a novel subgroup 
(Figure 10) (Ross, Zhou et al. 2003). Furthermore, leukemia subtype discriminating 
genes were identified. The expression patterns of the top 100 ranked genes for the 
six prognostically important subgroups are shown in Figure 11. As illustrated, distinct 
groups of genes being either over-expressed or under-expressed, clearly distinguish 
cases defined by the respective genetic subtype.  
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Figure 11. Two-dimensional hierarchic clustering of pediatric ALL (Ross, Zhou et al. 2003). 
Diagnostic leukemias (columns) vs. the top 100 chi-square ranked probe sets (rows) for the 6 
subtypes of ALL, as indicated at the panel bottom. Red colours represent gene expression above the 
mean and green colours below the mean. 
 
Later, Fine et al analysed gene expression in leukemic cell lines as well as primary 
leukemic blasts, thereby confirming many of the genes being previously associated 
with characteristic primary genetic change (Fine, Stanulla et al. 2004). Importantly, 
they highlighted a number of leukemia subtype specific features that were not 
immediately apparent in previous studies. For instance, they found that BCR/ABL-
positive ALL cases have a more heterogeneous pattern of gene expression than E/R 
or MLL positive ALL cases.  
Next, Anderson et al compared gene expression patterns of ALL and AML blasts to 
those of normal hematopoietic subpopulations of different lineages in order to show 
that leukemias segregate according to lineage and genetic subtype as well as identify 
genes that correlate with characteristic primary genetic change (Andersson, Olofsson 
et al. 2005). This approach also aimed to reveal de-regulation of pathogenetically 
important regulatory pathways. Collectively, a close relationship of lineages and 
maturation stages between malignant and normal hematopoietic cells could be 
observed. The degree of maturation of childhood leukemias with characteristic 
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genetic changes was visualized by projecting the primary leukemias onto the 
principal components determined only by the normal cells. For instance, E/R-positive 
cases clustered close to the precursor B-cells and, despite their common lack of the 
CD34 marker, E2A/PBX1-positive ALLs clustered close to the CD34/CD19 positive 
cells. These analyses also revealed that several genes were preferentially and highly 
expressed by leukemic cells and not in the various normal subpopulations, 
suggesting targets for future directed therapies. Obviously, leukemia cells display de-
regulated activation of transcriptional programs not active in normal cells. 
 
1.5.2 Gene expression features of ETV6/RUNX1-positive ALL 
Apart from the identification of differentially regulated genes, several studies aimed to 
unravel molecular mechanisms of perturbed pathways in E/R-positive ALL by using 
either patient-derived primary cells or leukemic cell lines.  
For instance, Fine et al found the erythropoietin receptor consistently highly 
expressed in E/R-positive samples (Fine, Stanulla et al. 2004). Later, these findings 
could be corroborated by our group, suggesting that this receptor might play a critical 
role in the development of E/R-positive ALL (Inthal, Krapf et al. 2008).  
Zaza et al aimed to unravel the molecular basis of treatment associated 
characteristics of E/R-positive ALL (Zaza, Yang et al. 2004). These investigators 
correlated low rates of de novo purine synthesis (DNPS) in E/R-positive ALL vs. E/R-
negative ALL with differential expression of 16 genes, providing a reasonable 
explanation for the favorable prognosis of E/R-positive ALL compared to other ALL 
subtypes. Importantly, anti-leukemic agents targeting DNPS, such as methotrexate or 
mercaptopurine are widely used. 
De-regulated expression of genes involved in nucleotide metabolism was later 
confirmed by Andersson et al. Furthermore, they identified in E/R-positive leukemia 
an up-regulation of genes involved in the phosphatidylinositol signaling system, 
including Ca2+ regulators as well as the protein tyrosine phosphatases (PTP)N18, 
PTPRF, PTPRK and PTPRM (Andersson, Olofsson et al. 2005). The latter protein 
tyrosine phosphatases are also implicated in β-catenin signaling. Consistently, de-
regulation of β-catenin signaling was shown to affect leukemic cell adhesion, 
proliferation, and survival (Chung, Hwang et al. 2002). Alterations of similar biological 
functions and processes in E/R-positive leukemias were later suggested by 
Gandemer et al. They performed gene-ontology (GO) analyses revealing that 
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differential expression of 16 genes tightly associated with E/R-positive leukemia, 
mapped to the GO terms ‘cell differentiation’, ‘cell proliferation’, ‘apoptosis’, ‘cell 
motility’ and ‘response to wounding’ (Figure 12) (Gandemer, Rio et al. 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Schematic representation of enriched genes and associated GO terms in E/R-
positive ALL; modified (Gandemer, Rio et al. 2007). Circles group genes that share common 
properties within relevant biological processes. Genes in brackets are expressed in a tissue-specific 
manner. 
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2. AIMS OF THE STUDY 
There is overwhelming evidence that the E/R fusion protein is critical for the initiation 
of leukemia by inducing a pre-leukemic state and creating favourable conditions for 
the acquisition of obligatory secondary alterations. By contrast, the relevance of the 
chimeric fusion protein for maintenance of overt disease is not clearly defined. We 
hypothesized that repression of the endogenous fusion protein and investigation of 
the cellular and molecular consequences will provide important information on E/R 
function in the leukemic cell. In particular, the aim of our study was to develop a 
model for efficient and stable E/R fusion protein knockdown by lentivirus mediated 
shRNA transduction into the leukemic cell lines REH and AT-2. 
 
E/R silenced cells were further used to 
I. evaluate the impact on the phenotype of the leukemic cell by assessing cell 
proliferation, apoptosis and cell cycle 
II. analyse their in vivo leukemia engraftment and outgrowth potential in 
xenotransplant experiments using NOD/SCID mice 
III. identify E/R regulated genes by RNA expression profiling; annotate regulated 
genes by DAVID and GSEA to describe suggested functions; compare gene 
regulation from E/R knockdown experiments with the signature from primary 
childhood E/R-positive ALL cases; finally validate selected target genes 
representative of various pathways or cellular functions by RT-qPCR 
IV. screen for modulations in cell signaling and pathways and confirmation at the 
functional level 
V. exploit inhibition of selected pathways activated by E/R and validate results in 
primary ALL cases.  
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ABSTRACT 
The ETV6/RUNX1 (E/R) gene fusion is generated by the t(12;21) and found in 
approximately 25% of childhood B-cell precursor acute lymphoblastic leukemia. In 
contrast to the overwhelming evidence that E/R is critical for the initiation of leukemia, 
its relevance for the maintenance of overt disease is less clear. To investigate this 
issue, we suppressed the endogenous E/R fusion protein with lentivirally transduced 
shRNA in the leukemia cell lines REH and AT-2 and found a distinct reduction of 
proliferation and cell survival. In line with the observed concurrent inactivation of the 
PI3K/AKT/mTOR pathway, pharmacological inhibition diminished the phosphorylation 
of AKT and RPS6 and significantly increased the apoptosis rate in E/R-positive 
leukemias. Moreover, PI3K/mTOR inhibitors sensitized glucocorticoid resistant REH 
cells to prednisolone, an observation of potential relevance for improving treatment of 
drug resistant relapses. Of note, knockdown of the E/R fusion gene also severely 
impaired the repopulation capacity of REH cells in NOD/SCID mice. Collectively, 
these data demonstrate that the E/R fusion protein activates the PI3K/AKT/mTOR 
pathway and is indispensible for disease maintenance. Importantly, these results 
provide a first rationale and justification for targeting the fusion gene and the 
PI3K/AKT/mTOR pathway therapeutically.  
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childhood ALL, ETV6/RUNX1, PI3K/AKT/mTOR pathway, RNA interference 
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INTRODUCTION 
The ETV6/RUNX1 (E/R) fusion gene (also known as TEL/AML1) is present in 
approximately 25% of childhood B-cell precursor acute lymphoblastic leukemia (BCP 
ALL) and represents the molecular equivalent of the t(12;21) [1]. Despite an overall 
excellent initial treatment response, up to 20% of these cases relapse [2-4]. The 
predominantly late occurrence of these relapses together with a considerable clonal 
variation between presentation and relapse implies that a postulated E/R-expressing 
(pre)leukemic sub-clone resists treatment and acquires distinct additional genomic 
aberrations during the secondary expansion and re-emergence [5-8]. In contrast to 
the general notion that these relapses may be as treatment sensitive as the 
corresponding original leukemias, recent data from our group suggest that a 
substantial proportion of these cases fare poorly and may even qualify for stem cell 
transplantation [5]. Treatment intensification may overcome resistance in some 
cases, but will also increase the frequency of severe side and late effects. Particularly 
in such forms of leukemia, new treatment modalities that only target and exploit the 
relevant specific genetic defect are clearly needed. 
Supported by ample evidence, the multi-step model of E/R-positive leukemia 
currently implies that the leukemia initiating gene fusion occurs already in utero and 
is followed by several additional mutational hits before the disease becomes clinically 
evident [9]. Provided the chimeric protein is also required for the leukemia 
replenishing process, as was suggested recently, both the specific molecular 
alteration itself as well as any affected signaling pathway components  would 
constitute ideal targets for specific therapeutic attacks [10].  
The phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) 
signaling pathway senses and responds to mitogenic stimuli, energy and nutritional 
status and thereby represents an essential regulator of many cellular processes such 
as protein synthesis, proliferation and apoptosis. Its constitutive activation in many 
forms of malignancies attests its pathogenetic importance [11, 12]. Consequently, a 
variety of small molecules have already been developed to therapeutically target 
specific pathway components [13]. Although T-cell precursor ALL (T-ALL) seems to 
be the most frequent ALL form with a constitutive PI3K/AKT/mTOR pathway 
activation, only some of these cases resist therapy and consequently have a poor 
prognosis [14]. Despite an apparent lack of mutations in specific PI3K/AKT/mTOR 
pathway components in the vast majority of BCP ALL cases, analyses of gene 
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expression data nevertheless suggest that the PI3K/AKT/mTOR pathway is also 
aberrantly activated in E/R-positive ALL [15-18]. To investigate these preliminary 
observations further, we silenced the E/R fusion gene with a lentiviral vector transfer 
of fusion gene-specific shRNAs into leukemia cell lines, studied the evoked effects on 
cellular functions and affected pathways in vitro and compared the in vivo malignant 
potential of untreated and treated cells in NOD/SCID mice. 
 
MATERIAL AND METHODS 
Cell culture 
The E/R-positive BCP leukemia cell lines REH (DSMZ, Braunschweig, Germany) and 
AT-2 [19] (kindly provided by J.D. Rowley, University of Chicago, IL) and primary 
leukemia blasts, obtained from bone marrow aspirations of children with ALL, were 
cultured as described previously [20]. In accordance with the Declaration of Helsinki, 
we obtained written infirmed consent from all patients' parents for using spare 
leukemia cells in this study. The study was approved by the ethical committees of the 
Children’s Cancer Research Institute and St. Anna Kinderspital. LY294002 
(Calbiochem Corporation, San Diego, CA) and PI-103 [21] (Selleck Chemicals, 
Houston, TX) were used at 40 µM and 2 µM concentrations, respectively. 
Prednisolone (Solu-Dacortin, Merck, Whitehouse station, NJ) was used at 1 mg/mL 
[20].  
 
Immunoblotting  
Cell lysates were prepared, resolved and transferred as described previously [20] 
using 90 µg of total protein. Membranes were incubated with anti-ETV6 (SB89, kindly 
provided by P. Marynen, VIB, Leuven, Belgium), anti-RUNX1 (Active Motif, Carlsbad, 
CA) and anti-GAPDH (6C5, Santa Cruz Biotechnology, Santa Cruz, CA) and 
secondary infrared dye-labeled antibodies (LI-COR Biosciences, Lincoln, NE). 
Membranes were scanned with Odyssey Infrared Imaging System (LI-COR 
Biosciences). Intensities of bands corresponding to E/R and RUNX1 were normalized 
to the signal of GAPDH. 
 
Assessment of protein phosphorylation by flow cytometry and ELISA 
REH cells were kept overnight in serum-free medium before stimulation with human 
recombinant stem cell factor, IL-3, IL-6 and IL-7 (10 ng/mL each) (Peprotech, Rocky 
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Hill, NJ) for 10 minutes, or kept in culture medium containing only 10% FCS, to 
assess induced and basal protein phosphorylation, respectively. Fixed and 
permeabilized cells were incubated with fluorescence conjugated antibodies binding 
RPS6 (Ser235/236), AKT (Ser473), p38 (Thr180/Tyr182), NFκB (Ser529), STAT5 
(Tyr694) and JNK (Thr183/Tyr185) (Cell Signaling Technology, Danvers, MA) and 
analyzed by flow cytometry (FACS Calibur, BD-Pharmingen, Franklin Lakes, NJ). 
AKT phosphorylation was also determined with the PathScan Apoptosis Multi-Target 
Sandwich ELISA (Cell Signaling Technology) according to the manufacturer's 
recommendations.  
 
RNA interference 
For E/R silencing two sequences targeting the fusion region (Figure S1) were used: 
shRNA A1 (5’-CACCGAATAGCAGAATGCATACTTCGAAAAGTATGCATC 
TGCTATT-3’) has been described and tested previously [10, 22] and shRNA G1 (5'-
CACCGGGAGAATAGCAGAATGCATCGAAATGCATTCTGCTATTCTCCC-3') was 
newly designed to confirm and extend our previous data.10 shRNA LacZ (Invitrogen, 
Carlsbad, CA) was used as a non-targeting shRNA control. Lentiviral particles were 
generated using the Block iT Lentiviral RNAi Expression System (Invitrogen) and, 
following ultracentrifugation, titers were assessed by ELISA-based quantification of 
virus associated HIV-1 p24 (Cell Biolabs, San Diego, CA) according to the 
manufacturer’s recommendations. Leukemia cells were transduced by a multiplicity 
of infection of 10 in the presence of 6 µg/mL polybrene and selected for lentiviral 
integration with 5 µg/mL blasticidin (Invitrogen) for 2 weeks.  
 
Quantitative RT-PCR (RT-qPCR) 
Total RNA was isolated by Trizol reagent (Life Technologies, Carlsbad, CA) and used 
for cDNA synthesis by SuperScript II Reverse Transcriptase (Invitrogen). RUNX1 and 
E/R transcripts were quantified by TaqMan RT–qPCR using the ABI Prism 7900 
Detection System (Applied Biosystems, Foster City, CA). For box plot diagrams cycle 
threshold ∆(CT) x -1 values (CTtarget – CTreference) of biological replicates were 
depicted. Published primer probe combinations were used for E/R and GUS as 
endogenous reference [5, 23]. RUNX1 mRNA levels were quantified by the following 
primer/probe combination: forward 5'-CCTTCGTACCCACAGTGCTT-3', reverse 5'-
CAACGCCTCGCTCATCTT-3', probe 5'-TCTAGAGACGTCCACGATGCCA-3'. 
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Cell cycle, apoptosis and viability assays 
DNA synthesis and cell cycle distribution was determined by Click-iT EdU (5-ethynyl-
2'-deoxyuridine) Flow Cytometry Assay (Invitrogen) according to the manufacturer's 
recommendations and analyzed using the FlowJo software (Tree Star, Ashland, OR). 
The proportion of apoptotic cells was assessed by flow cytometry using Annexin-
V/propidium iodide (PI) staining, and cleaved Caspase 3 (BD-Pharmingen) staining 
after gating on the viable cell population based on light scatter characteristics. MTT 
(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was performed 
as described previously [20].  
 
Gene expression profiling 
A detailed description on gene expression profiling is provided as Supplementary 
Information. Briefly, RNA from E/R silenced REH and AT-2 cells was used for gene 
expression profiling on Affymetrix HG-U133-PLUS2 (Affymetrix, Santa Clara, CA). 
Analyses were performed in R using Bioconductor packages [24] with mean values of 
biological replicates (n = 3) at two different time points after transduction of REH and 
AT-2 cells. Differential regulation of molecular functions was evaluated by gene set 
enrichment analysis (GSEA) using the Java tool 
(http://www.broadinstitute.org/gsea/index.jsp) [25, 26]. Data from primary childhood 
ALL were downloaded from the St. Jude’s data base 
(http://www.stjuderesearch.org/site/data/ALL3) [17].  
 
Leukemia xenograft experiments 
5 x 106 REH cells stably expressing either shRNA G1 or control shRNA were injected 
into the tail vein of NOD/SCID mice. Diseased animals were sacrificed and bone 
marrow, spleen and liver analyzed for the presence of human leukemia cells by flow 
cytometry using anti-human CD19 (30-F11) and anti-mouse CD45 (4G7) antibodies 
(both BD-Pharmingen). All animal experiments were approved by the Austrian 
Federal Ministry for Science and Research GZ:66.009/0065-II/10b/2009. 
 
Statistical analysis 
Differences between E/R silenced and control cells were assessed by the paired two-
tailed t-tests and between different model cell lines and various leukemias by the 
unpaired two-tailed t-tests. Statistical analysis of leukemia free survival of mice 
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between groups was performed using Log-Rank test. P-values ≤ 0.05 were 
considered statistically significant.  
 
RESULTS 
Lentiviral mediated transduction of E/R-directed shRNA expressing vectors 
silences the fusion gene 
Long-term suppression of E/R in the leukemia cell lines REH and AT-2 was achieved 
by a lentiviral transfer of shRNA expressing vectors A1 and G1 that target different 
sequences of the E/R fusion transcript.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. shRNA-mediated silencing of E/R in t(12;21) positive leukemia cell lines. Leukemia cell 
lines REH and AT-2 were transduced with lentiviral constructs coding for shRNA A1 (A1) or G1 (G1) 
targeting E/R or a non-targeting shRNA control (C). Upon selection, expression of E/R and wt RUNX1 
was quantified. Quantification of E/R (a) and RUNX1 (c) transcripts in biological replicates from REH 
and AT-2 cells (n = 5); **, P ≤ 0.01; ***, P ≤ 0.001  (paired t-test). Protein abundance of E/R (b) and 
RUNX1 (d) was detected by Western blot analysis using anti-ETV6 and anti-RUNX1 antibodies, 
respectively. GAPDH was used as loading control. Numbers between bands represent the ratio 
between RUNX1 and GAPDH quantification. Data are representative of at least three independent E/R 
knockdown experiments. 
 
The respective cell lines were derived from E/R-positive relapse samples, express wt 
RUNX1 and lack the non-rearranged ETV6 gene. We used a GFP-expressing 
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construct to confirm that the lentiviral infection was more than 90% efficient (data not 
shown). Hence, this particular lentiviral system was employed for the delivery of 
shRNA A1 and G1 as well as a non-targeting control shRNA. Lentiviral titers were 
assessed in each batch to assure constant transduction efficacy and the 
corresponding knockdown effects. One week after selecting the stable transfectants, 
both cell lines exhibited a substantial and constant reduction of E/R transcript and 
protein levels with merely minor variations between different experiments and cell 
lines (Figure 1a and b). Of note, knockdown of the fusion gene did not repress wt 
RUNX1 expression (Figure 1c and d). With this standardized procedure, which 
satisfactorily suppressed E/R two to three weeks after viral transduction, we were 
therefore able to evaluate the outcome of the respective depletion. 
 
E/R suppression abrogates cellular proliferation and survival 
Regular cell counts revealed a gradual decrease of cellular growth down to 40-50% 
in E/R depleted versus control REH and AT-2 cell lines two week after selection, 
which subsequently stabilized for additional three to four weeks (Figure 2a). Growth 
suppression tended to be more pronounced with shRNA G1 compared to shRNA A1, 
most likely reflecting the differences in reduction of the fusion gene transcripts. 
Taking into account previous work that dealt with modulating effects of forced E/R 
expression on apoptosis, cell cycle and proliferation [27-30], we were especially keen 
to determine which of these systems would be predominantly de-regulated in our 
endogenous E/R knockdown model and responsible for the observed growth 
suppression. In line with our earlier observations that siRNA induced fusion gene 
silencing augments apoptosis [10], the proportion of early apoptotic cells (Annexin-V-
positive/PI-negative) in E/R-silenced cells also increased 1.5 to 3-fold (Figure 2b). In 
contrast to our expectations that E/R depletion would unleash the break from G1 to S 
transition and proliferation [27-30], E/R knockdown led to a distinct decline of 
proliferating cells (from a mean of 37% in controls to 24% in silenced cells) (Figure 
2c). Together with the cell cycle distribution showing a modest increase of the G0/G1 
compartment in E/R silenced cells (Figure 2d), the decelerated proliferation rate can 
therefore - at least partly - be attributed to a G1 arrest with a concomitant increase in 
apoptosis at the transition to S that could account for the selective loss of S phase.  
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Figure 2. Suppression of E/R modulates cellular proliferation, survival and cell cycle 
distribution in leukemia cell lines. REH cells were subjected to shRNA-mediated silencing of E/R as 
described in Figure 1. (a) Cell growth was assessed by regular cell counts after transduction and is 
depicted for REH cells expressing shRNA A1 or G1 in relation to shRNA control. Shown are means 
with standard deviation of four independent E/R knockdown experiments. (b) Apoptosis was analyzed 
by Annexin-V/PI (left) and cleaved Caspase 3 staining (right). Bars represent fold changes of cells 
expressing shRNA G1 compared to shRNA control. Shown is one of four experiments from individual 
E/R knockdowns. (c) Evaluation of DNA synthesis by EdU incorporation. Left: Representative scatter 
plot; Right: Percentages of cells in S phase of the cell cycle of four independent E/R knockdown 
experiments. *, P ≤ 0.05 (paired t-test). (d) Influence of E/R knockdown on cell cycle distribution. 
Histograms represent one of four independent E/R knockdown experiments.  
 
A possible effect of E/R suppression on the mitotic checkpoint function [31] was 
addressed by phospho-histone H3 staining but did not reveal any differences 
between E/R depleted cells and controls (5-8% positivity in two independent E/R 
knockdown experiments; data not shown). 
These findings suggest that E/R silencing alters the growth pattern of the leukemia 
cell lines REH and AT-2 by impeding proliferation and survival.  
 
E/R suppression inhibits PI3K/AKT/mTOR activity  
To identify potential causes for the observed growth retardation, we compared the 
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gene expression profiles from E/R-silenced REH and AT-2 cells between day 20 and 
30 after viral transduction with those obtained from shRNA control cells and 
performed GSEA. This analysis revealed a substantial enrichment of the KEGG 
terms "phosphatidylinositol signaling system" (negative enrichment score = 0.426; P-
value = 0.082) and "mTOR signaling pathway" (positive enrichment score = 0.494; P-
value = 0.038) (Figure 3a). To further ascertain potential effects on the 
PI3K/AKT/mTOR cascade, we screened our microarray data for the presence of 
informative gene expression patterns [32]. The resulting genes along with information 
on their described influence on pathway regulation and/or downstream effectors [32] 
are listed in supplementary Table S1. Overall, E/R suppression down-regulates 
genes with activating and, vice versa, up-regulates those with inhibitory effects on the 
pathway and downstream components. A specific transcriptional regulation of these 
genes by E/R was further supported by inspecting publically available microarray 
data from primary childhood ALL [17]. In line with the results retrieved from our E/R 
knockdown experiments, we found an inverse correlation of the respective 
differentially expressed genes in the leukemias, which further corroborate the notion 
that E/R regulates especially pathway-associated genes with an anti-apoptotic and 
mitogenic function (Figure 3b). 
Given that PI3K/AKT/mTOR signaling is mainly regulated at the post-transcriptional 
level, we investigated whether E/R silencing also affects protein phosphorylation of 
selected downstream substrates. E/R suppression reduced the cytokine mediated 
phosphorylation of AKT at Ser473 and ribosomal protein S6 (RPS6) at Ser235/236 
by 50% and 30%, respectively (Figure 3c), whereas phosphorylation of other key 
signaling proteins that are frequently altered in hematologic malignancies remained 
largely unaffected [11].  
The impaired phosphorylation of RPS6, a substrate of mTOR, is of specific interest, 
because this protein controls cell growth and proliferation through its regulation of 
protein synthesis [33]. A reduced AKT phosphorylation at Ser473, and additionally at 
Thr308, was also seen with an ELISA system (Figure 3d). Since an E/R knockdown 
especially affects proliferation and apoptotic processes and, vice versa, E/R 
expression apparently activates the PI3K/AKT/mTOR pathway, we assume that the 
perturbation of these cellular effects are mediated by this pathway to at least some 
extent. To further investigate the influence of PI3K/AKT/mTOR signaling on 
proliferation and apoptotic processes in E/R-expressing leukemia cells, we compared 
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first basal phosphorylation of PI3K and mTOR downstream effectors in REH and AT-
2 cells upon E/R depletion with those of the pharmacologic pan-PI3K family inhibitor 
LY294002 and the small-molecule dual PI3K/mTOR inhibitor PI-103 [21]. 
 
Figure 3. Suppression of E/R reveals a distinct relationship between fusion gene expression 
and activation of the PI3K/AKT/mTOR pathway. Expression profiling was performed from REH and 
AT-2 cells upon suppression of E/R by shRNA G1 compared to shRNA control. (a) GSEA plots 
showing the distribution of differentially regulated genes from the KD experiments for the 
“phosphatidylinositol signaling system” (left) and “mTOR signaling pathway” (right). Lower portions of 
the figure (ranking metric score) depict the distribution of the log2-fold changes of all genes in the 
analysis, ordered from left with genes being highly expressed to the right with downregulated ones. 
Vertical black lines (hits) indicate the position of genes in ranked order. Upper portions show the 
enrichment score: if the peak of the graph (enrichment profile) lies on the left side, the pathway is 
enriched in up-regulated genes and vice versa. (b) Box plot diagram depicting the log2-fold changes of 
genes involved in PI3K/AKT/mTOR signaling (grey, repressing and white, activating the pathway 
and/or its downstream targets). Gene sets were extracted from microarray data derived from E/R-
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silenced REH and AT-2 cells vs. non-targeting controls (KD) and primary E/R-positive vs. E/R-
negative BCP ALL (E/R+ ALL). Boxes cover the median and the interquartile range (25-75th 
percentiles) and whiskers the minimum and maximum values. *, P ≤ 0.1; ***, P ≤ 0.01 (unpaired t-test). 
(c) Cytokine mediated phosphorylation of major components of various key signaling pathways. Bars 
depict fold-changes of median fluorescence intensity (MFI) of specific phospho-protein stainings of 
E/R silenced (G1) and control REH cells (control). Controls were set to one. Shown is the median with 
standard deviation of three independent E/R knockdown experiments. **, P ≤ 0.05 (paired t-test). (d) 
Quantification of phosphorylated AKT protein by ELISA upon cytokine stimulation. Bars indicate the 
mean absorbance (Abs) of triplicates with standard deviation from one of two independent E/R 
knockdown experiments. 
 
Pharmacological inhibition of PI3K/AKT/mTOR signaling affects survival and 
proliferation of E/R-positive leukemias 
LY294002 reduced phosphorylation of AKT and of RPS6 by 24% and 67%, 
respectively, in un-stimulated cells, which favorably compares with the 22% and 59% 
reduction that was achieved with E/R suppression (Figure 4a). Treatment of E/R-
depleted REH and AT-2 cells with LY294002, on the other hand, did not further 
decrease phosphorylation of both proteins (data not shown). The small PI-103 
molecule inhibited phosphorylation of AKT to a lesser but of RPS6 to a slightly higher 
extent than LY294002 (Figure 4a). Next, we tested whether PI3K/mTOR inhibitors 
are able to sensitize E/R-positive leukemia cells to prednisolone, a synthetic 
glucocorticoid that is widely used in ALL treatment regimens and to which relapse 
ALL cases may become resistant [3, 5]. Cell death and MTT assays collectively 
demonstrate that exposure of GC-resistant REH cells to either one of the two 
inhibitors or prednisolone alone affects cellular viability and apoptosis rates in a 
comparable manner. A joint exposure, on the other hand, significantly augments the 
GC-induced apoptotic effect (Figure 4b).  
Finally, we investigated the potential clinical value of these findings by analyzing 
primary ALL samples. A 24-hour exposure of BCP ALL cells - from children who had 
been consecutively enrolled in the current Austrian treatment protocol - to LY294002 
significantly increased the apoptotic rate of E/R-expressing cells in comparison to 
E/R-negative controls (Figure 4c). These data further support our notion that 
PI3K/AKT/mTOR signaling is aberrantly activated particularly in E/R-positive 
leukemias and that inhibition of this pathway could be a novel therapeutic option.  
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Figure 4. Activation of PI3K/AKT/mTOR signaling by E/R is blocked by fusion gene depletion or 
chemical inhibition. (a) Phospho-flow staining of AKT and RPS6 in REH cells cultured under 
standard conditions. Histograms showing phosphorylation under various conditions. Top: upon E/R 
silencing; middle: LY294002, and bottom: PI-103 treatment (black lines) and of respective controls 
(grey lines). Numbers indicate the median fluorescence intensity. Shown is one out of two independent 
experiments. (b) Apoptosis and viability assays of REH cells treated with either prednisolone (P), 
LY294002 (LY), or PI-103 (PI) alone or in various combinations for 24 hours. Percentages of Annexin-
V single positive cells (upper panel) and viability by MTT assay (lower panel) are depicted as fold-
change and percent of carrier control, respectively. Shown are the means of triplicates with standard 
deviation from one of three independent experiments. (c) Apoptosis levels in E/R-positive (E/R+) and 
E/R-negative (E/R-) BCP ALL samples after exposure to LY294002 for 24 hours indicated as fold-
changes of carrier control. *, P ≤ 0.05 (unpaired t-test).   
 
Silencing of E/R impairs engraftment of leukemia in a xenotransplant mouse 
model  
To address the functional consequences of E/R knockdown in vivo, we used 
differentially E/R-expressing REH cells in immunocompromized mice to investigate 
their repopulating capacity and ability to establish leukemia.  We injected either E/R-
3. FIRST AUTHORSHIP PUBLICATION I 
 
 39 
silenced or control shRNA expressing REH cells on day 15 after lentiviral 
transduction into the tail vein of NOD/SCID mice, which were then sacrificed either 
when they exhibited clinical signs of disease or electively in week 27. While all eight 
animals from the control group that had been transplanted with non-targeting shRNA 
infected REH cells, died from human leukemia, only five of eight recipients of E/R-
silenced REH cells developed leukemia. The three remaining animals neither 
developed leukemia nor showed any signs of leukemia infiltration at the end of the 
observation period. Strikingly, mice receiving E/R-depleted REH cells survived for 15 
weeks (median, range 8-15), whereas animals from the control group developed 
leukemia already 9 weeks (median, range 8-10) after injection.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Reduced repopulation capacity of E/R suppressed REH cells in NOD/SCID mice. 
shRNA G1 or shRNA control expressing REH cells were injected into NOD/SCID mice (G1, n = 8; 
control, n = 8). (a) Kaplan Meier plots depicting leukemia free survival (LFS) of animals until week 27 
after leukemia injection. Statistical analysis was done by the Log-Rank test. (b) Leukemia was 
confirmed in all sacrificed mice by flow cytometry. Staining of bone marrow cells was performed using 
anti-human CD19 and anti-mouse CD45 antibodies for the detection of human REH and mouse 
hematopoietic cells, respectively. Scatter plots represent examples from a non-injected control (NIC) 
and a transplanted animal with human leukemia (T).  
 
Figure 5a shows a Kaplan Meier plot indicating a significantly prolonged leukemia 
free survival of recipients of E/R-depleted cells. Light microscopy and flow cytometry 
confirmed the presence of human leukemia in the bone marrow (Figure 5b) and 
peripheral blood and the dissemination of leukemia cells into the spleen irrespective 
of E/R silencing in diseased animals (data not shown).  
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These results provide first evidence that E/R expression essentially governs the 
repopulation capacity of leukemic REH cells and may thus be a critical factor for 
leukemia persistence in patients. 
 
DISCUSSION 
In continuation of our previous work we investigated the long-term consequences of 
RNAi-mediated E/R fusion gene silencing [10]. For this purpose, we used a lentiviral 
shRNA transduction system and vectors targeting the fusion site in cell lines that are 
accepted models for the respective types of leukemia because of their similar 
molecular make-up [34].  We found that suppression of the E/R fusion gene with 
specific shRNAs ablates the respective chimeric protein, slows down proliferation, 
promotes apoptosis and consequently leads to a profound reduction of treated cells. 
Yet despite their propensity to undergo apoptosis, a significant proportion of E/R-
depleted cells still can survive and continue to grow in vitro at a low stable rate for 
many weeks. On the molecular level, E/R knockdown impedes the PI3K/AKT/mTOR 
signal pathway, which is aberrantly activated in E/R-positive childhood leukemias. Of 
particular practical and clinical relevance is the fact that an identical effect can also 
be achieved with pharmacological pathway inhibition in both systems. An 
indispensable role of the E/R fusion gene for cell survival and continuous cell 
replenishment is further corroborated by a diminished in vivo repopulation capacity of 
E/R-suppressed REH cells in a xenotransplant NOD/SCID mouse model. In case 
these mice develop leukemia at all within 27 weeks they did so significantly later than 
those receiving only mock treated cells.  
First preliminary evidence that experimental introduction of E/R fusion gene 
sequences into cells may activate their PI3K/AKT/mTOR signaling pathway originally 
derives from transfected BA/F3 cells (unpublished observation). Our E/R silencing 
experiments together with the analysis of published gene expression data confirm 
this finding, since we were able to prove that the aberrant activation of this particular 
pathway is a specific outcome of the E/R gene fusion and therefore exclusively 
confined to the affected type of B-cell precursor ALL also in the natural setting [16-
18, 35]. Conversely, the results of our experiments also preclude that any other type 
of genomic aberration, especially accompanying mutations of PI3K/AKT/mTOR 
pathway components, may be the cause of its constitutive activation [11]. As 
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evidenced by the drug resistance and poor outcome of some T-ALL cases with an 
activated PI3K/AKT/mTOR pathway, however, the extent of its activation as well as 
the ensuing biological effects are certainly also influenced by the particular cellular 
context in which they occur and are probably also modified by accompanying 
relevant mutations [14].  
Apart from E/R's specific influence on the PI3K/AKT/mTOR signaling cascade, it is 
conceivable that it also enhances some upstream signaling components, such as the 
receptors for erythropoietin (EPOR) and the stem cell factor (KIT), which may further 
augment subsequent pathway effects. In a recent paper, we already demonstrated 
that up-regulation of the EPOR concurs with a survival advantage of E/R-positive 
cells and PI3K/AKT pathway activation [20]. Whether KIT - based on its over-
expression in E/R-positive leukemias and differential regulation upon E/R knockdown 
(unpublished data) - also plays a similarly prominent role in E/R-positive leukemias 
as it does in acute myeloid leukemia, mastocytosis and gastro-intestinal stromal 
tumors, still remains to be shown. However, first preliminary evidence that this might 
indeed be the case was recently provided by the observation that at least RUNX1 
can regulate KIT [36, 37]. In consideration of the central position that the 
PI3K/AKT/mTOR signaling cascade occupies in many cellular tasks that are 
especially critical for neoplastic behaviour in general [11, 38], it is very likely that, as 
implied by the results of our experiments, its aberrant activation is not only essential 
for initiation but also for  the maintenance of E/R-positive leukemias. This assumption 
is further supported by the specific expression signature of E/R-positive leukemias, 
which also suggests the involvement of other PI3K/AKT/mTOR-regulated processes, 
including above all cell adhesion and DNA damage response [15, 39].  
Pharmacological inhibition of the aberrantly activated PI3K/AKT/mTOR pathway has 
emerged as one of the therapeutic options for overcoming drug resistance [13]. 
Although E/R-positive leukemias are in general highly treatment-sensitive at initial 
presentation, a substantial proportion of them apparently become drug-resistant 
when they relapse [2, 5, 40]. As a proof of principle, we show that in GC-resistant 
cells prednisolone sensitivity can be partially restored with PI3K/mTOR pathway 
inhibition. In line with similar problems that are encountered in T-ALL cases whose 
drug resistance results from activating mutations in particular PI3K/AKT/mTOR 
pathway components, we thus consider PI3K/mTOR inhibition as a potential, 
plausible and useful accessory therapeutic option for resistant E/R-positive ALL [14].  
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The significantly impaired repopulation capacity of E/R-silenced REH cells in a 
xenotransplant NOD/SCID mouse model - which renders them unable to reconstitute 
leukemia at all or at least only after a substantial delay - is also of utmost biological 
and clinical importance. These results again provide additional evidence that the E/R 
fusion gene is not only relevant for initiation but also essential for sustaining the 
leukemic process and that therefore, disease regression can be achieved through 
knockdown of its activity. The idea that products of tumor-initiating mutated genes are 
subsequently also required for the continuation and maintenance of the neoplastic 
process is not restricted to E/R-positive leukemias. Based on similar observations in 
several other tumors and tumor cell lines, which experience comparable proliferation 
holdups and the propensity to undergo apoptosis, this phenomenon has also been 
labeled as oncogene addiction [41]. In contrast to a recent report, which suggested 
that except for a modest increase in S phase fraction and higher proliferation rate E/R 
down-regulation has no other discernable effect on cell behavior or gene expression 
[42], all evidence presented herein implies otherwise and proves that E/R has to be 
added to the growing list of oncogenes that not only initiate but also nourish the 
leukemia [43-45].  
In conclusion, we have provided evidence herein that E/R expression is critical for the 
survival and propagation of the respective leukemia cells in vitro and in vivo. These 
findings have important biological and clinical implications. Based on what is known 
so far, the E/R gene fusion is the earliest and most specific alteration in this type of 
leukemia. Therefore, the fusion gene together with its products provides a 
tremendously interesting therapeutic target, because one need not pay attention to 
the extreme sub-clone variegation encountered in the E/R-positive cell pool [46]. The 
fact that key components of the PI3K/AKT/mTOR signaling pathway, which is under 
the control of the respective fusion gene, constitute already pharmaceutically 
accessible elements should therefore be further exploited experimentally.  
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3.2 Supplemental file 
Figure S1 depicts the binding regions of shRNA A1 and G1 on the E/R fusion 
transcript region. Table S1 lists genes being either involved in the PI3K/AKT/mTOR 
pathway or represent downstream effectors. Supplementary materials and methods 
describe technical aspects of gene expression analyses and functional gene 
annotation.  
 
 
 
 
 
 
Figure S1. Sequence of shRNA A1 and G1 targeting position within the fusion region. 
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Table S1. Regulatory effects of differentially expressed genes on the 
PI3K/AKT/mTOR pathway and/or its downstream effectors. 
Gene 
Symbol 
Gene name E/R KD1  E/R+ 
ALL2 
Regulatory 
Effect3 
AKT1 AKT1  0.09 -1.23 + 
AKT1S1 AKT1 substrate 1  0.12 ND - 
AKT2 AKT2  0.20 ND + 
AKT3 AKT3  0.26 -0.79 + 
BAD BCL2-associated agonist of cell death  0.11 -0.62 - 
CASP9 caspase 9, apoptosis-related cysteine 
peptidase 
 0.03 -1.13 - 
CDKN1A cyclin-dependent kinase inhibitor 1A  1.05 -0.67 - 
CDKN1B cyclin-dependent kinase inhibitor 1B  0.24 -0.86 - 
CHEK1 CHK1 checkpoint homolog  0.14 -0.85 - 
EIF4E eukaryotic translation initiation factor 4E  0.27  1.43 + 
EIF4EBP1 eukaryotic translation initiation factor 4E 
binding protein 1 
 0.30 -0.68 - 
FOXO1 forkhead box O1 -0.15 -0.05 - 
FOXO3 forkhead box O3  0.09  0.16 - 
GSK3B glycogen synthase kinase 3 beta  0.67 -2.00 - 
MDM2 Mdm2 p53 binding protein homolog -1.1  1.35 + 
PDK1 pyruvate dehydrogenase kinase, 
isozyme 1 
-0.29  0.72 + 
PTEN phosphatase and tensin homolog  0.02 -0.26 - 
RAF1 v-raf-1 murine leukemia viral oncogene 
homolog 1 
 0.00 -0.77 - 
RHEB Ras homolog enriched in brain -0.01  0.23 + 
RPS6KB1 ribosomal protein S6 kinase, 70kDa, 
polypeptide 1 
-0.26  0.67 + 
TSC1 tuberous sclerosis 1 -0.09 -0.48 - 
TSC2 tuberous sclerosis 2  0.14 -1.11 - 
 
Numbers indicate the log2-fold ratios. Of note, log2-fold transformation distributes up- and down-
regulated genes around zero.  
KD, Knockdown; ND, corresponding probe sets to KD not determined on microarrays used for E/R+ 
ALL. 
1E/R-KD vs. controls (mean of E/R silenced REH and AT2 cells).  
2E/R-positive vs. E/R-negative BCP ALL cases (E/R+ALL).  
3(+), activating and (-), inhibiting regulatory effect. 
 
SUPPLEMENTARY MATERIAL AND METHODS 
Gene expression analysis by microarray technology  
Changes in gene expression profiles upon knockdown of E/R were followed on 
Affymetrix HG-U133-PLUS2 arrays (Affymetrix, Inc., Santa Clara, CA). cRNA target 
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synthesis and GeneChip® processing were performed according to standard 
protocols (Affymetrix, Inc.). All further analyses were performed in R statistical 
environment using Bioconductor packages [1].  
Affymetrix CEL files for all experiments were normalized together using the gcrma 
logarithm [2]. For further analysis probe sets (ps) were called present or absent using 
the Bioconductor package “panp”, and ps were excluded which showed very low 
expression across all arrays (P > 0.02). Subsequently ps were excluded that did not 
pass a non-stringent variability cut-off across all arrays (standard deviation > 0.05). 
Thereby ps were excluded that did not show any variation across all experiments. 
Finally, for each gene one ps was selected for further analysis by the criterion of 
maximizing the expression variation across arrays and thereby the most informative 
ps was chosen for each gene. This procedure yielded a final number of 9498 ps that 
were used for all further analysis. 
Differentially expressed genes were determined using a moderated t-test in the R 
package “limma” [3]. All P-values were corrected for multiple testing using the 
“Benjamini-Hochberg” correction method. Significantly differentially expressed genes 
in the E/R knockdown vs. control experiments were determined by calculating ratios 
for each gene between the two conditions for each experiment separately, thus 
yielding five biological replicates of relative expression for each gene (REH n = 3, AT-
2 n = 2). Overall, relative gene expression was positively correlated with each other 
in all biological replicates. Then, for each gene, significance was determined using a 
weighted one-sample t-test against the null hypothesis of no expression change (µ = 
0). 
 
Functional annotation  
Gene set enrichment analysis was performed using the Java tool provided on the 
homepage of the BROAD institute (http://www.broadinstitute.org/gsea/index.jsp). The 
program was run in the ranked gene list mode with default parameters, where the 
input was the list of all genes from the array that passed initial filtering (see above) 
and their respective mean log2-fold change between the knockdown and control 
experiments. 
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ABSTRACT 
Background: ETV6/RUNX1 (E/R) (also known as TEL/AML1) is the most frequent 
gene fusion in childhood acute lymphoblastic leukemia (ALL) and also most likely the 
crucial factor for disease initiation; its role in leukemia propagation and maintenance, 
however, remains largely elusive. To address this issue we performed a shRNA-
mediated knock-down (KD) of the E/R fusion gene and investigated the ensuing 
consequences on genome-wide gene expression patterns and deducible regulatory 
functions in two E/R-positive leukemic cell lines. Findings: Microarray analyses 
identified 777 genes whose expression was substantially altered. Although 
approximately equal proportions were either up- (KD-UP) or down-regulated (KD-
DOWN), the effects on biological processes and pathways differed considerably. The 
E/R KD-UP set was significantly enriched for genes included in the "cell activation", 
"immune response", "apoptosis", "signal transduction" and "development and 
differentiation" categories, whereas in the E/R KD-DOWN set only the 
"PI3K/AKT/mTOR signaling" and "hematopoietic stem cells" categories became 
evident. Comparable expression signatures obtained from primary E/R-positive ALL 
samples underline the relevance of these pathways and molecular functions. We also 
validated six differentially expressed genes representing the categories "stem cell 
properties", "B-cell differentiation", "immune response", "cell adhesion" and "DNA 
damage" with RT-qPCR. Conclusion: Our analyses provide the first preliminary 
evidence that the continuous expression of the E/R fusion gene interferes with key 
regulatory functions that shape the biology of this leukemia subtype. E/R may thus 
indeed constitute the essential driving force for the propagation and maintenance of 
the leukemic process irrespective of potential consequences of associated secondary 
changes. Finally, these findings may also provide a valuable source of potentially 
attractive therapeutic targets. 
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INTRODUCTION 
The ETV6/RUNX1 (E/R) fusion gene (also known as TEL/AML1) is the hallmark of 
one of the most common genetic subtypes of B-cell precursor acute lymphoblastic 
leukemia (BCP ALL) in children [1, 2]. The fusion gene encodes a chimeric 
transcription factor that comprises the N-terminal portion of ETV6 and the almost 
entire RUNX1 protein and is thought to convert RUNX1 from a transcriptional 
modulator to a transcriptional repressor of RUNX1 target genes [3]. The current 
multistep model implies that this gene fusion occurs already during fetal development 
and constitutes the initiating - although not sufficient - event for neoplastic 
transformation [4, 5]. The idea that the ensuing gene product might perhaps also be 
relevant for maintenance of the malignant phenotype is derived from the results of 
recent experiments, which showed that RNAi-mediated silencing of the endogenous 
fusion gene reduces in vitro cell proliferation and cell survival as well as impairs the in 
vivo repopulation capacity of the treated cells [6] (Fuka et al. manuscript submitted).  
Microarray technologies made it possible to define the specific gene expression 
signatures of specific ALL subgroups, including those with an E/R fusion gene [7-12]. 
These diagnostically and clinically relevant molecular patterns derive from the 
comparison of a differentially expressed set of genes in a given type of leukemia 
relative to other subgroups included in such analyses. Since particular genetic 
subgroups can be clearly delineated and distinguished with this approach, it seems 
likely that primary underlying genetic defects, as for instance E/R, are the main 
determinants of the respective gene expression signature, although the 
transcriptional derangements will most likely also be modified to a certain extent by 
other factors, such as secondary genetic alterations. To investigate the specific 
impact of the chimeric E/R protein on overall gene expression, we knocked down the 
endogenous fusion gene in two leukemia cell lines utilizing fusion transcript specific 
short hairpin RNAs (shRNA) and compared the native and suppressed gene 
expression signatures. We also compared the E/R KD signature with that obtained 
from primary childhood ALL cases and validated the expression of selected target 
genes that represented various pathways or cellular functions, which were identified 
with this approach. 
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Defining target genes of E/R knockdown  
We silenced the endogenous fusion protein by lentiviral transduction of shRNA-
encoding vectors in the leukemia cell lines REH and AT-2. Detailed information on 
the experimental design is provided in the Supplemental Material and Methods 
section. Expression profiling was performed in cells that were selected for viral 
integration and stable fusion gene suppression (Figure S1). Differentially expressed 
genes were determined by microarray analyses using three and two biological 
replicates from independent knock-down (KD) experiments of the REH and AT-2 cell 
lines, respectively, as well as appropriate control cells that were transduced with a 
non-targeting shRNA vector (GEO, Accession numbers: will be provided during 
review).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Scatter plot of differential gene expression values upon E/R KD in two cell lines. Each 
dot represents the mean expression value (log2-fold change of E/R-repressed versus control cells) of 
three and two replicas, for REH and AT-2 cell lines, respectively. x-axis: REH cell line, y-axis: AT-2 cell 
line. Negative values indicate a decrease and positive values an increase in gene expression upon 
fusion gene KD. Green and red dots depict concordantly and significantly modulated genes in a joint 
analysis of both cell lines. 
 
Despite the dissimilar genetic background imposed by different secondary changes in 
the two cell lines there was a significant correlation of differential gene expression in 
both models (r = 0.31, P < 0.0001) (Figure 1). 
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Table 1. Top 50 regulated genes from microarray analysis upon E/R KD. 
Entrez 
Gene ID  Gene name Gene symbol 
E/R KD 
mean 
E/R KD 
REH 
E/R KD 
AT-2 
6689 Spi-B transcription factor  SPIB  2.60  1.61  3.59 
931 membrane-spanning 4-domains, subfamily A, member 1 MS4A1  2.58  1.83  3.32 
28755 T cell receptor alpha constant  TRAC  2.28  2.64  1.92 
197358 NLR family, CARD domain containing 3 NLRC3  2.13  1.59  2.67 
4852 neuropeptide Y NPY  2.11  1.54  2.68 
100132169 LOC100132169 LOC100132169  2.06  1.45  2.68 
7124 tumor necrosis factor TNF  1.91  1.47  2.35 
6696 secreted phosphoprotein 1 SPP1  1.86  1.46  2.27 
28514 delta-like 1 DLL1  1.80  1.70  1.89 
7168 tropomyosin 1 (alpha) TPM1  1.78  1.76  1.80 
3759 potassium inwardly-rectifying channel, subfamily J, member 2 KCNJ2  1.77  1.63  1.92 
1117 chitinase 3-like 2 CHI3L2  1.76  1.54  1.97 
9892 synaptosomal-associated protein, 91kDa SNAP91  1.72  2.32  1.13 
7940 leukocyte specific transcript 1 LST1  1.72  1.89  1.55 
3398 inhibitor of DNA binding 2 ID2  1.70  1.01  2.39 
131583 family with sequence similarity 43, member A FAM43A  1.63  0.53  2.73 
140706 chromosome 20 open reading frame 160 C20orf160  1.59  0.92  2.26 
971 CD72 molecule CD72  1.58  2.07  1.09 
54541 DNA-damage-inducible transcript 4  DDIT4  1.56  1.14  1.98 
4067 v-yes-1 Yamaguchi sarcoma viral related oncogene homolog LYN  1.56  0.94  2.19 
5790 protein tyrosine phosphatase, receptor type, C-associated protein PTPRCAP  1.56  1.07  2.04 
374403 TBC1 domain family, member 10C TBC1D10C  1.52  0.71  2.32 
7490 Wilms tumor 1 WT1  1.50  1.74  1.25 
54510 protocadherin 18 PCDH18  1.49  1.32  1.65 
8519 interferon induced transmembrane protein 1 IFITM1  1.46  1.96  0.96 
6275 S100 calcium binding protein A4 S100A4  1.45  1.02  1.88 
9639 Rho guanine nucleotide exchange factor 10 ARHGEF10  1.44  0.27  2.62 
4330 meningioma 1 MN1  1.41  0.98  1.85 
2014 epithelial membrane protein 3 EMP3  1.41  0.77  2.05 
10870 hematopoietic cell signal transducer HCST  1.41  0.76  2.06 
51523 CXXC finger 5 CXXC5  1.41  1.93  0.88 
170302 aristaless related homeobox ARX -1.42 -2.38 -0.46 
3983 actin binding LIM protein 1 ABLIM1 -1.45 -1.77 -1.13 
54549 sidekick homolog 2 SDK2 -1.48 -1.17 -1.79 
10579 transforming, acidic coiled-coil containing protein 2 TACC2 -1.50 -2.60 -0.40 
55107 anoctamin 1 ANO1 -1.52 -1.93 -1.10 
8842 prominin 1 PROM1 -1.56 -1.71 -1.40 
57556 semaphorin 6A SEMA6A -1.56 -1.55 -1.58 
9687 growth regulation by estrogen in breast cancer 1 GREB1 -1.59 -1.59 -1.59 
8642 dachsous 1 DCHS1 -1.60 -1.24 -1.97 
650 bone morphogenetic protein 2 BMP2 -1.63 -2.29 -0.98 
55303 GTPase, IMAP family member 4 GIMAP4 -1.64 -1.38 -1.89 
83698 calneuron 1  CALN1 -1.80 -1.45 -2.14 
147700 kinesin light chain 3 KLC3 -1.81 -1.93 -1.68 
5729 prostaglandin D2 receptor PTGDR -2.01 -1.18 -2.85 
5175 platelet endothelial cell adhesion molecule PECAM1 -2.04 -1.54 -2.54 
9619 ATP-binding cassette, sub-family G, member 1 ABCG1 -2.23 -2.50 -1.96 
5121 Purkinje cell protein 4 PCP4 -2.43 -0.70 -4.17 
8470 sorbin and SH3 domain containing 2 SORBS2 -2.47 -3.21 -1.73 
5142 phosphodiesterase 4D, cAMP-specific PDE4B -2.79 -3.27 -2.31 
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Depicted are genes found to be significantly de-regulated in the E/R knockdown. Columns 1-3: Gene 
identifiers; columns 4-6: log2-fold change values for the mean of AT-2 and REH (column 4), REH 
(column 5), AT-2 (column 6). 
 
A joint analysis identified 777 genes that were significantly (P < 0.05) and 
concordantly up- (KD-UP; n = 403) and down-regulated (KD-DOWN; n = 374) after 
the knockdown of the E/R fusion gene (Table S1). The top 50 regulated genes are 
listed in Table 1, along with the log2-fold changes from the array analysis. They 
include, for instance, the two direct RUNX1 targets ID2 and PTPRCAP. ID2 encodes 
a proposed inhibitor of tissue-specific gene expression and PTPRCAP is a key 
regulator of lymphocyte activation (Table S1) [13, 14]. Consistent with the notion that 
E/R acts as a constitutive repressor of RUNX1 target genes [3], these two genes are 
repressed in E/R-positive leukemias and up-regulated upon fusion gene KD. In 
contrast to our findings, Wotton et al. report that RUNX1-induced repression of ID2 is 
abrogated by E/R. This seemingly controversial result might possibly be explained by 
a context dependent gene regulation, since Wotton et al. used 3T3 murine fibroblast 
cells in their experiments. In line with our data, PTPRCAP transcription was found to 
be repressed by RUNX1-MTG8 and -MTG16 fusion genes, two RUNX1 fusions that 
are frequently found in acute myeloid leukemia [14]. Furthermore, the regulation of 
two other genes that are differentially expressed in E/R-positive ALL, also concords 
with our E/R KD results. CALN1, a brain-specific member of the calmodulin 
superfamily, is exclusively over-expressed [10], while MS4A1 (CD20), a regulator of 
B-cell activation and proliferation, appears repressed in E/R-positive ALL [15]. 
 
Functional annotation and pathway analysis of differentially expressed genes 
in the KD model  
To systematically assess the molecular functions that are modulated by E/R, we 
annotated all significantly regulated genes from the E/R KD experiments according to 
their regulation by the fusion gene. For this purpose, we used the “Database for 
Annotation, Visualization and Integrated Discovery“ (DAVID) [16] to classify gene lists 
into functionally related gene groups. The raw output from DAVID, derived from the 
analysis of up- and down-regulated genes (Table S2 and Table S3), was further 
parsed to work out more clearly the significance levels and affiliation to broader 
functional groups of annotation terms (Figure 2). First inspection of these functional 
annotations revealed a large discrepancy between E/R KD up- and down-regulated 
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genes (Figure 2; right and left panel, respectively). While up-regulated genes 
significantly associate with various cellular functions and pathways, the down-
regulated gene set, after correction for multiple testing, yielded no significant 
annotation term at all (the highest ranking term with P < 0.3 was the KEGG pathway 
04070:Phosphatidylinositol signaling system). These striking differences indicate that 
despite the similar number of up- and down-regulated genes only the KD-UP ones 
relate, to a high degree, to similar functions and were therefore enriched by the 
DAVID analysis. The KD-DOWN genes, on the other hand, do not cluster into 
common functions and therefore not a single term was found to be significant. Hence, 
the channeling of KD-UP genes to specific pathways suggests that E/R exerts its 
distinct and relevant gene de-regulation through repression of specific classes of 
target genes. Conversely, the general lack of such a KD-DOWN-related “pathway-
channeling” implies that the E/R-associated up-regulation of genes might be 
biologically far less relevant. Alternatively, KD-DOWN genes may encode signaling 
pathway components that are mostly regulated by posttranslational modifications, as 
is, for instance, the case in the phosphoinositide-3-kinase (PI3K)/AKT/mammalian 
target of rapamycin (mTOR) pathway. Considering that E/R probably acts as 
transcriptional repressor of RUNX1 target genes [3], we looked for RUNX1 
consensus motifs in the promoter region of the KD-UP genes, but did not find an 
enrichment of such motifs (data not shown). This observation suggests that also 
indirect late effects of gene regulation result either from an initial, or more likely, 
continuous E/R-mediated gene repression.  
Given their apparent biological relevance, we focused our further analysis on the 403 
KD-UP genes and their molecular functions as well as involvement in pathways. 
Based on the gene-level clustering, the top 100 annotation terms were manually 
curated into 14 functional meta-groups (Figure 3). Note that the name of the meta-
groups reflects only the most prominent annotation terms that are comprised in the 
respective meta-group. A list including all terms within the 14 meta-groups is shown 
in Table S2. Applying stringent statistical criteria (P < 0.05), only the meta-groups 
“cell activation”, “immune response”, “apoptosis”, “development and differentiation”, 
“GTPase regulation", and “protein phosphorylation and phosphate metabolism” were 
found to contain at least one significant annotation term (Figure 3A). The regulation 
of individual genes within the top six meta-groups upon E/R KD is shown in Figure 
3B. 
4. FIRST AUTHORSHIP PUBLICATION II 
 
 59 
 
Figure 2. Functional annotation clustering of differentially expressed genes upon E/R KD. 
Visualization of the similarity of functional annotations that were determined by DAVID for down- (left) 
and up-regulated (right) genes upon E/R KD. The 100 most significant terms (ranked by P-value) are 
shown for both sets of annotation terms. Significance levels of functional terms are indicated by a color 
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code shown at the bottom of the figure. Due to large differences in the range of P-values for the 
functional groups resulting from up- and down-regulated genes upon KD, a different color-scheme was 
used in each panel. 
 
The remaining groups (“cell proliferation”, “response to wounding”, “nucleic acid 
binding”, “DNA damage response”, “cell adhesion and migration”, “chemical 
homeostasis”, “RNA synthesis” and “enzyme binding”) contained no nominally 
significant annotation term.  
The DAVID pathway analysis was based on the overrepresentation of “significant 
genes” in certain gene sets and pathways. To assess the functional impact of 
differentially expressed genes from the E/R KD experiments independent of a 
specific P-value threshold, we performed gene set enrichment analysis (GSEA). This 
analysis resulted in many more up-regulated GO terms (147) from KD-UP than down-
regulated terms (13). Importantly, these GO terms largely mapped to the same meta-
groups identified in the DAVID analysis (Table S4).  
The same discrepancy (324 vs. 49 gene sets) held true for a large collection of > 
2.500 gene sets that were obtained from experimental data (“curated gene sets, C2” 
from MSigDB) (Table S5). The conclusions from the DAVID analysis were thus 
qualitatively confirmed by GSEA. Moreover, in the GSEA analysis the "Jaatinen 
hematopoietic stem cell UP" signature emerged as the most significantly down-
regulated gene set. This result may be an indicator for an intriguing new function of 
E/R, namely that it induces genes that are normally expressed in cord blood-derived 
hematopoietic stem cells [17]. To corroborate these findings, we supplemented our 
comparison with two other gene sets that were obtained from sorted CD34+/lineage-
negative versus CD34- normal bone marrow cells designated "Andersson-UP" and 
"Andersson-DOWN" (microarray data were kindly provided by Andersson et al [10]). 
In line with the above results, the "Andersson-UP" gene set also scored significantly 
in the GSEA analysis (Table S5). Combining the data from Jaatinen's and 
Andersson's gene sets, CALN1, PROM1, KIT and CDK6 were the most highly up-
regulated genes and they are similarly induced by E/R. With the exception of CALN1, 
whose function in the hematopoietic system is currently not known, all other genes 
are considered to be associated with hematopoietic stem or progenitor cells [18]. To 
the best of our knowledge, only one other group has previously analyzed the 
expression patterns of primary E/R-positive ALL cases and assigned them to GO 
categories [11]. 
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Figure 3. Meta-groups of functional annotations for up-regulated genes upon E/R KD. Meta-
groups were curated based on gene-clustering of annotation terms. A: Top 100 annotation terms from 
up-regulated genes, their P-values and their affiliation to meta-groups. Similarity of the meta-groups 
was based on the number of shared genes. For distance calculations between the meta-groups genes 
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from all contributing terms were taken together. B: Change in expression of individual genes in meta-
groups that contain significant annotation terms. The color code at the bottom of the figure indicates 
the extent of log2-fold changes in gene expression.  
 
Consistent with our data, they also observed a distinct association with the categories 
“cell differentiation”, “cell proliferation”, “apoptosis”, “cell motility” and “response to 
wounding”. Moreover, ectopic E/R expression in a 3T3 mouse cell line model induced 
the categories “adhesion” and “survival” [13]. 
 
Genes concordantly modulated by E/R KD in leukemia model cell lines and 
primary ALL  
Next we investigated to which extent gene expression changes that result from an 
E/R KD might also be reflected in a reciprocal fashion in primary ALL samples. For 
this purpose we used previously published data sets [8] that were generated by 
comparing expression profiles from E/R-positive with E/R-negative BCP ALL cases. 
The ensuing "E/R ALL signature" comprised 1.980 differentially regulated genes (P < 
0.05, moderated t-test), 1.008 of which were under- and 972 over-expressed in E/R-
positive ALL. Combining the data sets of both the E/R KD and primary ALL 
experiments, a total of 5.119 genes were represented on both microarray platforms 
and passed initial quality filters (Table S6). This gene set comprised approximately 
50% of genes from the E/R KD signature (n = 409; 175 KD-DOWN and 234 KD-UP). 
Taking into account the specific regulation of these genes in primary ALL, we 
identified a set of genes whose expression is inversely correlated in the KD and ALL 
signatures. This set comprises 66 of the 175 KD-DOWN and 71 of the 234 KD-UP 
genes and they account for approximately one third (137/409) of the E/R signature 
genes present in both data sets (Table S7). The top 50 regulated genes of this set 
are listed in Table 2. They are associated with the categories "cell activation" (TRIB, 
FYB, LYN and CD72), "immune response" (CXCR7, FAIM3, CD48, CD72, FKBP5), 
"development and differentiation" (SPIB, CD72, S100A4/13, PLP2), "cellular 
proliferation" (LGALS1, CXCR7, SOX11, E2F5, GAB1, CDKN1A, EMP3, LYN, 
DDIT4, CD72 and LGALS1), "cell survival" (DRAM1, MDM2, GAB1, INPP5D, FAIM3, 
CDKN1A, LGALS1, DDIT4, CD72), "proliferative signaling" (GIMAP4, RAC2, 
ARHGEF4, PSD4), "cell adhesion and/or migration" (DCHS1, CXCR7, PCDH, 
ITGA4, LGALS1, ITGB2, EMP3, S100A4, LYN) and "DNA damage response" 
(DRAM1, MDM2, CDKN1A, PSD4). 
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Table 2. Top 50 E/R regulated genes from microarray analysis of KD 
experiments and primary ALL. 
Entrez gene 
ID Gene name 
Gene 
symbol 
E/R KD 
mean 
E/R+ vs. 
E/R- ALL 
6689 Spi-B transcription factor SPIB  2.60 -1.83 
28755 T cell receptor alpha constant TRAC  2.28 -1.03 
971 CD72 molecule CD72  1.58 -0.80 
54541 DNA-damage-inducible transcript 4 DDIT4  1.56 -1.37 
4067 v-yes-1 Yamaguchi sarcoma viral related oncogene homolog LYN  1.56 -1.26 
6275 S100 calcium binding protein A4 S100A4  1.45 -1.80 
2014 epithelial membrane protein 3 EMP3  1.41 -0.88 
3689 integrin, beta 2 ITGB2  1.31 -1.35 
23550 pleckstrin and Sec7 domain containing 4 PSD4  1.30 -0.35 
26112 coiled-coil domain containing 69 CCDC69  1.25 -1.50 
3956 lectin, galactoside-binding, soluble, 1 LGALS1  1.11 -2.00 
64777 required for meiotic nuclear division 5 homolog B RMND5B  1.06 -0.21 
1026 cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A  1.05 -0.56 
51063 calcium homeostasis modulator 2 CALHM2  0.99 -1.09 
9404 leupaxin LPXN  0.95 -1.55 
5355 proteolipid protein 2 PLP2  0.90 -1.47 
2289 FK506 binding protein 5 FKBP5  0.89 -0.95 
962 CD48 molecule CD48  0.89 -0.81 
55501 carbohydrate (chondroitin 4) sulfotransferase 12 CHST12  0.86 -0.72 
9679 family with sequence similarity 53, member B FAM53B  0.86 -1.07 
10437 interferon, gamma-inducible protein 30 IFI30  0.85 -0.55 
3676 integrin, alpha 4 ITGA4  0.83 -1.08 
5880 ras-related C3 botulinum toxin substrate 2 RAC2  0.82 -0.53 
6284 S100 calcium binding protein A13 S100A13  0.81 -0.75 
272 adenosine monophosphate deaminase 3 AMPD3  0.80 -0.34 
9331 beta 1,4- galactosyltransferase, polypeptide 6 B4GALT6 -0.72  1.68 
10656 KH domain containing, RNA binding, signal transduction 
associated 3 KHDRBS3 -0.75  2.04 
5101 protocadherin 9 PCDH9 -0.77  1.68 
1875 E2F transcription factor 5 E2F5 -0.81  0.68 
50649 Rho guanine nucleotide exchange factor 4 ARHGEF4 -0.81  3.32 
9214 Fas apoptotic inhibitory molecule 3 FAIM3 -0.84  0.74 
6664 SRY (sex determining region Y)-box 11 SOX11 -0.84  2.39 
10402 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 ST3GAL6 -0.87  0.74 
26011 odz, odd Oz/ten-m homolog 4 ODZ4 -0.88  0.49 
57007 chemokine (C-X-C motif) receptor 7 CXCR7 -0.91  1.19 
2533 FYN binding protein FYB -0.91  2.48 
8349 histone cluster 2, H2be HIST2H2BE -0.91  0.94 
5095 propionyl CoA carboxylase, alpha polypeptide PCCA -0.94  1.38 
3635 inositol polyphosphate-5-phosphatase INPP5D -1.03  0.37 
2549 GRB2 associated binding protein 1 GAB1 -1.05  1.23 
54847 SID1 transmembrane family, member 1 SIDT1 -1.06  0.92 
10221 tribbles homolog 1 TRIB1 -1.09  1.11 
4193 mouse double minute 2 MDM2 -1.11  0.56 
55332 DNA-damage regulated autophagy modulator 1 DRAM1 -1.16  2.28 
950 scavenger receptor class B, member 2 SCARB2 -1.21  0.46 
57556 semaphorin 6A SEMA6A -1.56  1.95 
8642 dachsous 1 DCHS1 -1.60  1.18 
650 bone morphogenetic protein 2 BMP2 -1.63  1.53 
55303 GTPase, IMAP family member 4 GIMAP4 -1.64  1.14 
5142 phosphodiesterase 4D, cAMP-specific PDE4B -2.79  0.78 
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Depicted are genes found to be significantly and concordantly de-regulated by E/R in KD experiments and E/R-positive vs. E/R-
negative primary BCP ALL from Ross et al. (2003). Columns 1-3: Gene identifiers; columns 4-5: log2-fold change values for the 
mean of AT-2 and REH (column 4) and E/R-positive vs. E/R-negative primary BCP ALL (column 5). 
 
The above pathways and functions match almost perfectly with those identified in the 
KD model, which underscores their specific relevance for E/R-positive leukemia.  
Two thirds (272/409) of the E/R KD signature genes that concurred with the ALL data 
set were not specific for E/R-positive ALL, but were also evident in the other 
subgroups. This observation evokes two, not mutually exclusive explanations, 
namely that these genes are either de-regulated in a similar fashion in a variety of 
ALL subtypes or that they represent a kind of basic but essential "BCP-ALL 
housekeeping gene set". The notion that other initiating genetic events can elicit a 
similar gene de-regulation effect as E/R is, for instance, supported by the fact that 
PROM1 is also up-regulated in MLL-rearranged and high-hyperdiploid ALL cases, 
thereby counterbalancing its low expression in other ALL subtypes. Consequently, 
PROM1 de-regulation was not considered as being a specific feature of E/R-positive 
ALL (data not shown). 
 
Validation of selected E/R target genes by RT-qPCR 
We validated the differential expression of several selected candidate genes 
contained in the KD signature, which were previously either not associated with E/R-
positive ALL (PROM1, PECAM1, IFITM1; Figure 4A) or concordantly regulated in 
both systems (SPIB, MDM2 and DDIT4; Figure 4B). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Validation of selected differentially expressed genes from the KD experiments by RT-
qPCR. Quantification of transcripts of differentially expressed genes. A: Concordantly de-regulated by 
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E/R in the KD and primary leukemias. B: Only regulated in the KD experiments. Boxes cover the 
median and the interquartile range (25-75th percentiles) and whiskers the minimum and maximum 
values. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 (paired t-test). 
 
These genes were chosen because of their potential biological relevance, since they 
play an important role in the context of stemness and differentiation, adhesion and 
migration, immune response, DNA damage response as well as apoptosis. Notably, 
their differential expression in the context of E/R is novel. Quantification results of 
these transcripts in both cell lines from independent KD experiments concurred with 
those of the microarray experiments (Figure 4). 
 
Functions of selected E/R regulated genes and potential implications for 
leukemia pathogenesis 
Given that GSEA analysis of E/R KD regulated genes highlighted gene sets that are 
also up-regulated in hematopoietic stem cells, we chose PROM1 (CD133) as the 
most prominent and attractive candidate from this set. PROM1 is implicated in 
maintaining stem cell properties by suppressing differentiation and has recently 
gained much attention as a marker of tumor-initiating cells in a variety of human 
cancers [19]. The fact that E/R might regulate the expression of this gene is new and 
intriguing and provides additional arguments to the ongoing debate dealing with the 
structural hierarchy of ALL and its potential replenishment from rare leukemic stem 
cells [20]. In favor of this notion is a recent observation, which indicates that primitive 
leukemia-initiating cells with long-term in vitro and in vivo proliferation capabilities are 
exclusively found in the CD133+CD19-CD38- cell compartment [21]. However, this 
observation is in contrast to the scenario proposed by le Viseur et al., which suggests 
that the vast majority of ALL blasts may maintain the propensity to reconstitute 
leukemia in vivo [22]. The ER-induced "stemness" expression signature, represented 
for instance by PROM1 and the stem cell factor ligand KIT in our model, therefore 
supports the later view.  
The E/R-induced overexpression of stem cell markers in the respective leukemias 
can either be interpreted as a residual relict of a transformed primitive stem cell or, 
more likely, as the reflection of a continuously active stem cell program [23]. Although 
neither possibility excludes that the gene fusion process already occurs in a primitive 
hematopoietic stem cell [24], the latter requires that inappropriate stemness genes 
remain active or become perhaps reactivated at the level of maturation in which the 
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bulk of the leukemic cells is arrested. This interpretation is supported by the fact that - 
similar to the Andersson data - E/R-positive leukemias cluster best with normal large 
pre-B II cells even after suppression of the fusion gene (data not shown) [10, 25]. It is 
thus tempting to speculate that up-regulation of PROM1 may play a critical role in 
E/R-positive ALL. This possibility is also relevant for our recent finding that the E/R 
fusion gene is apparently required for the in vivo propagation of the respective cells 
(Fuka et al. manuscript submitted). 
PECAM1 (CD31) encodes a homophilic adhesion receptor that mediates adhesion 
between endothelial cells and leukocytes and could therefore probably influence 
adhesion and migration of leukemic cells across the micro-vascular endothelium in 
various niches [26]. Since it is also contained in Andersson's CD34+ stem cell 
signature, we envision that its over-expression also contributes to the stem cell 
properties of E/R-positive ALL. 
In contrast to the up-regulation of stem cell signature genes, genes encoding B 
lineage differentiation markers are frequently repressed in BCP-ALL. Thus, it is not 
surprising that SPIB, a B-lymphoid restricted transcription factor, is one of the genes 
that is strongly suppressed by E/R. Being directly induced by paired box 5 (PAX5), 
the master regulator of B-lineage commitment, SPIB is a key player in B-cell 
development and B-cell receptor signaling [27]. This SPIB down-regulation could thus 
contribute to the impaired B-cell differentiation in E/R-positive ALL.  
The E/R-associated down-regulation of IFITM1, a transcriptional target of interferon 
gamma (IFNγ) [28], fits also well into one particular point of the current concept of 
childhood ALL etiology, namely the one which suggests that certain forms of 
childhood ALL may be the unfortunate consequence of an abnormal immune 
response to common infections [29]. The proposed mechanism implies that 
inflammatory cytokines suppress the growth of normal hematopoietic cells, whereas 
they do not exert such an effect on, for instance, E/R-expressing cells. Consequently, 
fusion gene carrying cells may experience a relative growth advantage. In support of 
this notion it was recently shown that E/R-expressing cells are more resistant to the 
anti-proliferative effects of transforming growth factor (TGF)β [30]. Since TFGβ and 
INFγ are both key modulators of the immune system, one expects that the 
suppression of IFITM1 either concurs with or even augments these effects in 
response to an interferon release during common infections. In line with the proposed 
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function of TGFβ, the suppression of IFITM1 may thus additionally fuel the expansion 
of an E/R-expressing leukemic clone [5]. 
Taking into account further mechanisms that might impair an INFγ associated 
inhibition of proliferation, it is noteworthy that CDKN1A is induced via the tumor 
suppressor protein p53 pathway activation and leads to a G1 cell cycle arrest [31]. 
The attenuation of the p53 activity together with the transcriptional repression of its 
direct target p21, the gene product of CDKN1A, either by E/R-mediated repression of 
IFITM1 or up-regulation of the p53 inhibitor MDM2, as implied in our KD model, 
opens another fascinating layer of complexity to the E/R-mediated gene regulation 
process. Given that p53 acts as a gatekeeper of genome integrity [32], p53 down-
regulation by any of the above outlined means may thus favor leukemia 
development. Intriguingly, MDM2 is induced by RUNX1-RUNX1T1 and may therefore 
be involved in the route of transformation in a similar fashion in other RUNX1-
associated leukemias, as for instance the E/R-positive ones [33]. Furthermore, 
MDM2 may also promote tumorigenesis via a p53 independent mechanism [34]. 
Such findings are not only crucial for our understanding of leukemia development per 
se, but may be particularly helpful for the identification of especially relevant targets 
for tailored future therapies.  
Another E/R-down-regulated gene that is involved in the p53 pathway is DDIT4 (also 
known as REDD1). It is primarily induced by stress and negatively regulates the 
mTOR pathway. DDIT4 is activated by DNA damage via p53-dependent and -
independent mechanisms, but also by hypoxia or energy stress [35]. Particularly this 
latter feature is interesting in the context of E/R-positive leukemia, because the 
majority of affected children are anemic at diagnosis, which seemingly grants hypoxic 
conditions a central role in their pathogenesis [36]. Noteworthy, E/R-associated 
DDIT4 suppression may further contribute to the observed PI3K/AKT/mTOR pathway 
activation and an improved cell survival [37]. Whether this suppression is a direct 
p53-related consequence that, as recently observed in breast cancer, also leads to 
hypoxia inducible factor (HIF)1α accumulation, is currently not known [38]. 
Taken together, the above clues reinforce the essential role that E/R plays in the 
entire process of leukemia development and maintenance: i) It induces genes that 
confer stem cell properties endowing cells with unlimited self renewal capability and 
simultaneously represses genes that otherwise promote differentiation; ii) it alters the 
DNA damage response by attenuating the p53 pathway, which in addition enables 
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the survival and clonal expansion of cells with accumulating secondary genetic 
changes; iii) it triggers proliferation and cellular growth via PI3K/AKT/mTOR pathway 
activation, which in turn adapts extracellular signaling as well as stress and hypoxia 
response accordingly; iv) it also attenuates the response to inflammatory signals. All 
these features, sustaining proliferative signaling, evading growth suppression, 
resisting cell death, and induced genome instability, are typical and well established 
hallmarks of cancer in general [39]. 
Based on the analyses of our KD model, we have established a functional map of the 
consequences of E/R expression in an endogenous background. The modulation of 
various specific and more general key processes that are pivotal for leukemia 
pathogenesis was thus highlighted. These processes include "development and 
differentiation", "apoptosis", "adhesion and migration" as well as "DNA damage 
response". Finally, these data provide also a valuable source of interesting targets 
and pathways whose functional validation will provide further insights into the biology 
of E/R-positive leukemia and possibly also promote the identification of novel targets 
for treatment.  
 
MATERIAL AND METHODS 
Quantitative RT-PCR (RT-qPCR) 
Total RNA was isolated from biological replicates of E/R-silenced REH (n = 3) and 
AT-2 (n = 3) cells obtained from independent KD experiments by Trizol reagent (Life 
Technologies, Carlsbad, CA). cDNA was synthesized by SuperScript II Reverse 
Transcriptase according to the manufacturer's recommendations (Invitrogen, 
Carlsbad, CA). Transcripts were quantified by TaqMan RT-qPCR using the ABI Prism 
7900 Detection System (Applied Biosystems, Foster City, CA). The following 
primer/probe combinations were used: SPIB 5'-GGGCCACACTTCAGCTGTCT-3', 5'-
CAGTCCAGTCCCACAGGGAG-3', 5'-CCTGGACAGCTGCAAGCATTCCA-3'; MDM2 
5'-CACGCCACTTTTTCTCTGCT-3', 5'-CCTGATCCAACCAATCACCT-3', 5'-
CCACCTCACAGATTCCAGCTTCGG-3'; DDIT4 5'-CTGGACAGCAGCAACAGTG-3', 
5'-CATCAGGTTGGCACACAAGT-3', 5'-CCGGAGGAAGACACGGCTTA-3; PROM1 
5'-TTGTGGCAAATCACCAGGTA-3', 5'-TCAGATCTGTGAACGCCTTG-3', 5'-
CCCGGATCAAAAGGAGTCGGA-3'; PECAM1 5'-AGGTGTTGGTGGAAGGAGTG-3', 
5'GTGTATTGGGGCCTTTTCCT-3', 5'-AGGCCATCCAAGGTGGGATCGT-3' and 
IFITM1 5'-GGCTTCATAGCATTCGCCTA-3', 5'-ATGAGGATGCCCAGAATCAG-3', 
4. FIRST AUTHORSHIP PUBLICATION II 
 
 69 
5' TCCACCGCCAAGTGCCTGAA-3'. GUS was detected by a previously published 
primer/probe combination [40] and used as endogenous reference. Shown are cycle 
threshold ∆(CT) values. 
 
Gene expression analysis by microarray technology 
Gene expression changes upon knockdown of E/R were followed on Affymetrix HG-
U133-PLUS2 arrays (Affymetrix, Inc., Santa Clara, CA). cRNA target synthesis and 
GeneChip® processing were performed according to standard protocols (Affymetrix, 
Inc., Santa Clara, CA). Microarray data were performed in compliance to MIAME 
guidelines and submitted to GEO - accession numbers will be provided during 
review. All further analyses were performed in R statistical environment using 
Bioconductor packages [41]. 
Affymetrix CEL files were preprocessed as described previously [42], yielding a final 
number of 9.498 probesets that were used for all further analyses. 
Differentially expressed genes were determined using a moderated t-test in the R 
package “limma” [43]. All P-values were corrected for multiple testing using the 
“Benjamini-Hochberg” correction method. Significantly changing genes in the E/R KD 
vs. control experiments were determined by calculating ratios for each gene between 
the two conditions for each experiment separately, thus yielding five biological 
replicates of relative expression for each gene (REH, n = 3; AT2, n = 2). Then, for 
each gene, significance was determined using a weighted one-sample t-test against 
the null hypothesis of no expression change (µ = 0). 
For the re-analysis of the Ross data set, CEL files were downloaded from the St. 
Jude's data server and microarray data was pre-processed as described previously 
[42], generating a data set of 12.068 genes. To test E/R-positive vs. E/R-negative 
BCP ALL samples, a moderated t-test (Bioconductor package. “limma”) was 
performed. All P-values were corrected by the Benjamini-Hochberg method. 
 
Functional annotation  
The “Database for Annotation, Visualization and Integrated Discovery“ (DAVID) was 
used to annotate the 403 up- and 374 down-regulated genes from the joint analysis 
of the E/R knockdown in REH and AT-2 cells. The “Functional Annotation Tool” in the 
online version of DAVID was run (http://david.abcc.ncifcrf.gov/) using the default 
parameters and focusing on the categories Gene Ontology-Molecular Function, 
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Gene-Ontology-Biological Process and KEGG/Biocarta Pathways. All annotation 
terms that met the inclusion criteria were downloaded as “Functional Charts”. 
 
Hierarchical clustering of annotation terms 
For further analysis and visualization of the similarity among annotation terms, the 
functional charts were first sorted by their P-value (corrected for multiple testing by 
the Benjamini-Hochberg method) and then, to determine the relationships of the top 
100 annotation terms, similarity between all terms was measured by the number of 
their shared genes (gDist as described in Kauer et al. 2009) [42].  The matrix of pair 
wise gDist values (as dissimilarities: 1-gDist) for the 100 most significant terms was 
used as input for hierarchical clustering using the R function “hclust” in combination 
with the “average linkage” algorithm. Finally, the similarity among the annotation 
terms was visualized as dendrogram in combination with a heatmap indicating 
significance levels of the clustered terms. Names of meta-groups were chosen or 
modified from upstream gene ontology terms (http://www.geneontology.org/).  
 
Gene set enrichment 
To define functional categories of de-regulated genes independent of a P-value cutoff 
for “significant genes”, we performed gene set enrichment analysis (GSEA) using the 
“pGSEA” package in the Bioconductor/R environment [44-46]. Gene-wise log2 
expression ratios (logFC) of knockdown versus control for the cell lines REH and AT-
2, and for the mean of their logFCs, were used as input for pGSEA. Gene sets were 
downloaded from the MSigDB v3.0 (http://www.broad.mit.edu/gsea/msigdb/ 
Cambridge, USA). We tested two different gene set collections available from 
MSigDB: curated gene sets from canonical pathways and experimental data (C2) and 
GO terms (C5). To validate the enrichment on genes involved in hematopoietic stem 
cells, we added two more gene sets to the C2 group: genes up- and down-regulated 
in the Andersson et al. 2005 data set (CD34+/lineage negative vs. CD34- 
hematopietic cells) [10].  
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4.2 Supplemental file 
SUPPLEMENTARY MATERIAL AND METHODS 
Cell lines 
The E/R-positive BCP leukemia cell lines REH (DSMZ, Braunschweig, Germany) and 
AT-2 [1] (kindly provided by J.D. Rowley, University of Chicago, IL) were both 
established from relapsed leukemia. Cells were cultured in RPMI 1640 medium with 
Glutamax (Invitrogen, Carlsbad, CA), supplemented with 10% heat-inactivated FCS, 
100 IU/mL penicillin and 100 µg/mL streptomycin (all PAA Laboratories, Pasching, 
Austria) and kept in humidified incubators at 37° C  and 5% CO2. 
 
RNA interference 
shRNA G1 (5'-CACCGGGAGAATAGCAGAATGCATCGAAATGCATTCTGCTATTCT 
CCC-3') is directed against the fusion region of E/R and was newly designed to 
repress the endogenous fusion protein REH and AT-2 cells. The non-targeting 
shRNA LacZ (Invitrogen, Carlsbad, CA) was used as a control. Lentiviral 
supernatants were produced with the Block iT Lentiviral RNAi Expression System 
(Invitrogen), followed by quantification of lentiviral titers by ELISA-based 
quantification of virus associated HIV-1 p24 (Cell Biolabs, San Diego, CA) according 
to the manufacturer’s recommendations. Leukemia cell lines were transduced and 
selected for lentiviral integration with 5 µg/ml blasticidin for two weeks.  
 
Immunoblotting  
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Cell lysates were obtained with RIPA buffer supplemented with 1mM NaVO4 and 1% 
protease inhibitor cocktail (Roche, Basel, Switzerland) and 90 µg of total proteins 
were resolved by 12% SDS PAGE gel electrophoresis and transferred to 
nitrocellulose membranes (Whatman, Kent, UK). Non-specific binding on the 
membranes was blocked with PBS containing 5% dry milk. Membranes were 
incubated with anti-ETV6 (SB89, kindly provided by P. Marynen, VIB, Leuven, 
Belgium), anti-RUNX1 (Active Motif, Carlsbad, CA) and anti-GAPDH (6C5, Santa 
Cruz Biotechnology, Santa Cruz, CA) and secondary infrared dye-labeled antibodies 
(LI-COR Biosciences, Lincoln, NE). Membranes were scanned with Odyssey Infrared 
Imaging System (LI-COR Biosciences). Intensities of bands corresponding to E/R 
and RUNX1 were normalized to the signal of GAPDH. 
 
SUPPLEMENTARY FIGURES 
 
 
 
 
 
 
 
 
 
 
Figure S1. shRNA mediated silencing of E/R leads to chimeric protein depletion. The E/R-
positive leukemia cell lines REH and AT-2 were transduced by lentiviral constructs encoding either 
non-targeting shRNA (control) or shRNA G1 (G1), targeting the E/R fusion transcript region. Protein 
levels of E/R (A) and RUNX1 (B) were detected by immunoblotting using anti-ETV6 and anti-RUNX1 
antibodies, respectively. GAPDH was used to ensure equal loading. Numbers between bands 
represent the ratio between tested proteins and GAPDH quantification. Shown is one of at least three 
independent E/R knockdown experiments per cell line. 
 
SUPPLEMENTARY TABLES* 
Table S1. Genes found to be significantly de-regulated on Affymetrix HGU-133-
PLUS2 arrays from E/R knockdown experiments. Columns1-3: Gene identifiers; 
                                                 
*
 Due to extensive size of excel sheets, supplementary tables are only available online upon manuscript acceptance. 
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columns 4-6: log2-fold change values (mean of AT-2 and REH) (column 4), REH 
(column 5), AT-2 (column 6); column 7: P-value for the mean log2-fold changes of 
the E/R KD (from column 4) corrected by the Benjamini-Hochberg method. 
 
Table S2. Output from the DAVID analysis (version 6.7) for significantly UP-
regulated genes upon E/R knockdown. The Categories “GO-Molecular Function”, 
“GO-Biological Process” and “Pathways” were selected for testing. Description of 
columns: “Category” – categories from DAVID; “Term” – specific terms within DAVID-
categories; “Metagroup” – affiliation of “Term” into a metagroup, “Gene symbols” – 
genes from the tested gene list involved in “Term”; “Fold enrichment” – enrichment of 
genes involved in “Term” over random expectation;” P-value” – P-values for 
enrichment calculated by the EASE method used in DAVID; “Benjamini” – P-values 
corrected for multiple testing by the Benjamini Hochberg method. For details of the 
calculations: http://www.nature.com/nprot/journal/v4/n1/pdf/nprot.2008.211.pdf. 
 
Table S3. Output from the DAVID analysis (version 6.7) for significantly DOWN-
regulated genes upon E/R knockdown. Column descriptions as for Table S2. 
 
Table S4. Results from the GSEA analysis for GO gene sets (MSigDB: C5). 
Column 1: name of the MSIGDb gene set; columns 2-4: z-scores of from the pGSEA 
algorithm; columns 5-7: P-values from the pGSEA algorithm; column 8: genes 
involved in gene set; columns 9-12: descriptions of MSigDB gene set from MSigDB. 
 
Table S5. Results from the GSEA analysis for “curated gene sets” from 
MSigDB (C2). Column descriptions as for Table S4. 
 
Table S6. All 5119 probe sets that passed quality filters that were present on 
both, the HGU-133-PLUS2 arrays from our E/R knockdown experiments and 
E/R-positive vs. E/R-negative primary BCP ALL (from Ross et al. 2003; HGU-
133-A arrays). Columns1, 2: Gene symbol (column 1) and Probe set (column 2) 
identifiers; columns 3, 4: log2-fold change values (column 3) and P-values (column 4) 
for the mean value of the E/R KD; column 5, 6: log2-fold change values (column 5) 
and P-values (column 6) for E/R-positive vs. E/R-negative primary BCP ALL. Mean 
log2-fold change and P-values were calculated as described in the M&M section. 
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Table S7 Overlap of significantly de-regulated genes from the E/R KD signature 
and E/R-positive vs. E/R-negative primary BCP ALL (from Ross et al. 2003). The 
subset of 137 genes from Table S4 with P < 0.05 for both, the mean from E/R 
knockdown vs. control and E/R-positive vs. E/R-negative primary BCP ALL. Column 
1, 2 descriptions as for Table S1 and column 3-6 descriptions as for Table S6. 
 
REFERENCES 
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expression of TCL1 during pre-B-cell acute lymphoblastic leukemia 
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5. DISCUSSION 
This PhD thesis describes the consequences of RNAi-mediated endogenous E/R 
fusion gene suppression on the leukemic phenotype, cell signaling pathways and the 
expression signature of t(12;21) positive leukemia.  
Specific shRNAs directed against endogenous E/R slowed down cell proliferation and 
enhanced the apoptosis rate in leukemic cell lines. E/R KD also impaired the 
repopulation capacity, since leukemia outgrowth in a murine xenotransplant model 
was either absent or delayed. Importantly, these effects were accompanied by a 
concurrent inactivation in PI3K/AKT/mTOR signaling. Similarly, pharmacological 
PI3K/AKT/mTOR pathway inhibition in E/R-positive cell lines and primary leukemic 
cells induced apoptosis and also sensitized resistant cells to prednisolone. Genome-
wide gene expression studies upon E/R silencing of REH and AT-2 cells identified a 
significant de-regulation of 777 genes. Gene annotation by DAVID and GSEA 
revealed an enrichment of several terms for the E/R KD up-regulated genes that 
were further clustered into the metagroups “cell activation”, “immune response”, 
“apoptosis”, “protein phosphorylation and phosphate metabolism” and “development 
and differentiation”. By contrast, E/R KD down-regulated genes affected only a few 
terms associated with “phosphatidylinositol signaling” and “stem cell signatures”. We 
validated the E/R KD signature by comparison with the E/R expression signature 
from published primary childhood ALL cases and finally by RT-qPCR of genes 
representative of various pathways or cellular functions. 
 
In a previous study, we used siRNA to suppress endogenous E/R in one leukemic 
cell line (Diakos, Krapf et al. 2007). However, with such an approach, suppression of 
the fusion protein has been of transient nature since siRNA is usually rapidly 
degraded and diluted with cell division. To evaluate long term effects of endogenous 
E/R suppression, we decided to use lentivirally delivered shRNA for this study. 
Even though endogenous shRNA expression has tremendous potential, it also 
possesses some intrinsic risks that should be considered. For instance, similar to the 
externally introduced synthetic siRNA, endogenous expression of siRNAs can lead to 
an activation of the innate immune system as a consequence of an interferon 
response (Hornung, Guenthner-Biller et al. 2005). Furthermore, both siRNA and 
shRNA molecules can induce off-target effects. However, off-target effects can be 
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minimized by proper shRNA design and appropriate controls (Manjunath, Wu et al. 
2009). It should also be noted that shRNAs partially share the machinery used for 
generation and export of other non-coding RNAs such as cellular miRNAs. Excessive 
shRNA synthesis could therefore lead to competitive effects. 
In order to achieve efficient shRNA transfer into E/R-positive cell lines, which are 
generally difficult to transfect, we established a lentiviral delivery system. Lentiviruses 
are regularly used for shRNA expression and have proven effective in transducing 
dividing and non-dividing cells in a variety of organs. Importantly, the viral DNA gets 
incorporated in the host genome and induces long-term transgene expression 
(Wiznerowicz and Trono 2005). The constructs being commonly used are usually 
non-replicating and generate a virus that, after a single round of infection, ensures 
stable integration of the shRNA with only a minimal component of the viral genome. 
Consistently, following selection for transduced cells with the antibiotic blasticidin, we 
achieved a stable E/R knockdown. We decided to use HIV-based vectors since, due 
to the extensive characterization of the basic biology of HIV replication, their design 
has been steadily improved in the past (Cockrell and Kafri 2007).  
  
Stable E/R suppression opened the possibility to evaluate the consequences of 
fusion protein depletion in vivo. These experiments revealed a severely delayed or 
even absent repopulation capacity of E/R repressed leukemic cell lines upon 
transplantation, suggesting a reversion of neoplastic nature due to oncogene 
depletion. Apparently, leukemic cells remain dependent on E/R expression. However, 
this observation is not restricted to t(12;21) leukemia. To date there is an extensive 
list of other tumors as well as tumor cell lines which display comparable alterations in 
cell proliferation, propensity to undergo apoptosis and impairment of repopulation 
capacity. In hematological malignancies, essential roles have been described for the 
fusion proteins BCR/ABL, MLL/AF4 in ALL and MLL/ENL in AML, since targeting 
these molecules was effective to eradicate overt disease (Thomas, Gessner et al. 
2005; Kharas, Janes et al. 2008; Horton, Walf-Vorderwulbecke et al. 2009). 
Weinstein et al defined the phenomenon that a cell becomes dependent on a 
mutated gene, representing an early or initiating event during the cell transformation 
process, by the term oncogene addiction (Weinstein 2002). This suggests that 
oncogenes induce a distinct and complex signaling state that, following oncogene 
inhibition, results in synthetic lethality. From this point of view, our data suggests that 
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the E/R fusion protein should be added to the growing list of oncogenes that not only 
initiate but also play an important role in leukemia maintenance.  
 
We also applied gene expression profiling to characterize the impact of E/R on gene 
expression in t(12;21) positive leukemias. This technique has been used extensively 
in biological research in the past decade and has contributed to significant advances 
in the understanding of the molecular mechanisms of complex diseases including 
hematological malignancies. However, application of this technique has certain risks 
and limitations that should be considered (Kim, Zakharkin et al. 2010). First of all, one 
should keep in mind that biological systems are dynamic and constantly changing 
and microarray experiments present only snapshots of a biological system at a given 
time point. Since biological variations were shown to be the greatest source of 
experimental variation (Zakharkin, Kyoungmi et al. 2005), we decided to perform 
microarray analyses from several replicates obtained from different time points after 
lentiviral shRNAs transduction in different cell lines and transduction experiments. 
Importantly, the rates of synthesis and degradation for different mRNAs also vary. 
Certain mRNAs are synthesized more slowly than others but are more stable and 
accumulate at higher levels. By contrast, some mRNAs are degraded rapidly, leading 
to an inability to detect them (Cheadle, Fan et al. 2005). For these reasons, we aimed 
to keep activities of RNases low and kept samples during RNA isolation and 
processing steps, prior to gene expression analyses, on ice.  
We also considered published gene expression data following proposed guidelines 
concerning the performance of microarray experiments in leukemia (Staal, Cario et 
al. 2006) for validation of the E/R KD. For instance, these guidelines propose 
purification of leukemic cells (when tumor loads are less than 90%), especially when 
signaling pathways are analyzed. However, data comparison turned out to be 
demanding, since most studies were performed with primary ALL blasts and for 
analyses, compared one leukemic subtype with the mean of all others, obviously 
varying in composition and sample sizes.  
In general, cross-platform comparisons are nowadays regarded as certainly possible, 
assuming standardized protocols are considered (Staal, Cario et al. 2006). Notably, 
due to differences in the numbers of probe sets as well as total number of probes on 
each array, we could not correlate the expression levels of every gene of the E/R KD 
with E/R-positive primary ALL from Ross et al.  
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Upon E/R KD, gene expression profiling identified similar numbers of up- and down-
regulated genes. However, up-regulated genes mapped to a variety of similar 
functions, while repressed genes mapped to more diverse functions, appearing thus 
not significantly enriched and might therefore be of less biological relevance. Since it 
has been postulated that the E/R fusion converts RUNX1 from a conditional 
transcriptional activator and repressor to a constitutive repressor of its target genes 
(Fenrick, Amann et al. 1999), the significant association with functions/processes 
from up-regulated genes upon E/R KD, i.e. candidates for E/R repressed genes, 
might result, at least partly, from initial direct gene regulation. However, since our 
data represent expression profiles from stable KD of E/R, we did not identify an 
enrichment of potential directly regulated genes by RUNX1 consensus binding site 
search.  
Given that many more genes were identified upon E/R KD compared to the signature 
of primary ALL cases, we thus could identify genes being also regulated in other ALL 
subtypes. For instance, PROM1, which plays a role in maintenance of stem cell 
properties by suppressing differentiation, was also enriched in leukemias harbouring 
rearrangements of the MLL gene. The potential regulation of PROM1 by these 
chimeric proteins that are considered as initial events in leukemia pathogenesis 
supports the view that malignant cells are replenished from rare leukemic stem cells 
(Bomken, Fiser et al. 2010). Consistently, a recent study has demonstrated that 
primitive leukemia-initiating cells with long-term in vitro and in vivo proliferation 
capabilities are exclusively found in the CD133+CD19-CD38- cell compartment (Cox, 
Diamanti et al. 2009). 
Transcriptional levels do not always correlate with the amount of protein being 
translated in the cell. Even more importantly, they do not provide any evidence for the 
presence and quantity of post-translational protein modifications. Therefore, we 
determined the phosphorylation state of important signaling nodes. These 
experiments confirmed preliminary evidence obtained from gene expression profiling 
that E/R specifically influences PI3K, downstream AKT and mTOR signaling as well 
as modulates the expression of several pathway effectors.  
Given that the PI3K/AKT/mTOR pathway is of fundamental importance for many 
cellular tasks that are critical for neoplastic behaviour (Hanahan and Weinberg 2000; 
Steelman, Pohnert et al. 2004), pathway activation could potentially contribute to 
leukemia development and maintenance. Regulation of the PI3K/AKT/mTOR 
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pathway by E/R in our KD model precludes that activating mutations are present, at 
least in the investigated cell lines. Whether E/R leads to an activation of 
PI3K/AKT/mTOR pathway components, upstream signalling molecules, or both, 
remains to be further evaluated.  However, a recent study from our group showed an 
up-regulation of the erythropoietin receptor in E/R-positive cells which concurred with 
a survival advantage via PI3K/AKT/mTOR pathway activation (Inthal, Krapf et al. 
2008). Furthermore, gene expression data of E/R-positive leukemias as well as E/R 
silenced cells indicated a regulation of KIT by the fusion protein that would also lead 
to PI3K/AKT/mTOR activation. Importantly, a recent study also reported that RUNX1 
regulates KIT expression (De Vita, Canzonetta et al. 2010). Even though the 
experimental evidence for the relevance of KIT in E/R-positive leukemias remains to 
be shown, prominent roles for this receptor have been described in other cancers like 
acute myeloid leukemia, mastocytosis and gastro-intestinal stromal tumors (Masson 
and Ronnstrand 2009). 
 
Altogether, the observation that E/R expression is mandatory for the survival and 
propagation of the respective leukemic cells could also be of important clinical 
relevance. It has been postulated that targeted cancer therapy may only be effective 
when directed against mutant molecules that represent initiating events in leukemia 
development, being also present in persistent pre-leukemic clones. This notion may 
especially be valid for E/R-positive ALL cases because targeting the E/R gene fusion, 
presumed to represent a prenatal and initiating event, could circumvent the extremely 
high sub-clone variegation and variation between diagnosis and relapse encountered 
in these leukemias (Anderson, Lutz et al. 2011; Kuster, Grausenburger et al. 2011). 
Experimental evidence supporting this treatment concept was presented for 
RUNX1/ETO in acute myeloid leukemia. Selective interference with the 
oligomerization domain of ETO abrogated the ability of RUNX1/ETO to form high 
molecular weight complexes which are a functional characteristic of this fusion 
protein and attenuated its leukemogenic effects by inducing apoptosis (Wichmann, 
Chen et al. 2007). For E/R, the importance of oligomerization domains analogous to 
RUNX1/ETO remains to be further evaluated. 
We recently evaluated genome-wide copy number alterations of 18 matched 
diagnosis and relapse samples, revealing high frequencies of deletions in genes 
being implicated in the response to glucocorticoids, including the BCL2 modifying 
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factor (BMF), the glucocorticoid receptor NR3C1 and components of the mismatch 
repair pathways (Kuster, Grausenburger et al. 2011). For BMF deletions, we could 
provide evidence that these correlate with poor response to glucocorticoids being 
frequently observed in relapse leukemias. Consistently, in those E/R-positive 
relapses without BMF deletions, the expression levels were also found to be reduced. 
In this study, we explored a potential benefit of the PI3K/AKT/mTOR pathway 
inhibition for glucocorticoid resistant leukemias. Given that PI3K/AKT/mTOR 
signaling impacts on several BCL2-family members, pathway inhibition may also 
prove effective against relapsed E/R-positive ALL (McCubrey, Steelman et al. 2008).  
 
Apart from the described influence of E/R on the PI3K/AKT/mTOR pathway, we 
consider global gene expression analyses upon fusion protein suppression to 
contribute to a better understanding of the mechanisms of leukemia biology. The 
novelty of our study, compared to previous concepts, was the investigation of E/R 
mediated gene expression alterations in the context of a fully developed leukemia. 
Consistent with the observation that E/R expression is mandatory for propagation of 
leukemic cells, functional gene annotation suggested that the chimeric protein 
impacts on important biological functions such as cellular adhesion and stem cell 
features. Furthermore, our data suggested that E/R could modulate DNA damage 
response by inducing expression of MDM2, a potent negative regulator of p53 
function. Following DNA damage, overexpressed MDM2 could provide a mechanism 
to evade tumor suppressor protein p53 induced apoptosis. Importantly, MDM2 
already represents a potential target for leukemia therapy, since its inhibitor Nutlin 
has already been tested in clinical trials.  
 
Even though our E/R KD approach contributed to study the influence of E/R on the 
leukemic cell phenotype and correlate alterations with differential gene expression, 
our approach was not capable of identifying direct E/R target genes. Therefore, we 
next aim to establish an inducible E/R KD model, suitable to perform chromatin 
immunoprecipitation with massively parallel DNA sequencing (ChIP-Seq) that could 
represent a tool to identify gene regulatory regions under the control of the fusion 
protein.  
Finally, we envision that findings from E/R could be beneficial for other cancers, 
especially those involving other RUNX1 fusion proteins.  
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LYMPHOID NEOPLASIA
ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently
acquire deletions of genes implicated in glucocorticoid signaling
Lilian Kuster,1 Reinhard Grausenburger,1 Gerhard Fuka,1 Ulrike Kaindl,1 Gerd Krapf,1 Andrea Inthal,1 Georg Mann,2
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Approximately 25% of childhood acute lym-
phoblastic leukemias carry the ETV6/RUNX1
fusion gene. Despite their excellent initial
treatment response, up to 20% of patients
relapse. To gain insight into the relapse
mechanisms, we analyzed single nucleotide
polymorphism arrays for DNA copy number
aberrations (CNAs) in 18 matched diagnosis
and relapse leukemias. CNAs were more
abundant at relapse than at diagnosis (mean
12.5 vs 7.5 per case; P .01) with 5.3 shared
on average. Their patterns revealed a direct
clonal relationship with exclusively new ab-
errations at relapse in only 21.4%, whereas
78.6% shared a common ancestor and
subsequently acquired distinct CNA.
Moreover, we identified recurrent, mainly
nonoverlapping deletions associated with
glucocorticoid-mediated apoptosis target-
ing the Bcl2 modifying factor (BMF)
(n  3), glucocorticoid receptor NR3C1
(n  4), and components of the mismatch
repair pathways (n  3). Fluorescence in
situ hybridization screening of additional
24 relapsed and 72 nonrelapsed ETV6/
RUNX1-positive cases demonstrated that
BMF deletions were significantly more
common in relapse cases (16.6% vs 2.8%;
P  .02). Unlike BMF deletions, which
were always already present at diagnosis,
NR3C1 and mismatch repair aberrations
prevailed at relapse. They were all associ-
ated with leukemias, which poorly re-
sponded to treatment. These findings im-
plicate glucocorticoid-associated drug
resistance in ETV6/RUNX1-positive re-
lapse pathogenesis and therefore might
help to guide future therapies. (Blood.
2011;117(9):2658-2667)
Introduction
The ETV6/RUNX1 (E/R) fusion gene (also known as TEL/AML1)
results from the chromosomal translocation t(12;21) and is present
in approximately 25% of childhood B-cell precursor acute lympho-
blastic leukemia (BCP ALL).1 This leukemia subtype is generally
associated with good prognostic parameters and excellent molecu-
lar response to treatment.2-6 Although almost all children can be
treated successfully, predominantly late relapses occur nevertheless
in up to 20% of the patients.7-9
In the multistep model of E/R leukemia development, the gene
fusion represents the first transforming event. It virtually always
takes place during fetal development but is per se unable to
generate overt disease.10,11 One of the earliest and most prominent
of the many currently recognized lesions that drive the disease
process is the deletion of the second, nonrearranged ETV6 allele,
which is found in approximately two-thirds of the cases.12,13
Already a decade ago, the observation of distinct ETV6 deletions
together with incongruent clonotypic immunoglobulin (Ig)/T-cell
receptor (TCR) rearrangement patterns at diagnosis and relapse
suggested that the majority of relapses do not represent a genuine
reemergence of the original clone. Rather, both the initial and
relapse leukemia seemed to evolve from a shared ancestral
clone.14-19 These observations further implied that such preleukemic/
leukemic ancestral subclones must resist treatment to be able to
once more expand to a full-blown, treatment-responsive, disease.
Genome-wide single nucleotide polymorphism (SNP) geno-
typing serves to identify recurrent copy number aberrations
(CNAs) that may contribute to the pathogenesis of childhood
BCP ALL.20-22 CNAs compose deletions, duplications, and
amplifications that preferentially target genes involved in key
cellular signaling pathways, in particular the development and
differentiation of B cells, cell-cycle regulation, DNA repair, and
drug resistance. Although initial analyses focused especially on
the evaluation of CNA in diagnostic samples, consecutive
studies also compared diagnostic and relapse CNA patterns.23-25
The latter are frequently more pronounced and affect regions
containing genes that are also functionally relevant in the same
pathways. The fact that several such abnormalities, which were
apparently exclusively present in relapse, were subsequently
also identified in a minute cell compartment at diagnosis, proves
that relapses can indeed originate from small preexistent
subclones.23 So far, CNA studies of childhood ALL composed
the whole heterogeneous spectrum of genetic subgroups and
therefore paid no particular attention to potentially relevant
subgroup-specific characteristics.
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To gain further insights into the molecular mechanisms that
contribute to the development of relapses in E/R-positive leuke-
mias, we assessed genome-wide CNA changes of 18 matched
diagnosis and relapse samples and, for comparison and further
evaluation, complemented them with previously published SNP
array data from 47 nonrelapsed cases.20
Methods
Patients
This study was composed of 18 cases of E/R-positive relapsed BCP ALL.
Thirteen were selected according to the availability of material and a blast
count of more than 85% in leukemic samples. Five cases were taken from
an earlier study.23 All patients, patients’ parents, or legal guardians gave
written informed consent, in accordance with the Declaration of Helsinki,
for inclusion into this study. The study was approved by the ethical
committee of the CCRI and St Anna Kinderspital. Nine patients were from
Austria (3-11) and 4 from Germany (1, 2, 14, and 15). The SNP array data of
5 further patients (12, 13, 16-18; IDs: TEL-AML1-SNP-#48/#48GL/#48R,
TEL-AML1-SNP-#49/#49GL/#49R, TEL-AML1-SNP-#10/#10R, TEL-
AML1-SNP-#44/#44R, and TEL-AML1-SNP-#50/#50R) were kindly pro-
vided by C.G. Mullighan, St Jude Children’s Research Hospital.23 The
Austrian and German patients were enrolled in the ALL-BFM 90 and
95 treatment protocols.4 Seventeen of the 18 patients had a bone marrow
(BM) relapse and one (patient 11) an isolated relapse in the testis. In the
latter case, we isolated leukemic cells from the testis for SNP profiling. To
determine the constitutional genotype, early remission BM samples were
available in cases 1 to 14.
Median age of patients 1 to 11, 14, and 15 at diagnosis was 4.0 years
(range, 2.1-9.3 years), and median first remission duration was 44.5 months
(range, 16-79 months). Clinical findings are summarized in Table 1. To
evaluate the potential relevance of CNA and affected genes of our cases, we
compared the 14 cases with paired remission samples and the diagnosis- or
relapse-specific CNA of the remaining 4 cases with previously published
data from 47 E/R-positive cases.20 Although 3 of these 47 patients were
reported to have relapsed later,23 this did not influence our statistical
evaluation.
DNA extraction and sample preparation
DNA was extracted from BM mononuclear cells at diagnosis, remission,
and relapse and, in one instance, from leukemic cells of the testis as
described previously.26 Hybridization to Affymetrix GeneChip Human
Mapping 250K Nsp and 250K Sty arrays (n  6) or to Affymetrix
Genome-Wide Human SNPArray 6.0 (n 7) were performed by imaGenes.
Copy number analysis
Raw signal intensities were analyzed for CNA with the Partek Genomic
Suite software, Version 6.4 (Partek). We applied the genomic segmentation
algorithm for detection of CNA-containing regions and normalized seg-
mented DNA copy numbers to a median of 2 copies.27 Segmentation
parameters were chosen as follows: 5 minimum genomic markers per
segment (defining how small a region can be), a P value threshold of .001
(controlling for outlying probes), and a signal-to-noise value of 1.
Diagnosis- and relapse-specific somatic CNAs were identified by compari-
son with the matched germline remission pattern. In case this was not
possible, a HapMap reference, consisting of 270 or 794 HapMap samples
(depending on array type), was used for comparison, and detected CNA
were compared with known copy number variations that were provided in a
Copy Number Variant Database from Partek. Copy number changes
detected by genomic segmentation were verified by comparison with the
log2 ratio visualization in the Partek Genome Browser.
In the final tables, figures, and counts, we excluded all those deletions
and duplications that might have resulted from known copy number
variation or Ig and TCR gene rearrangement-related processes at 2p11.2
(IGK), 7p14.1 (TCRG), 7q34 (TCRB), 14q11.2 (TCRD/A), 14q32.33 (IGH),
and 22q11.22 (IGL). Deletions of the latter region were only excluded if
they derived from an IGL rearrangement but not if they resulted from a
focal deletion of VPREB1.
FISH for BMF and NR3C1 gene deletions
BMF and NR3C1 copy numbers were determined by fluorescence in situ
hybridization (FISH) on methanol/acetic acid fixed cells using the follow-
ing probes: BAC clone CTD-2251F23 (122kb; obtained from Invitrogen
Research Genetics), which encompasses the entire BMF gene, was hybrid-
ized together with the -satellite centromer-specific reference probe
D15Z1; NR3C1 gene locus-specific BAC clones RP11-278J6 (165 kb;
obtained from imaGenes) and RP11-138C1 located at 5p13. FISH was
performed according to standard procedures, and at least 100 interphase
nuclei per sample were scored. The cut-off for heterozygous deletions was
more than 20%.
Table 1. Clinical characteristics of 18 E/R-positive relapse cases that were analyzed with SNP arrays
Patient ID Sex Age, y Remission, mo Relapse site MRD Outcome, mo Source
1 Male 3.7 46 BM NA SCT, relapse,* Germany
2 Male 4.2 51 BM NA SCT, remission 96 Germany
3 Male 2.3 19 BM NA SCT, relapse* Austria
4 Male 3.7 78 BM IR SCT* Austria
5 Male 4.3 50 BM LR Remission 126 Austria
6 Male 3.4 16 BM IR SCT, remission 86 Austria
7 Male 2.1 43 BM NA SCT, remission 78 Austria
8 Male 4.7 40 BM NA Remission 21 Austria
9 Female 3.6 32 BM IR SCT, remission 23 Austria
10 Male 9.3 29 BM IR SCT, relapse, remission 26 Austria
11 Male 3.3 79 Testis IR SCT, remission 69 Austria
12 Male NA NA BM NA NA St Jude #48
13 Female NA NA BM NA NA St Jude #49
14 Male 3.2 68 BM LR Remission 14 Germany
15 Male 4.5 27 BM IR Remission 35 Germany
16 Male NA NA BM NA NA St Jude #10
17 Male NA NA BM NA NA St Jude #44
18 Female NA NA BM NA NA St Jude #50
MRD indicates minimal residual disease; NA, not available; SCT, hematopoietic stem cell transplantation; IR, intermediate risk; and LR, low risk.
*Death.
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BMF mRNA quantification
Total RNA was isolated either using the RNeasy Mini Kit (QIAGEN) or
Trizol Reagent (Invitrogen). Random hexamer priming and SuperScript II
(Invitrogen) were used to generate cDNA. Quantification of BMF mRNA
abundance was done using TaqMan real-time RT-PCR. ABL and GUS were
used for endogenous control amplification. Primer sequences, PCR condi-
tions, and interpretation of results are available as supplemental data
(available on the Blood Web site; see the Supplemental Materials link at the
top of the online article).
Mutational screening of BMF
Mutational screening of BMF was performed using primers flanking the
coding exons 3, 4, and 5 (details provided in supplemental data).
shRNA-mediated knock-down of BMF in REH cells
ETV6/RUNX1-positive REH cells were cultured as described previously.28
Lentiviral vectors expressing shRNA sequences directed against the human
(pHR-THT-sh-hBMF-SFFV–eGFP) BMF or murine (pHR-THT-sh-mBmf-
SFFV–eGFP) Bmf, nontargeting the human BMF,29 were used to transduce
REH cells. Details on shRNA sequences and lentiviral supernatant produc-
tion and transduction are provided in the supplemental data.
Glucocorticoid treatment and apoptosis assay
REH cells transduced with shRNA against BMF or control shRNA were
treated with 1 mg/mL prednisolone (SoluDacortin, Merck) over a time
period of 96 hours. Prednisolone treatment was performed 11 days after
lentiviral transduction and apoptosis assessed by annexin V/propidium
iodide staining as reported previously.30
Information on bioinformatic analysis, pathway analysis targeted by
presentation- or relapse-specific CNA, and statistical analysis are provided
as supplemental data.
Results
Comparison of CNA in matched diagnosis and relapse samples
The results of our genome-wide copy number analysis of the
14 cases with paired remission samples are summarized in Table 2,
Figure 1A, and supplemental Table 1. CNAs in paired samples
were identical, partially shared, or completely different (Table 2).
Overall, 73% of copy number losses and 54% of copy number
gains remained stable. In 13 of the 14 cases, several of the lesions
that were observed at diagnosis were also seen in relapse, although
all cases also lost and/or acquired some lesions in relapse. Only in
one patient (patient 5), the 2 CNA patterns were completely
different. Overall, 31 of 105 CNAs present at diagnosis were lost in
relapse, whereas 101 were gained. Thus, the mean diagnosis-
specific CNA number per case was significantly lower (mean, 2.2;
range, 0-7) than the relapse-specific one (mean, 7.2; range, 2-16;
P  .0001, Welch unpaired t test). Moreover, 3 cases (21.4%)
acquired new CNA at relapse but did not lose any, whereas
11 (78.6%; including the one case with the complete change) lost as
well as acquired several alterations. Data from patients without
remission sample are similar to the paired samples, as they show
similar patterns of distinct CNA between diagnosis and relapse but
tend to have higher shared CNA counts, which most probably can
be explained by the contribution of copy number variation (supple-
mental Tables 1, 2). Comparison of high-quality heterozygous SNP
calls showed concordance between paired samples in all cases.
Comparison of CNA in relapse and nonrelapse cases
The CNA frequency of our 14 diagnosis and relapse samples was
comparable with the one established in the 47 nonrelapse cases
(Table 3). As regards specific CNA in individual cases, however, on
average only median 75% (range, 25%-100%) remained identical
on both occasions. Approximately 30% of the diagnosis samples
contained deletions of tumor suppressor and cell cycle regulator
genes. Heterozygous and homozygous CDKN2A/B and CDKN1B
deletions, in particular, were present with an equal frequency in
diagnosis and relapse samples (Figure 1B; supplemental Tables 1,
2). Because ETV6, VPREB1, CDKN2A/B, CD200, BTLA, TBL1XR1,
and PAX5 deletions already prevail at diagnosis and recur mostly
unchanged in relapse samples, they are presumed to reflect a very
early and essential event in leukemia development. The fact that
specific patterns of individual deletions were only identical in 50%
Table 2. Frequency of somatic CNAs in 14 E/R-positive cases at diagnosis and relapse
Patient
ID
CNAs
Losses Gains All
Diagnosis Relapse Shared Diagnosis Relapse Shared Diagnosis Relapse Shared
1 4 7 0 2 2 1 6 9 1
2 6 12 (1) 6 0 0 0 6 12 (1) 6
3 7 6 6 0 2 0 7 8 6
4 4 9 3 0 0 0 4 9 3
5 1 7 (1) 0 2 1 0 3 8 (1) 0
6 6 10 (1) 6 2 3 2 8 13 (1) 8
7 3 5 2 0 1 0 3 6 2
8 7 (1) 9 5 0 1 0 7 (1) 10 5
9 10 11 7 0 1 0 10 12 7
10 14 (1) 13 10 1 7 0 15 (1) 20 10
11 8 (1) 8 (1) 2 (1) 1 0 0 9 (1) 8 (1) 2 (1)
12 3 14 (1) 2 0 0 0 3 14 (1) 2
13 10 (1) 18 (1) 10* (1) 2 2 2 12 (1) 20 (1) 13 (1)
14 9 16 (3) 8 3 10 2 12 26 (3) 10
Total 92 (4) 145 (9) 67 (2) 13 30 7 105 (4) 175 (9) 74 (2)
Mean 6.6 10.4 4.8 0.9 2.1 0.5 7.5 12.5 5.3
Included are only cases with available remission samples. Indicated are all CNAs in the respective leukemia; in case of biallelic deletions, the number is given in
parentheses.
*For simplicity reasons, 2 deletions at relapse overlapping with 1 deletion at diagnosis were counted as 1 deletion (details about the affected regions can be found in
supplemental Tables 1 and 5).
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Figure 1. Heatmaps of CNAs in 18 relapsed E/R-positive leukemias. (A) Overview of somatic CNA in diagnosis and relapse samples. Copy number changes are mapped
according to their chromosomal position and indicated by color (blue represents losses; and red, gains) for each chromosome from 1 to X (row) and each sample (column).
Each row represents a segment of the genome with a CNA across samples. Regions in the genome without CNA events are not shown in the heatmap. Each column is labeled
with the patient IDs at the bottom of the graph, and sample types are indicated by the color bars: white represents diagnosis; and gray, relapse. Samples with and without paired
remission samples are separated by a bold vertical line. (B-C) Heatmaps for recurrent genomic deletions were constructed by zooming in on genes of interest and plotting along
chromosomal coordinates (y-axis) color-coded presence (blue for monoallelic/black for biallelic) and absence (white) of deletions. Deletions of tumor suppressor genes and cell
differentiation markers at 12p13.2 (ETV6, BCL2L14, CDKN1B), 12q21.33 (BTG1), 9p21.3 (CDKN2A/B), 9p13.2 (PAX5), 5q33.3 (EBF1), and 7p12.2 (IKZF1) are shown in
panel B, and deletions of genes implicated in GC signaling and MMR at 5q31.3 (NR3C1), 4q31.22 (NR3C2), 2p21 (MSH2), 3p21.3 (MLH1), and 15q15.1 (BMF) are shown in
panel C. Genome position (Mb) according to the University of California Santa Cruz Genome Browser (NCBI Build 36.1) is given for each graph.
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to 80% of matched samples (Table 3; supplemental Figure 2) seems
to indicate that they may also arise at a later stage during the course
of the disease. Therefore, the sequence of such events may actually
be quite variable.
Irrespective of the apparently equal frequency of recurrent CNA
at diagnosis and relapse, we were able to discern particular
alterations that might be either predictive or characteristic of
relapse. Apart from the gene deletions that are described in more
detail in the next paragraph, a deletion of the EBF1 gene, which
encodes an early transcriptional regulator of B-cell development,
was exclusively seen in 2 cases at relapse. In one of these cases
(patient 8), it concurred with a deletion of the IKZF1 gene, which
encodes the lymphoid transcription factor IKAROS (Table 3,
Figure 1B, supplemental Tables 1-2, and supplemental Figure 3).
Deletions of genes involved in GC receptor signaling, drug
resistance and MMR pathways
Of great interest were deletions of genes that so far had not been
directly associated with E/R-associated leukemogenesis (Figure 1C;
supplemental Table 1). They encode factors of the nuclear receptor
subfamily 3 (NR3C1, NR3C2) and key components of the mis-
match repair (MMR) pathway (MSH2, MLH1). Although the
development of relapses from drug-resistant clones is well known
in childhood ALL, this particular matter is not considered to pose a
significant therapeutic problem in the E/R-positive subgroup.7,24,31-33
For the following analyses, also relapse-specific CNA encom-
passing these gene loci from patients without paired remission
samples were included. Deletions of the NR3C1 gene that encodes
the glucocorticoid (GC) receptor were seen exclusively at relapse
in 4 of the cases, including one homozygous deletion (patient 12).
The NR3C1 deletion in patient 7 was confirmed with FISH
(supplemental Figure 4). The NR3C2 gene, encoding the mineralo-
corticoid receptor, was deleted in 2 cases, in one of them only at
relapse (Figure 1C, Table 3, supplemental Figure 5).
MLH1 and MSH2 genes encode key components of the MMR
pathway. Deletions of the one or the other of these genes were
found only in the relapse samples of 3 cases (Figure 1C, Table 3,
supplemental Tables 1, 2, supplemental Figure 4). The respective
MMR proteins form different heterodimers and initiate repair by
binding to DNA mismatches.34 MMR gene deletions concurred
with that of the NR3C2 gene in one case (patient 4).
Deletion of BMF
SNP profiling also revealed a novel deletion at 15q15.1 in both the
diagnosis and relapse samples of 3 of 18 cases (Figure 1C;
Figure 2A-B). BMF, the only gene located in the overlapping
Table 3. Frequency of recurrent CNAs in 14 E/R-positive relapse patients at diagnosis and relapse with paired analysis compared with
those observed at diagnosis in 47 nonrelapse patients
Cytoband Gene
47 without
relapse 14 with relapse
Diagnosis Diagnosis Relapse Shared
N % N % N % N %
Losses
12p13.2 ETV6 33 70 8 57 8 57 7 88
22q11.22 VPREB1 32 68 8 (3) 57 (38) 10 (5) 71 (50) 8 (2) 100 (20)
9p21.3 CDKN2A 12 26 3 (1) 21 (33) 4 (1) 29 (25) 3 (0) 100 (0)
3q13.2 CD200, BTLA 7 15 5 36 4 29 3 60
9p21.3 CDKN2B NA NA 3 (1) 21 (33) 3 (1) 21 (33) 2 (0) 67 (0)
3q26.32 TBL1XR1 6 13 4 29 3 21 3 75
9p13.2 PAX5 13 28 3 21 3 21 2 67
12p13.1 ATF7IP NA NA 5 36 6 43 4 80
12p13.3 VWF NA NA 4 29 1 7 1 25
12p13.2 BCL2L14, CDKN1B NA NA 5 36 5 36 3 60
9p21.3 MTAP NA NA 2 (0) 14 (0) 3 (1) 21 (33) 2 (0) 100 (100)
12q21.33 BTG1 6* 13* 3 21 0 0 0 0
15q15.1 BMF 0 0 2† 14 2† 14 2† 100
6q21 ARMC2, SESN1 7 15 1 7 1 7 0 0
5q31.3 NR3C1 6 13 0 0 3‡ (1) 21 (33) 0 0
21q22.12 RUNX1 3§ 6§ 2 14 2 14 2 100
9p21.3 IFN cluster 0 0 1 7 1 7 1 100
12p13.2 GABARAPL1 NA NA 4 29 4 29 3 75
5q33.3 EBF1 5 11 0 0 2 14 0 0
7p12.2 IKZF1 0 0 0 0 1 7 0 0
4q31.22 NR3C2 5¶ 11¶ 0 0 2 14 1 50
2p21 MSH2 0 0 0 0 1 7 0 0
3p21.3 MLH1 0 0 0 0 0# 0 0 0
Gains
21q Includes RUNX1 4 9 5 36 4 29 3 60
Numbers represent cases/percentages with genomic aberrations; number of cases with biallelic deletions in parentheses.
NA indicates not applicable.
*3 of BTG1.
†One additional case with a conserved BMF deletion in the group with unpaired analysis.
‡One additional case with a relapse-specific deletion among the cases with unpaired analysis.
§Immediately distal to RUNX1.
Analyzed in only 13 patients.
¶Telomeric to NR3C2.
#Two cases with a relapse-specific deletion among the cases with unpaired analysis (supplemental Tables 1 and 2).
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minimal deleted region, encodes a member of the BH3-only group
of Bcl2-related proteins, which together with other proapoptotic
proteins plays a role in mitochondrial regulation of apoptosis,
cancer development, and drug resistance.35
FISH screening of patients 3 to 11, 14, and 15 verified the
presence of heterozygous BMF deletions in patients 3, 10, and 15 in
50% to 80% of nuclei (Figure 2C). To further assess the frequency
of BMF deletions in a larger cohort of E/R-positive leukemias, we
screened another 24 relapse as well as 72 consecutively recruited
nonrelapse cases. The identification of 4 additional heterozygous
BMF deletions in the relapse and another 2 in the nonrelapse group
proved that the frequency of BMF deletions is indeed higher in
relapse cases (16.6% vs 2.8%; P  .02, Fisher exact test). Because
4 cases with a BMF deletion experienced an early and 3 a late
relapse (defined as shorter and longer than 30 months in remission),
the presence of such a deletion could, however, not be used to
predict time to relapse. The remission of the 2 cases in the
relapse-free cohort, on the other hand, has already lasted almost
10 years, and we consider it therefore unlikely that they will still
relapse. In consideration of the potential tumor suppressor function
of BMF, a notion that is based on the accelerated development of
thymic lymphomas in Bmf deficient mice,36 we also amplified and
sequenced all coding exons (exons 3-5) of BMF at the genomic
level in 15 relapsed cases (including 5 with a deletion) but did not
detect any mutations.
Quantitative RT-PCR of E/R-positive and E/R-negative BCP
ALL (in long-term remission) revealed that BMF is significantly
higher expressed in E/R-positive leukemias (Figure 2E). However,
within this genetic subgroup, mRNA levels were significantly
lower in the relapse cohort, irrespective of their BMF deletion
status (supplemental Figure 6). Because BMF is induced by GC
before GC triggered cell death and GC is used as a systemic
one-week induction monotherapy in ALL BFM-treatment proto-
cols, we examined the sequential expression profiles of sorted
leukemic cells (with  95% purity), which were obtained from
9 E/R-positive and 13 E/R-negative BCP ALL cases during their in
vivo GC treatment.29 In line with the quantitative RT-PCR data,
basal BMF transcription (ie, before GC treatment) was significantly
higher in E/R-positive than in E/R-negative BCP ALL (P  .05,
Welch unpaired t test). Although statistically not significant, there
was a more pronounced induction of BMF expression in
E/R-positive than in E/R-negative cases (data not shown). Thus,
E/R-positive blasts exhibit higher BMF expression and this is, at
least in some cases, increased during initial GC therapy.
Figure 2. BMF deletions and functional consequences of reduced BMF expression in E/R-positive ALL. (A) Log2-ratio copy numbers of genomic deletions
encompassing BMF (indicated by an arrow) are shown for 2 patients with a deletion at 15q15.1. (B) Segmental deletions at 15q15.1 in 3 cases (3, 10, and 15). (Top) A partial
ideogram of the 15q region and the position of the FISH probe used for confirmation of the deletions. The scale indicates genomic positions of the deletions in megabases
according to the University of California Santa Cruz Genome Browser (NCBI Build, Version 36.1). Each black horizontal bar represents a deletion in a single patient as inferred
by SNP array. Vertical lines indicate the overlapping region encompassing the only commonly deleted gene (BMF) (bottom). (C) Verification of the BMF deletion by FISH in
patient 10 in 57% of nuclei (green represents BMF; and red, chromosome 15 centromer). (D) Genomic breakpoint of the BMF deletion from case 10 was cloned (details
provided in supplemental data; accession code #GU984796) and sequence information used for nested PCR. The resulting PCR products from initial diagnosis (middle lane)
and relapse (right lane) are shown. Left lane indicates size marker. (E) Quantification of BMF expression in E/R-positive (E/R, n  15) and E/R-negative (E/R, n  15) BCP
ALL cases without relapse. Data represent relative expression values of BMF compared with GUS. Boxes include values between the 25th and
75th percentile, and whiskers indicate the minimal and maximal values. The black line indicates the median BMF expression of all samples. For statistical evaluation,
Welch unpaired t test was used. (F) Western blot analysis of REH cells on BMF repression by RNAi. Protein lysates were prepared from green fluorescent protein-sorted
cells expressing the shRNA vector targeting human BMF (KD) or a nontargeting control shRNA (C). BMF isoforms (BMF1, BMF2, and BMF3, top-down) are marked with
arrows. GAPDH levels were used as a loading control. (G) Glucocorticoid-induced apoptosis on BMF repression in REH cells. BMF silenced cells were treated with
prednisolone for the indicated times, and apoptosis was assessed by annexin V/propidium iodide staining in green fluorescent protein-positive cells carrying the
lentiviral shRNA construct. Apoptosis was calculated by subtraction of annexin single-positive cells in untreated from prednisolone-treated cells. Percentages of
4 independent experiments from 3 separate infections are shown. Bars represent mean  SD. *P  .05 (paired Student t test). **P  .01 (paired Student t test).
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Finally, to assess a potential functional consequence of a
heterozygous BMF deletion, we transduced REH cells with lenti-
viral vectors expressing 2 different shRNA targeting BMF and
subjected these cells to glucocorticoid treatment. As shown in
Figure 2F and supplemental Figure 7A, a significant reduction of
BMF levels was achieved, which resulted in increased resistance to
prednisolone (Figure 2G; supplemental Figure 7B). Thus, these
data suggest that impaired BMF function may also have an impact
on GC-induced apoptosis in primary leukemias.
Comparison of CNA with clone-specific Ig/TCR gene
rearrangement patterns
Given the frequent differences of clone-specific Ig/TCR rearrange-
ments between initial diagnosis and relapse in E/R-positive
ALL,14,15,18 we investigated to which extent the respective Ig/TCR
rearrangement and CNA patterns correlate. Although recurrent
CNAs are part of leukemogenesis, clone-specific Ig/TCR rearrange-
ments are not. They arise from V(D)J recombination, the process
that mediates the formation of a functional immune receptor during
lymphoid development. Hence, Ig/TCR rearrangements are fre-
quently assessed and used as a clone-specific marker for the
detection of minimal residual disease.
Data from 9 cases (patients 3-11) are given in supplemental
Tables 3 and 4. A total of 28 identical and 2 related rearrangements
of the 40 rearrangements present at initial diagnosis were preserved
at relapse (75%), and identical Ig/TCR rearrangements significantly
outnumbered related and changed rearrangements (P  .0001,
Welch unpaired t test).
When viewed separately, both the Ig/TCR rearrangements and
CNA patterns revealed a clear relationship between the original
predominant and relapse clone in all but one case (patient 5).
Ig/TCR rearrangements were identical, modified by ongoing recom-
bination, or completely different. However, it was not possible to
merge the results of the 2 investigations into a single clonal development
scheme because the information derived from the Ig/TCR rearrange-
ment analyses did not concur with that of the CNA.
Nevertheless, we propose that, in the majority of cases, both the
CNA and Ig/TCR rearrangement-generating mechanism must at
least be operative during the same period of time (provided in
supplemental Figure 8). A rare complete clonal change (patient 5),
on the other hand, might indicate that distinct subclones were
derived from an E/R-rearranged hematopoietic stem cell. This
notion is supported by recent findings demonstrating that this gene
fusion and its subsequent expression may indeed transform already
uncommitted hematopoietic stem cells.37,38 Because many of the
consecutive secondary leukemia-promoting changes are mediated
by V(D)J recombination, they can only take place during early
B-cell development.20,39,40
Discussion
To elucidate the routes leading to disease recurrence in E/R-positive
leukemias, we compared SNP array-derived CNA configurations of
18 matched diagnosis and relapse samples. The changes of CNAs
in the majority of relapse cases (89%) was the result of a mixture of
genuinely acquired novel deletions and duplications as well as to
the absence of deletions that were originally present in the
corresponding diagnostic sample. Only one case had a complete
clonal change. Despite the considerable discordance of various
recurrent deletions in the diagnosis and relapse samples of indi-
vidual cases, the overall frequency of CNAs affecting genes that
are involved in B-cell development and differentiation as well as
cell cycle regulation was nevertheless comparable. This observa-
tion suggests that, although these clones are closely related, in most
instances the relapse clone does not evolve directly from the one
identified at diagnosis, but rather that both clones are derived from
a shared ancestor. Except for a few specific and intriguing
exceptions, the overall CNA frequency and pattern did also not
significantly differ from nonrelapse cases, thereby precluding their
application as predictive prognostic markers.
Two cases had acquired a deletion encompassing the EBF1
gene; one of them even had an IKZF1 deletion. Although this
constellation has been reported previously in E/R-negative relapse
cases in which the respective genes were deleted in 4.2% and 8.9%
versus 25% and 35% at diagnosis and relapse, respectively,24,41 it
has, to the best of our knowledge, not yet been documented in
E/R-positive relapse cases. Given that both EBF1 and IKZF1
expression is required for early B-cell development and precedes
PAX5 expression during lineage commitment, the presence of these
deletions in the recurrent leukemia suggests that the relapse clone
probably originates from a slightly less differentiated cell. In
support of this notion, one of the relapse cases actually had a PAX5
deletion at diagnosis that was, however, absent in the EBF1-deleted
relapse clone. Moreover, and at least in this particular case, the
concurrence of other deletions in both samples further suggests that
impairment of B-cell differentiation seems to occur late during the
transformation process. However, the immunophenotype as well as
clonotypic Ig/TCR rearrangements of these cases appeared un-
changed. Whether late-appearing IKZF1 deletions confer a poor
prognosis similar to those already present at diagnosis in BCR/ABL-
positive or “BCR/ABL-like” ALL cases13,20,24,40,41 needs to be
assessed in a large group of relapse patients.
Recent studies reported deletions of CDKN2A/B, which encode
the p16INK4A /p14ARF and p15INK4B proteins, respectively, in the
diagnostic samples of poor prognosis E/R-negative cases, on the
one hand, and a higher frequency of such deletions in the relapse
samples,23,24,31-33 on the other hand, whereas another study did
not.42 In line with the latter, the frequency of CDKN2A/B and
CDKN1B (p27KIP) deletions at diagnosis in our cohort concurs with
that at relapse as well as with the 26% overall frequency of
nonrelapse E/R-positive cases.20 Notably, the fact that CDKN2A/B
deletions at diagnosis did not forecast a shorter time to relapse, as
has been proposed for E/R-negative leukemias,24 further empha-
sized the lack of any prognostic relevance in our E/R-positive
leukemia cohort.
The deletion of the nonrearranged ETV6 gene, a transcription
factor required for bone marrow hematopoiesis, is one of the most
frequent secondary aberrations that probably also collaborates with
E/R in leukemia development.12 Even though this deletion is
presumably one of the earliest genomic alterations, we identified
different deletions in the diagnosis and relapse samples of 3 cases, a
finding that precludes the relapse clone as having evolved directly
from the one originally present. (The genomic boundaries of the
various deletions are provided in supplemental Table 6.) These
properties concur with similar earlier observations, which also
demonstrated that, although both clones derive from the same
source, some of their genetic features might, nevertheless, differ
completely.14,16,19 Taking into account that, even in cases without a
deletion the nonrearranged ETV6 gene is generally not ex-
pressed,43,44 it appears likely that ETV6 inactivation is a critical step
in the pathogenesis of E/R-positive leukemia.
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Other noteworthy findings in our study were the identification
of novel deletions affecting BMF, NR3C1, and genes encoding key
proteins of the MMR pathway. BMF deletions were in all instances
detected already at diagnosis and preserved at relapse, whereas
NR3C1 and MMR gene deletions either prevailed or were only
detected at relapse. All these genes play a pivotal role in apoptosis,
GC, and MMR pathways and contribute to GC-induced apoptosis.
This association suggests that drug resistance is perhaps also
relevant for disease recurrence in these cases. BMF is a central
player in GC-mediated induction of apoptosis, as its down-
regulation renders leukemic cell lines GC resistant.29,35 In line with
these reports, our data provide the first evidence that BMF deletions
lead to haploinsufficency and resistance to GC treatment in
E/R-expressing leukemias. Conversely, forced expression of BMF
makes leukemic cells highly drug-sensitive,29,35 and the observed
increase of BMF transcripts in E/R-positive leukemias together
with its induction after in vivo GC treatment,29 correlates well with
the known GC sensitivity of E/R-positive leukemias and might thus
contribute to their favorable prognosis.7 In E/R-positive relapses,
however, expression seems to be relatively decreased, irrespective
of whether BMF is deleted or not. It is therefore conceivable that a
reduced BMF expression may attenuate GC response35 and raises
the possibility that also epigenetic mechanisms could inactivate
BMF in these cases. In line with this notion, it was recently shown
that histone deacetylase-inhibitors preferentially up-regulate BMF
expression in a broad range of cancer cell lines and that hyperacety-
lation of the BMF promoter region induces its transcriptional
activation.45
The physiologic role of BMF in the human system is largely
unknown. However, Bmf deficiency in mice results in an abnormal
resistance of B cells to apoptotic stimuli and the development of a
B-cell restricted lymphadenopathy.36 In light of these data, it is
therefore possible that, apart from an increased resistance to
apoptosis induction, BMF deletions, which seem to occur in an
early stage of leukemia development, also confer a survival
advantage to preleukemic cells, particularly in growth factor-
restricted unfavorable conditions. Moreover, BMF may also act as
a tumor suppressor, as evidenced by the accelerated development
of thymic lymphomas in Bmf-deficient mice.36 There are only
indirect signs for a similar function in humans. BMF was found to
be lost in breast and lung cancers,35 and it may be affected in those
rare childhood ALL cases with 15q13–15 deletions.46 Along this
line is the considerably higher frequency of BMF deletions in
E/R-positive relapse compared with nonrelapse cases, be it at
diagnosis or relapse, as seen in our analysis.
NR3C1 deletions were found almost exclusively at relapse in
28% of our patients. This comparatively high frequency differs
from that obtained in an earlier study in which such GC receptor
deletions were far less common.47 Whether this difference is the
result of the higher resolution of the SNP arrays used in our study or
whether it results from a selection bias remains elusive. However,
in another study of 61 relapsed ALL that merely included
5 E/R-positive cases, Mullighan et al also identified only 2 cases
with NR3C1 deletions at diagnosis (conserved at relapse) and in
additional 3 cases solely at relapse.23 Of further interest is an earlier
study of 242 childhood ALL cases that incorporated 47 E/R-positive
ALL cases. The fact that 6 of 9 NR3C1 deleted cases were
E/R-positive corroborates our observations and the notion that
NR3C1 deletions are characteristic of this particular genetic
subgroup.20 Although the mode of GC resistance has been the
subject of controversial discussions for a long time, recent evidence
suggests that the GC receptor expression level, as well as the
GC-induced regulation of both proapoptotic and antiapoptotic
BCL2 family member-dependent pathway components, plays a
major role.29,48 Minimal residual disease response evaluation in
3 of our NR3C1-deleted cases revealed a poor blast cell clearance
in the BM after 2 months of treatment with equal or more than 103
cells, a leukemic cell load that is currently used as indication for
stem cell transplantation in BFM-based therapy protocols.49 NR3C1
deletions acquired at relapse were not considered as sole progres-
sion markers because other genomic alterations that were present at
diagnosis had not been retained. Although it is not known when the
NR3C1 deletions had actually taken place, their identification only
at relapse does not necessarily preclude that they already preexisted
in a minute cell fraction much earlier, as was previously recorded in
a single late relapse case.47
Defects in the MMR pathway can alter the apoptotic
response to DNA-damaging agents and can therefore also cause
resistance to drugs that are used for treatment of childhood
ALL.34 Binding of an MSH2 and MSH6 heterodimer (MutS
complex) to the mispair sets off DNA repair, followed by
binding of an MLH1 and PMS2 heterodimer (MutL complex),
which then initiates excision and replacement of the respective
mispair. The third MSH2 and MSH3 complex (MutS	) detects
small insertion or deletion loops in the DNA. Thus, attenuation
of either component of these 3 heterodimers, for instance,
because of the heterozygous MSH2 and MLH1 gene deletions
encountered in 3 of 18 relapse patients, is expected to lead to a
reduced MMR function. In support of this notion, Yang et al
reported MSH6 and MSH2 deletions together with a decreased
MSH6 expression in 2 of 20 E/R-negative ALL that concurred
with mercaptopurine and, of particular interest in the context of
our findings, also with GC resistance, even though MMR is
apparently not directly related to this specific pathway.24
However, it remains to be shown whether chemotherapy is
indeed a relevant factor for the selection of MMR-defective
clones and to which extent certain commonly used drugs may
even directly cause such defects and thereby contribute to
disease recurrence. Although E/R-positive leukemias are in
general exceptionally drug sensitive,2-6 it is not yet clear to
which degree this is also true for relapses. Even though the
currently available clinical data seem to implicate that the
majority of E/R-positive relapses achieve a second remission
with an overall good outcome, only long-term follow-up studies,
currently not available, could substantiate this view because in
this particular subgroup relapses may still occur after long
remission periods.7 Neither CNA nor GC response nor molecu-
lar minimal residual disease parameters, alone or in combina-
tion, were able to provide consistent and conclusive information
with regard to disease resistance at first presentation.6 Although
minimal residual disease persisted beyond day 33 of initial
treatment in 7 of 8 analyzed cases, which included 6 with
deletions of the aforementioned genes, no concordance with any
of the particular deletions or first remission duration became
evident. Of note, 5 of the 7 BMF-deleted cases (3 identified with
SNP arrays and 4 with FISH) experienced a second relapse, 4 of
5 after stem cell transplantation and another one as a result of
resistant disease. Even though these observations leave the
impression that certain CNAs could indeed be of predictive
value, they still have to be interpreted with caution because they
derive from a small number of patients. Nevertheless, these
preliminary findings seem to justify further investigations of this
issue in a larger cohort of unselected patients with sufficiently
long follow-up periods.
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In conclusion, the heterogeneous and divergent CNA patterns in
E/R-positive diagnosis and relapse leukemias unequivocally prove
that both diseases can frequently evolve from a common ancestral
clone. A substantial proportion of the associated deletions affect
genes that play an important role in B-cell development as well as
the GC and MMR pathways, which in turn may explain, to some
extent, disease recurrence and a poorer treatment response in these
patients. Of note in this context is the high incidence of BMF gene
deletions in patients who experienced a second relapse even after
hematopoietic stem cell transplantation. Particularly for this patient
group, novel treatment approaches seem to be warranted. In the
future, such alternative therapy options may include, for instance,
BH3 mimetics or histone deacetylase-inhibitors, which are cur-
rently already evaluated in clinical trials and which will help to
restore the function of the GC pathway.50,51
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SHORT COMMUNICATION
ETV6/RUNX1 abrogates mitotic checkpoint function and targets its key
player MAD2L1
G Krapf1, U Kaindl1, A Kilbey2, G Fuka1, A Inthal1, R Joas1, G Mann3, JC Neil2, OA Haas3
and ER Panzer-Gru¨mayer1,3
1Children’s Cancer Research Institute, Vienna, Austria; 2Molecular Oncology Laboratory, Institute of Comparative Medicine, Faculty
of Veterinary Medicine, Glasgow, UK and 3St Anna Kinderspital, Vienna, Austria
Approximately 25% of childhood B-cell precursor acute
lymphoblastic leukemia have an ETV6/RUNX1 (E/R)
gene fusion that results from a t(12;21). This genetic
subgroup of leukemia is associated with near-triploidy,
near-tetraploidy, and trisomy 21 as rather speciﬁc types
of secondary changes. Here, we show that, unlike various
controls, E/R-expressing Ba/F3 clones acquire a
tetraploid karyotype on prolonged culture, corroborating
the assumption that E/R may attenuate the mitotic
checkpoint (MC). Consistent with this notion, E/R-
expressing diploid murine and human cell lines have
decreased proportions of cells with 4N DNA content and a
lower mitotic index when treated with spindle toxins.
Moreover, both RUNX1 and E/R regulate mitotic arrest-
deﬁcient 2 L1 (MAD2L1), an essential MC component,
by binding to promoter-inherent RUNX1 sites, which
results in down-regulation of MAD2L1 mRNA and
protein in E/R-expressing cells. Forced expression of
E/R also abolishes RUNX1-induced reporter activation,
whereas E/R with a mutant DNA-binding site leads to
only minor effects. Our data link for the ﬁrst time E/R,
MC, and MAD2L1 and provide new insights into the
function of the E/R fusion gene product. Although
tetraploidy is an almost exclusive feature of E/R-positive
leukemias, its rarity within this particular subgroup
implies that further yet unknown factors are required for
its manifestation.
Oncogene (2010) 29, 3307–3312; doi:10.1038/onc.2010.53;
published online 1 March 2010
Keywords: ETV6/RUNX1; t(12;21); acute lymphoblastic
leukemia; mitotic checkpoint MAD2L1; tetraploidy
Introduction
The t(12;21)(p13;q22) with its molecular counterpart,
the ETV6/RUNX1 (E/R) (also known as TEL/AML1)
gene fusion, characterizes approximately 25% of child-
hood B-cell precursor ALL cases. E/R is unique among
the fusion genes involving RUNX1, as it is associated
with acute lymphoblastic leukemias rather than myeloid
leukemias (Speck and Gilliland, 2002). Accumulating
evidence suggests that this fusion gene can initiate
leukemia development, and although it is not sufﬁcient
to cause overt leukemia per se, it is necessary for its
maintenance (Zelent et al., 2004; Diakos et al., 2007;
Hong et al., 2008). E/R encodes a chimeric protein that
is composed of the N-terminal non-DNA-binding
region of ETV6 and almost the entire RUNX1 protein.
It retains the runt domain of RUNX1 that is required
for DNA binding and heterodimerization and, there-
fore, also provides an essential function of RUNX1
fusion genes (Hiebert et al., 1996; Morrow et al., 2007;
Roudaia et al., 2009; Wolyniec et al., 2009). The E/R
protein acts as an aberrant transcription factor and
represses or disrupts the regulation of RUNX1 target
genes in a cellular context-dependent manner (Pui et al.,
2004; Zelent et al., 2004; Wotton et al., 2008).
Approximately 15% of E/R-positive leukemias
acquire an extra chromosome 21 as a secondary change
(Attarbaschi et al., 2004). Furthermore, near-tetraploid
and near-triploid karyotype patterns in childhood
B-cell precursor ALL were recently recognized as rather
speciﬁc secondary abnormalities, although they occur in
only approximately 5% of E/R-positive cases (Attar-
baschi et al., 2006; Raimondi et al., 2006).
On the basis of these observations, we reasoned that E/
R can affect chromosome segregation, most likely by
compromising the surveillance mechanisms of the mitotic
checkpoint (MC) (Weaver and Cleveland, 2005; Peters,
2007). The MC guarantees that all sister chromatids are
properly attached to the spindles before cell-cycle
progresses through mitosis. A central component of this
checkpoint is the ‘mitotic arrest-deﬁcient 2’ (MAD2)
protein. Partial loss of function as well as over-expression
of MAD2L1 leads to the abrogation of MC, chromo-
some mis-segregation, aneuploidy, and failure to arrest
mitosis in the presence of microtubule poisons (Sotillo
et al., 2007). The unexpected ﬁnding of a tetraploid
karyotype of Ba/F3 cells on stable expression of E/R
prompted us to pursue this issue further. We have,
therefore, investigated the inﬂuence of E/R on MC and
especially on its major component MAD2L1.
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Results and discussion
To assess the function of E/R, we used Ba/F3, a murine
IL-3-dependent putative pro B-cell line, that is fre-
quently used as a model cell line to study the effects of
genes involved in the development of B-cell precursor
ALL. For this purpose, we have created stable E/R-
expressing Ba/F3 clones as reported earlier (Diakos
et al., 2007) and selected those with low expression of
the chimeric protein. After continuous culture for
approximately 2 months, all E/R-expressing clones
(n¼ 5) acquired a tetraploid karyotype, whereas cells
containing plasmids encoding either full-length ETV6, a
truncated form of ETV6 (ETV6-F, with dominant-
negative effect over ETV6 wt function) (Sasaki et al.,
2004), RUNX1, GFP, or an empty vector remained
diploid. This change in ploidy was conﬁrmed by DNA
content analysis and cytogenetics of several individual
clones (Figures 1a and b). To corroborate the speciﬁcity
of this effect, E/R-positive Ba/F3 clones and controls
were synchronized by a short exposure to low doses of
nocodazole and accumulated—unlike control cells—at
Figure 1 E/R expression induces a tetraploid karyotype in Ba/F3 cells. Representative histograms visualizing DNA content analysis
(PI) of two E/Rþ clones (#1 and #2) and empty vector (EV) control clones at early and late passages. (b) Box blot analysis depicting
chromosome numbers of E/R-expressing or EV Ba/F3 cells from cultures as in (a). Welch’s t-test, *Pp0,05. (c) DNA content analysis
of untreated (left part) and synchronized E/R and EV Ba/F3 clones on nocodazole treatment (right part). Cells were released from the
ﬁrst arrest (nocodazole 75 ng/ml for 14 h) for 3 days before they again were exposed to nocodazole. One of at least three independent
experiments is shown.
Figure 2 E/R attenuates the MC. Cell-cycle distribution of a mixture of three Ba/F3 clones that stably expressed E/R or contained an
empty vector (EV) by DNA content analysis. (a) Shown are representative histograms in the absence (left) and presence (right) of
nocodazole (333ng/ml for 48h). (b) Bar graphs indicate percentages of E/R-expressing and EV Ba/F3 cells with 2N and 8N after treatment
with nocodazole for 20 and 48h. The median and standard deviation (indicated at the top of each bar) are taken from ﬁve different
experiments. Welch’s t-test, *Pp0.05; **Pp0.01. (c) Mitotic index of stably E/R-expressing and EV Ba/F3 cells was determined by
phospho-histone H3 staining on MC activation by nocodazole for the indicated times. Experiments depict the average and standard errors
of the mean of three individual experiments. Welch’s t-test, *Pp0.05. (d) Cell-cycle distribution of Ba/F3 clones stably expressing E/R or
various control vectors (ETV6, truncated ETV6, RUNX1, GFP, or EV) by DNA content analysis with PI. Box blots depict the percentage
of cells in G0/G1 of E/Rþ clones and controls from 5 and 7 independent experiments, respectively. (e/f) Apoptosis rates were assessed
by PI staining in stably E/R-expressing and EV Ba/F3 cells. Percentages of PI-positive cells are depicted under optimal culture conditions
(e) and on nocodazole treatment for 24h relative to untreated cells (f). Welch’s t-test, P¼ 0.8.
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8N on a second exposure to the spindle toxin
(Figure 1c). These ﬁndings indicate that tetraploidiza-
tion is a speciﬁc effect of E/R-expressing Ba/F3 cells in
long-term cultures.
Hence, we used diploid E/R-expressing Ba/F3, and
several E/R-positive and E/R-negative leukemia cell
lines to investigate the inﬂuence of the chimeric E/R
protein on MC. Consistent with the notion that cells
with an attenuated MC are unable to fully arrest their
cell cycle in mitosis when treated with spindle poisons
(Kops et al., 2005), the proportion of E/R-positive cells
with a 2N and 8N DNA content was signiﬁcantly
increased under the inﬂuence of nocodazole as com-
pared with controls (Figures 2a and b; Supplementary
Figures 1a and b). The higher percentage of E/R-
positive cells with 8N implies that these cells did not
accurately segregate their chromosomes and/or termi-
nate cytokinesis. Determination of mitotic cells with the
phospho-histone H3 staining, which is tightly correlated
with chromosome condensation during mitosis, revealed
consistently lower mitotic indexes in nocodazole-treated
E/R-expressing Ba/F3 cell lines and leukemias, but not
in E/R-negative model and leukemia cell lines
(Figure 2c; Supplementary Figure 1c).
Given that the cell-cycle distribution assessed by
DNA content analysis of E/R-positive Ba/F3 cell lines
showed only a minor—statistically not signiﬁcant—G0/
1 increase compared with several controls (empty vector,
expression vectors for RUNX1, ETV6, ETV6-F, or
GFP) (Figure 2d), its deregulation is unlikely to be the
cause of the low mitotic index, especially as cells were
also measured after a long exposure to nocodazole.
These ﬁndings accord with the observed reduction of G1
phase cells by RUNX1 and its increase by CBF
oncoproteins (Lou et al., 2000; Strom et al., 2000; Ford
et al., 2009).
Of note and in line with a latent MC destabilization
(Kops et al., 2005), the spontaneous apoptosis rate of
both E/R-positive Ba/F3 as well as E/R-positive
leukemic cell lines were already slightly, but not
signiﬁcantly, higher than those of the respective parental
Ba/F3 and E/R-negative control cell lines under optimal
culture conditions (Figure 2e; Supplementary Figure
1d). We also excluded the possibility that nocodazole per
se might selectively increase the apoptotic rate of mitotic
E/R-positive cells by showing that the proportion of PI-
positive cells did not increase considerably over basic
levels (Figure 2f; Supplementary Figure 1e). The E/R-
dependent MC impairment was further conﬁrmed by the
reduced levels of the checkpoint-associated protein
securin, whose degradation at the start of anaphase
initiates sister chromatid separation (Pines, 2006), and
thus concords with the lower mitotic index (Supplemen-
tary Figure 1f). These ﬁndings strikingly resemble those
recently obtained in similar experiments using acute
myeloid leukemia samples and cell lines with a truncated
RUNX1/ETO, a fusion protein that is closely related to
E/R (Boyapati et al., 2007; Wolyniec et al., 2009).
Having shown the inﬂuence of E/R on MC function,
we set out to unravel its potential molecular mechanism.
For this purpose, we interrogated publicly available
Affymetrix data sets from childhood ALL (Ross et al.,
2003) for the expression of genes implicated in MC
function. MAD2L1 and BUB3 (budding uninhibited by
benzimidazole 3), two key players of MC, were
consistently repressed in E/R-positive leukemias com-
pared with all other ALL subgroups (Figure 3a). The
ﬁnding that the MAD2L1 promoter region contained
four perfect matches for RUNX binding (TGT/CGGT)
and 13 sites with 85% homology within 3 kb upstream
of the transcription start site makes it a likely candidate
Figure 3 E/R represses MAD2L1 expression. (a) Micro-array
analysis of MAD2L1 expression in various subgroups of childhood
ALL. Published data were analyzed for M-values (log2(FC)) of
probe sets from genes instrumental in MC function. Shown is the
MAD2L1 expression from E/R-positive leukemias relative to their
E/R-negative counterparts in each leukemic subgroup. Mean, the
mean of all leukemic groups; T-ALL, T-ALL; MLL, ALL with
MLL fusion genes; H50, high hyperdiploid ALL; E2APBX, TCF3/
PBX1 (E2A/PBX1) gene rearrangement positive ALL; BCRABL,
ALL with BCR/ABL fusion gene. (b) MAD2L1 mRNA was
quantiﬁed by TaqMan qRQ–PCR and the ABI Prism 7900
detection system (Applied Biosystems, Foster City, CA, USA) in
10 cases each of the after distinct childhood ALL subgroups:
E/Rþ , high hyperdiploid (HD) and T-cell precursor (T-ALL). The
ABL gene was used as a standard reference for normalization. Box
plots display the relative expression of MAD2L1 using STS 2.2
software. Shown are the median and interquartile range, 95% of
the values are within the range of a whisker. Median values were
used for statistical analysis; Welch’s t-test, *Pp0.05. (c) Western
blot analysis was performed from whole cell lysates of E/R-positive
(REH, AT-2) and E/R-negative leukemic cell lines (K562 and
Nalm-6). The MAD2L1 protein was detected with a speciﬁc anti-
MAD2L1 antibody (ab 3632, Abcam, Cambridge, UK). Anti-
GAPDH (6C5, Santa Cruz Biotechnology, CA, USA) was used as
loading control. Left: protein levels under standard culture
conditions and on nocodazole treatment (50 ng/ml nocodazole,
18 h). Right: box plots show the quantiﬁcation of MAD2L1 protein
in the respective groups from four independent experiments.
MAD2L1 protein was normalized to GAPDH expression using
the LICOR software (I.I., Integrated Intensity counts). Welch’s
t-test, *Pp0.05. (d) Western blot analysis (left) and quantiﬁcation
(right) of MAD2L1 in E/Rþ Ba/F3 clones and EV controls. One
of three independent experiments is shown. Welch’s t-test,
*Pp0.05.
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for a direct target of RUNX1 and also E/R. In contrast,
no perfect RUNX-binding site was present within 3 kb
of the promoter region of BUB3.
We, therefore, focused our further work on MAD2L1
and validated the expression of MAD2L1 by quantita-
tive RT–PCR in primary childhood ALL samples and
conﬁrmed a signiﬁcant difference between E/R-positive
and E/R-negative leukemias (Figure 3b). In accordance
with mRNA expression, protein expression of MAD2L1
was less abundant in E/R-positive leukemic and model
cell lines (Figures 3c and d). Conversely, MAD2L1
mRNA expression was up-regulated after E/R silencing
in AT-2 and REH leukemic cell lines, further emphasiz-
ing its regulation by E/R (our unpublished observation).
To test the possibility that MAD2L1 expression is
directly regulated, we determined its transcriptional
activity in the context of RUNX1 and E/R. Two
constructs that contained endogenous promoter se-
quences with one or three perfect RUNX1 consensus
sites were used for luciferase-based reporter assays
(Guardavaccaro et al., 2008). Both promoter constructs
revealed a dose-dependent activation on RUNX1
transfection and E/R-associated repression of RUNX1-
induced MAD2L1 activity in NIH3T3 cells (Figures 4a
and b). Similarly, forced expression of RUNX1 led to
induction of MAD2L1 promoter activation and coex-
pression of E/R to its abrogation in HEK293 cells (data
not shown). In contrast, transfection of NIH3T3 cells
with an expression vector with a point mutation in the
runt domain (E/RR201Q) that had been earlier shown to
diminish DNA binding, but not heterodimerization
with CBFb (Song et al., 1999; Li et al., 2003), resulted
in only partial reduction of RUNX1-induced activation
(Figure 4c). These data accord with earlier studies
Figure 4 Direct regulation of MAD2L1 by RUNX1 and abrogation of this effect by E/R. Luciferase assays were performed using a
1.2 kb MAD2L1 genomic reporter fragment containing three perfect RUNX1-binding sites (a–c). NIH3T3 cells were transfected
(JetPEI Polyplus transfections, Illkirch, France) with RUNX1, E/R, E/RR201Q, or a combination thereof. Cells were cotransfected with
CBFb (12.5 ng) to enhance RUNX1 binding and TK Renilla for transfection control. The total amount of DNA for each experiment
was kept constant. Values obtained from EV control samples were set to 100%. Luciferase activity is depicted using (a) increasing
amounts of RUNX1 pcDNA3.1-expression vector (100 and 500ng) or (b) E/R (200, 400, and 800 ng) in addition to RUNX1 (400 ng)
to show dose-dependent reporter activation by RUNX1 and its repression by E/R, respectively. Box plots of three representative
experiments are depicted. Welch’s t-test, *Pp0.05. (c) NIH3T3 cells were transfected using various combinations of 267 ng empty
vector (EV), E/R, or a DNA-binding mutant E/RR201Q, and/or 100 ng RUNX1-expression vector. One of three representative
experiments is depicted. Welch’s t-test, *Pp0.05. (d) RUNX1 and E/R occupation of MAD2L1 promoter region in vivo was assessed
by ChIP. Chromatin from Myc-tagged E/R, Myc-RUNX1, or Myc-tagged EV stably expressing HEK293 cells was
immunoprecipitated with anti-c-Myc (9E11, Abcam) or control antibody (anti-N cadherin, 610920, BD). Aliquots of the isolated
DNA fragments (without antibody (noAb), with control or speciﬁc Ab and input DNA) were subjected to PCR with speciﬁc primers
that amplify regions of the MAD2L1 promoter (Supplementary Methods) and analyzed by DNA gel electrophoresis. Speciﬁc primers
were used to amplify speciﬁc regions of p21WAF1 and PHOX promoters as positive and negative controls, respectively. The gel from one
of two independent experiments is shown. A vertical line has been inserted to indicate where the gel lane was cut. These gels came from
the same experiment. (e) Schematic diagram of the 1.2 kb of the promoter region of the MAD2L1 gene cloned into the pGL3. The three
perfect RUNX1-binding motifs (TGT/CGGT) are indicated by gray boxes. Arrows ﬂanking the two RUNX1 sites (#1 and #2) indicate
primer positions used for PCR ampliﬁcation of isolated DNA fragments after ChIP. Numbers refer to the size of the expected PCR
product. Graph is not to scale.
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and indicate that DNA binding is essential for E/R
activity and that E/R modulates RUNX1-induced
gene regulation (Hiebert et al., 1996; Friedman, 1999;
Morrow et al., 2007; Wotton et al., 2008; Roudaia
et al., 2009).
We then went on to show a direct in vivo interaction
between E/R and the MAD2L1 promoter by ChIP
analysis. Using Myc-RUNX1 or Myc-E/R stably
expressing HEK293 cells, we were able to prove that
both RUNX1 and E/R bind to the chromatin at two
consensus RUNX1 sites, which were also present in the
constructs used for the reporter assays (Figures 4d and e).
Collectively, these data suggest that direct suppression
of MAD2L1 by E/R binding speciﬁcally adds to the
destabilization of the MC (Perez de Castro et al., 2007).
However, as only a small subgroup of E/R-positive
leukemias acquires non-random-speciﬁc numerical chro-
mosomal abnormalities (Attarbaschi et al., 2004, 2006;
Raimondi et al., 2006), it seems unlikely that MAD2L1-
associated MC attenuation alone is responsible for this
phenomenon. Furthermore, it remains to be investigated
whether the E/R-induced deregulation of MAD2L1 or
any other MC components might also contribute in
other ways to leukemogenesis, such as perhaps p53
activation or deregulation of the DNA damage response
pathways (Michel et al., 2004; Kops et al., 2005; Fang
et al., 2006; Ha et al., 2007; Perez de Castro et al., 2007).
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Role of the Erythropoietin Receptor in ETV6/RUNX1-PositiveAcute
Lymphoblastic Leukemia
Andrea Inthal,1Gerd Krapf,1Dominik Beck,1RuthJoas,1MaxO. Kauer,1,3 Lukas Orel,1Gerhard Fuka,1
GeorgMann,2 and E. Renate Panzer-Gru« mayer1,2
Abstract Purpose:We explored themechanisms leading to the distinct overexpression of EPORaswell as
the effects of EPO signaling on ETV6/RUNX1-positive acute lymphoblastic leukemias.
Experimental Design: ETV6/RUNX1-expressing model cell lines and leukemic cells were used
for real-time PCR of EPOR expression. Proliferation, viability, and apoptosis were analyzed
on cells exposed to EPO, prednisone, or inhibitors of EPOR pathways by [3H]thymidine
incorporation, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide assay, andAnnexin
V/propidium iodide staining.Western blot analysis was done to detect activation of signaling
proteins. Serum EPO levels and sequences of the EPOR (n = 53) as well as hemoglobin levels
were taken from children with acute lymphoblastic leukemia enrolled in Austrian protocols.
Results:We show here that ectopic expression of ETV6/RUNX1 induced EPOR up-regulation.
Anemia, however, did not appear to influence EPOR expression on leukemic cells, although
children with ETV6/RUNX1-positive leukemias had a lower median hemoglobin than
controls. Exposure to EPO increased proliferation and survival of ETV6/RUNX1-positive
leukemias in vitro, whereas blocking its binding site did not alter cell survival. The latter was not
caused by activating mutations in the EPOR but might be triggered by constitutive activation of
phosphatidylinositol 3-kinase/Akt, themajor signalingpathway of EPORin these cells.Moreover,
prednisone-induced apoptosis was attenuated in the presence of EPO in this genetic subgroup.
Conclusions: Our data suggest that ETV6/RUNX1 leads to EPOR up-regulation and that
activation by EPOmight be of relevance to the biology of this leukemia subtype. Further studies
are, however, needed to assess the clinical implications of its apoptosis-modulating properties.
The t(12;21)(p13;q22) with its molecular counterpart, the
ETV6/RUNX1 (also known as TEL/AML1) fusion gene, is
present in f25% of childhood B-cell precursor (BCP) acute
lymphoblastic leukemia (ALL) and generally implies a good
prognosis (1, 2). Accumulating evidence suggests that the
fusion gene formation occurs already in utero based on its
presence at birth in the majority of children with ETV6/
RUNX1-positive ALL (3). The cell, however, in which the
fusion gene originates is not known, but it is presumably at a
progenitor stage preceding the transition from pro-B to pre-B
(4, 5). Based on studies in healthy newborns and animal
models, the fusion gene alone is not sufficient for the clinical
manifestation of the leukemia, which requires secondary
events (4, 6–10).
Gene expression profiling has been employed to characterize
the different genetic subgroups of leukemias (1, 11). By this
means, a relatively high expression of EPOR was found to
distinguish the ETV6/RUNX1-positive leukemias from the other
subgroups of ALL. It was therefore assumed that signaling by
EPOR might be important for the pathogenesis of this leukemia
subtype (11).
Expression of the EPOR and its activation by EPO has, for a
long time, been exclusively associated with the erythroid
lineage in which EPOR signaling is pivotal for differentiation,
proliferation, and survival of progenitor cells (12, 13). Over the
last years, it has become well established that the EPOR is also
expressed in many normal and malignant tissues, suggesting a
potential influence on cell survival (12, 13). This fact turned
out to be an important issue when recombinant human EPO
became available for clinical use to alleviate cancer-associated
anemia and its side effects. Consequently, many in vivo and
in vitro studies have been initiated to explore the effect of EPO
on its apoptosis-modulating function in tumor cells. These
efforts have led to contradictory results, potentially reflecting
distinct biological features and activated pathways of the
different malignancies (12, 13).
The signaling cascade triggered by EPO has been widely
studied in the erythroid lineage. On engagement of EPO with
its receptor, Janus kinase 2 is activated, which, in turn,
phosphorylates the EPOR. The ensuing signaling cascade
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includes the STAT5, mitogen-activated protein kinase, and
phosphatidylinositol 3-kinase (PI3K)/Akt pathways conferring
proliferative and antiapoptotic function (12, 13). At present,
there is only little information on the signaling pathways
affected by the EPOR in leukemia cells.
Herein, we provide first evidence that the EPOR is expressed
as a function of the ETV6/RUNX1 fusion protein. EPO
promotes proliferation of ETV6/RUNX1-positive leukemias
and interferes with prednisone-induced apoptosis in vitro .
The PI3K/Akt pathway appears to be involved in the observed
EPO-mediated survival advantage.
Materials andMethods
Leukemic cells and cell culture. REH, AT-1, and AT-2 (ETV6/RUNX1-
positive BCP leukemia cell lines), (AT-1 and AT-2 were kindly provided
by J.D. Rowley, University of Chicago), Nalm6 and SEM (both BCP
ALL), K562 (erythroid blast crisis of chronic myeloid leukemia), and
Jurkat (T-ALL) cells were cultured in RPMI 1640 with Glutamax (Life
Technologies/Invitrogen) supplemented with 10% heat-inactivated
FCS, 100 IU/mL penicillin, and 100 g/mL streptomycin (all PAA).
Mouse pro-B Ba/F3 cells were grown in RPMI 1640 containing 10%
FCS and 5% WEHI-3B conditioned medium as a source for interleukin-
3. Stably ETV6/RUNX1-expressing Ba/F3 clones and empty vector
controls were established as reported previously (14).
HEK 293 cells, transformed human embryonic kidney cells, were
grown in RPMI 1640 containing 10% FCS. ETV6/RUNX1 cDNA
was inserted into a pcDNA3.1-myc expression vector (Invitrogen).
Stably expressing ETV6/RUNX1 clones were obtained after single-cell
dilution and clonal expansion of transfected and G418 (900 Ag/mL)-
selected cells.
Primary leukemic cells were obtained from bone marrow aspirations
from children with ALL. Written informed consent was obtained from
the patients or their parents. The study was approved by the ethical
committees of the Children’s Cancer Research Institute and the St. Anna
Kinderspital. Cells were isolated by density-gradient centrifugation
before further processing. For positive selection, mononuclear cells
containing >95% of leukemic blasts were incubated with anti-CD10
FITC antibody (DakoCytomation) followed by incubation with anti-
FITC magnetic beads and magnetic field separation using MACS
separation columns (Miltenyi Biotec) according to the manufacturer’s
recommendation and cultured within 4 h after aspiration in IMDM
with 20% FCS, 100 IU/mL penicillin, and 100 g/mL streptomycin at
37jC in 5% CO2 in a humidified incubator.
For stimulation with growth factors and treatment with pathway
inhibitors, cells were washed in PBS and serum-deprived overnight in
RPMI 1640 containing 0.1% bovine serum albumin (Invitrogen). The
PI3K and Jak kinase inhibitors Ly294002 and AG490 (Calbiochem)
were used at 25 and 10 Amol/L concentrations, respectively. To assess
cell proliferation and viability, cells were plated in triplicates at a
density of 1  105 to 2  105 in flat-bottomed 96-well plates (Iwaki) in
100 AL RPMI 1640 without supplements and stimulated with different
concentrations of EPO (10-100 units/mL; Neorecormon; Roche). The
monoclonal anti-human EPOR antibody MAB307 (R&D Systems),
which binds to the extracellular part of the EPOR and was shown to
block specifically EPO-mediated effects, was used as a blocking
antibody at a concentration of 30 Ag/mL as reported previously (15).
Exposure to drugs was done as described above in the presence of 10%
FCS with the addition of prednisone (Solu-Dacortin; Merck) in LC50
concentrations (REH, 1 mg/mL; AT-1 and AT-2, 1 Ag/mL; Nalm6 and
SEM, 0.5 mg/mL; primary leukemia cells, 50 Ag/mL).
SDS-PAGE and Western blot analysis. Whole-cell lysates were
prepared with radioimmunoprecipitation assay buffer (50 mmol/L
Tris, 1% NP-40, 0.25% sodium deoxycholate, 150 mmol/L NaCl,
1 mmol/L EDTA) supplemented with 1 mmol/L NaVO4 and 1%
protease inhibitor cocktail (Roche) as described previously (14, 16).
For equal loading, the protein concentration of each sample was
determined by Bio-Rad protein assay kit. Proteins were resolved
by 8% SDS-PAGE and transferred to a polyvinylidene difluoride
membrane (Whatman). Nonspecific binding on the membranes was
blocked with PBS containing 5% dry milk. The membranes were
probed with antibodies specific for phospho-AKT, AKT (Cell Signaling
Technology), poly(ADP-ribose) polymerase (PARP; C210; Becton
Dickinson), and glyceraldehyde 3-phosphate dehydrogenase
(6C5; Santa Cruz Biotechnology) or tubulin (DM1A; Calbiochem)
in 1% dry milk in PBS at 4jC overnight. Using infrared dye-labeled
secondary antibodies (LI-COR Biosciences), the membranes were
directly scanned with Odyssey Infrared Imaging System (LI-COR
Biosciences). Bands were quantified using LI-COR Odyssey Software.
Proliferation, viability, and apoptosis assays. Cells were cultured as
described above with different agents for 48 h. [3H]thymidine (1 ACi/
well; Hanke Laboratory Products) was added for 24 h. Cells were
harvested onto filters and counted in a scintillation counter.
In 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
assays, a 5 mg/mL stock solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (20 AL; Sigma) were added according to
the times indicated. After 3 to 5 h, 100 AL stop solution [10% SDS and
50% formamide (pH 4.7) with acetic acid] was added to dissolve
formazan crystals. The absorbance was read at 562 nm in a microplate
reader. To assess survival of cells, the mean value of cells cultured
with the respective agent was divided by themean value of control cells
100%.
The presence of early and late apoptotic cells was determined by flow
cytometry (FACSCalibur; BD Biosciences) with anti-Annexin V FITC-
labeled antibody (BD Pharmingen) and propidium iodide. Cells were
washed in 10 mmol/L HEPES (pH 7.4), 140 mmol/L NaCl, and 2.5
mmol/L CaCl2. Antibody and propidium iodide were added and
incubated for 15 min in the dark before analysis. All experiments were
done in triplicates and reproduced at least three times in independent
experiments.
Translational Relevance
The data presented here suggest that the EPOR is over-
expressed as a function of ETV6/RUNX1 in BCPALLwith a
chromosomal translocation t(12;21). EPOR signaling
promotes survival and evasion from prednisone-induced
apoptosis in ETV6/RUNX1-positive leukemias in vitro.
Recent developments in the treatment of cancer-related
anemia by recombinant erythropoietin and its consequen-
ces have raised concerns about the safety and potential
adverse effects of the drug, such as the promotionof tumor
growth. The data provided here suggest that although
signaling via EPOR is not pivotal for the overt leukemia, as
exemplified in cell lines and a limited number of primary
leukemic cells, it may enhance proliferation and survival
of ETV6/RUNX1-positive leukemic cells. Moreover, EPO
mitigated the apoptosis rate induced by prednisone, an
essential drug in virtually all treatment protocols forALL, in
ETV6/RUNX1-positive leukemias in vitro. Of note, the
concentrations of EPO used in our experiments exceed
those reached under physiologic conditions. Such consid-
erations may, however, not be relevant in situations when
erythropoiesis-stimulating agents are applied to the
patients given the chance that EPO levels might differ
considerably from normal. EPO analyses in patients receiv-
ing erythropoiesis-stimulating agents are currently still
missing.
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Sequencing of the EPOR gene. Genomic DNA was isolated with
QIAamp DNA Blood Mini Kit (Qiagen). Specific primers for exons 2 to
4 and 6 to 8, located at the respective flanking intronic sequences, were
used for amplification.
The nucleotide sequence of the EPOR was determined by sequencing
analysis (VBC Genomics) and compared with public database
sequences.4
EPO serum levels and EPOR mRNA quantification. The EPO serum
levels were determined by an automated chemiluminescent immuno-
assay (DPC Immulite; ref. 17).
Random hexamer priming and SuperScript II (Invitrogen) were used
to generate cDNA. Quantification of EPOR mRNA abundance
in primary leukemias was done as reported previously (11). h2-
Microglobulin was used for endogenous control gene amplification.
The quantitative PCRs were done in a total volume of 25 AL containing
12.5 AL TaqMan Universal PCR Master Mix (Applied Biosystems),
200 nmol/L forward and reverse primers each, and 100 nmol/L Taqman
probe. The reactions were carried out on an ABI Prism 7700 Sequence
Detection System (Applied Biosystems).
For amplification of EPOR mRNA expression in cell lines, SYBR
Green PCR was done. Primers and conditions were the same as for
TaqMan PCR. For murine cell lines, the following EPOR and HPRT (for
control amplification) primers were used: EPOR forward 5¶-GCC-
CCCTCTGTCTCCTACT-3¶, EPOR reverse 5¶-TCCCAGAAACACACCAA-
GTCTT-3¶, HPRT forward 5¶-GGGGGCTATAAGTTCTTTGC-3¶, and HPRT
reverse 5¶-TCCAACACTTCGAGAGGTCC-3¶.
Blood counts including measurement of hemoglobin (Hb) from
patients was analyzed by Advia 120 Hematology System (Bayer).
Statistical analysis. Differences of Hb levels in various leukemia
subgroups were assessed by the Wilcoxon two-sample test. The Welch t
test was used to analyze the increase in EPOR mRNA expression in cells
stably transfected with ETV6/RUNX1, proliferation assays, and cell
viability assays. Probability values (P < 0.05) were considered
statistically significant.
Results
ETV6/RUNX1 induces up-regulation of EPOR mRNA expres-
sion. Based on the high expression of the EPOR in ETV6/
Fig. 1. EPOR expression in ectopic ETV6/RUNX1 transfectants and leukemic cell
lines. Quantification of EPOR mRNA expression by real-time quantitative PCR.
A, EPOR expression in ectopically ETV6/RUNX1 (E/R)-expressing HEK 293 and
Ba/F3 cells. B, EPOR expression in ETV6/RUNX1-positive (REH, AT-1, and AT-2)
and ETV6/RUNX1-negative (SEM, Nalm6, Jurkat, and K562) leukemic cell lines.
EPOR mRNA levels were determined at least in triplicates and normalized to either
HPRT in Ba/F3 cells or h2-microglobulin expression in the remaining cell lines.The
n-fold expression was calculated from ETV6/RUNX1-expressing cells relative to
control vector-containing cells in A or toJurkat cells in B. Bars, SD. *, P < 0.01.
Fig. 2. LowHb levels inversely correlate with serum EPO levels but not with EPOR
mRNA expression in ETV6/RUNX1-positive leukemias. A, Hb levels from patients
with various subtypes of BCP leukemia.The box shows the median and the
interquartile range (25-75th percentiles). Ninety-five percent of the values arewithin
the range of a whisker and the circles indicate the minimum and maximum values in
each group. *, P < 0.001 (Wilcoxon two-sample test). B, correlation between EPO
and Hb levels in patients with ETV6/RUNX1-positive leukemia. C, comparison
of individual patients’Hb level, as a surrogate parameter of EPO, with relative
expression levels of EPOR, normalized to h2-microglobulin (b2MG) and shown on
a log2 scale, in matched leukemic cells.
4 Sanger Vega Gene ID : ht tp ://vega.sanger.ac.uk/index.html and
ENSG00000187266.
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RUNX1-positive leukemias, we assessed whether EPOR is up-
regulated as a result of the fusion gene expression. Stably ETV6/
RUNX1-expressing clones of human embryonic kidney HEK
293 cells and murine pro-B Ba/F3 cells showed a 2- to 3.5-fold
difference in mRNA expression compared with empty vector
controls (Fig. 1A).
Next, we determined the expression levels of EPOR in our
model cell lines. In line with data by Fine et al. (11),
quantification of mRNA revealed that the EPOR is highly
expressed in all ETV6/RUNX1-positive BCP ALL cell lines but
barely detectable in the ETV6/RUNX1-negative BCP and T-ALL
cell lines (Fig. 1B). Jurkat was used for normalization and K562
was used as a positive control for EPOR overexpression. We
further evaluated whether these transcriptional differences
between ETV6/RUNX1-positive and ETV6/RUNX1-negative
leukemias would also be detectable at the protein level. Because
lack of specificity of several EPOR antibodies cautions its usage
for Western blotting (18, 19), the directly labeled EPOR
antibody (MAB307-PE), which competes with EPO for the
binding to its receptor (20), was used for surface protein
detection by flow cytometry. There was, however, no clear
difference between ETV6/RUNX1-positive and ETV6/RUNX1-
negative leukemias (data not shown) possibly due to generally
low abundance of EPOR expression on the cell surface (19).
Low Hb is associated with the ETV6/RUNX1 genetic subtype of
ALL. We also considered the possibility that, in ETV6/RUNX1-
positive leukemias, EPOR expression is, to some extent, further
influenced by other factors known to up-regulate the receptor
(21), as, for example, hypoxemia, the fundamental physiologic
stimulus that causes a rapid increase in renal production of
EPO (22). It was thus assessed whether children with ETV6/
RUNX1-positive ALL have lower Hb levels than those with
other subgroups of BCP ALL. For this purpose, 476 patients
with BCP ALL, who were consecutively registered in the
Austrian BFM 95 and 2000 studies (23, 24), were included.
BCP leukemias were grouped in ETV6/RUNX1-positive cases,
leukemias with a high hyperdiploid chromosome number
(subsequently designated as hyperdiploid leukemias), and
‘‘others’’ (n = 150, 137, and 189, respectively). The latter are
characterized by the lack of the previous group characteristics.
As shown in Fig. 2A, the median Hb level of children with
ETV6/RUNX1-positive ALL is significantly lower (P < 0.001)
Fig. 3. EPO promotes proliferation and
survival of ETV6/RUNX1-positive leukemia
cells. Cell proliferation was determined by
[3H]thymidine incorporation in REH (A)
and Nalm6 (B) cells cultured in the
presence of increasing concentrations of
EPO and in REH cells grownwith EPO
and anti-EPOR antibody (C). One
representative example of at least three
independent experiments is shown.
(The difference in counts between A and C
results from different cell numbers used for
these experiments). D, differences in the
metabolic status of cells used to assess
cell viability (%) was determined in
ETV6/RUNX1-positive (E/R+) and
ETV6/RUNX1-negative (E/R-) primary
leukemias by 3-(4,5-dimethylthiazol-2-yl)
-2,5-diphenyltetrazolium bromide assay
after exposure to EPO (50 units/mL) for
72 h. Leukemic cells were isolated and
cultured within 4 h after bone marrow
aspiration. *, P < 0.05; **, P < 0.01.
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compared with those with hyperdiploid and ‘‘other’’ leukemias,
whereas the difference between the latter two groups is not
significant (P = 0.77). Next, we confirmed that for this
particular genetic subgroup of leukemias, Hb and EPO are
inversely correlated (Fig. 2B), indicating that EPO production is
adequate for the Hb level, a finding that has been reported
previously for genetically undefined cases of childhood ALL
(25). This allowed us to use Hb levels as a readily available
correlate for the amount of EPO in the serum. Hence, to
evaluate an influence of EPO on its receptor expression,
patients were selected according to their Hb level to fit into
one of the three arbitrarily chosen groups (Hb levels 3-5, >5 to
8, and >8 to 15 g/dL). This approach should enable the analysis
of a wide range of physiologic EPO concentrations in the serum
(0.01-10 units/mL). As illustrated in Fig. 2C, the amount of
EPOR mRNA did not change as a function of Hb, supporting
our view that EPO does not play a major role in EPOR mRNA
up-regulation in ETV6/RUNX1-positive leukemia.
Lack of activating mutations of the EPOR in ETV6/RUNX1-
positive leukemias. Based on the observation that overex-
pressed receptor kinase genes (e.g., FLT3, C-KIT , and NOTCH1)
are frequently constitutively activated by mutations in acute
Fig. 4. EPO attenuates prednisone-induced apoptosis in ETV6/RUNX1-positive leukemias. A, apoptosis rates were determined byAnnexinV/propidium iodide staining in
REH cells cultured for 48 and 72 h in the presence of prednisone (Pred ; 1mg/mL) and EPO (50 units/mL).The percentage of viable, AnnexinV-positive/propidium
iodide-positive cells is depicted.MeanF SDof four experiments. Evasion fromprednisone-induced apoptosis by EPOin AT-1and AT-2 cell lines (B), Nalm6 and SEM (C), and
ETV6/RUNX1-positive and ETV6/RUNX1-negative primary leukemias (D and E). Cells were exposed to prednisone (50 Amol/L) in the presence and absence of EPO
(50 units/mL) and viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay after 72 h.The increase in cell viability by EPO is
indicated in percentage. MeanF SD from triplicates (in cell lines, one of three independent experiments, in primary leukemic cells from one experiment). *, P < 0.05;
**, P < 0.01.
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leukemia (26–28) and that activating mutations of the EPOR
are present in polycythemia vera (29), we evaluated whether
such mutations would also occur in ETV6/RUNX1-positive ALL.
Exons 2, 3, and 6 to 8 of the EPOR were chosen for sequencing
based on their functional importance and the presence of
previously identified mutations in these regions (29, 30). As no
genomic variations in the EPOR sequence were, at least in the
dominant clone of the leukemic population, detected in ETV6/
RUNX1 -positive leukemias (primary leukemias, n = 53;
leukemic cell lines, n = 3), we assume that activating mutations
are rarely present in these leukemias, if they occur at all.
EPO enhances proliferation of ETV6/RUNX1-positive leuke-
mias and attenuates the sensitivity to prednisone-induced
apoptosis in vitro. After that, we evaluated whether the
overexpression of EPOR provides a proliferative or survival
advantage to ETV6/RUNX1 -positive leukemias. REH was
compared with Nalm6, an ETV6/RUNX1-negative BCP leuke-
mia cell line. Cells were cultured under reduced serum
conditions in the presence of different doses of EPO for 72 h.
REH cells exhibited a dose-dependent increase in proliferation
on addition of EPO (Fig. 3A), whereas Nalm6 did not (Fig. 3B).
Specificity of these effects was confirmed by an anti-EPOR
blocking antibody, which abrogates EPO-induced effects, as
shown in Fig. 3C. Enhanced viability by EPO was also observed
in two ETV6/RUNX1-positive primary leukemias but in none of
the three ETV6/RUNX1-negative cases (Fig. 3D). Collectively,
these data suggest that the EPOR conveys a survival advantage
in ETV6/RUNX1-expressing leukemic cells.
It has been reported previously that EPO may modulate the
response of malignant cells to drugs (12, 13). We therefore
explored the effects of EPO on drug-induced apoptosis in REH
cells as a model system. Different drugs (prednisone, vincristine,
Fig. 5. EPO reduces PARP cleavage in ETV6/RUNX1-positive leukemias exposed to prednisone. PARP cleavage was determined byWestern blot analysis in AT-2, REH,
Nalm6, and SEM cells after exposure to prednisone and EPO for the indicated times. Glyceraldehyde 3-phosphate dehydrogenase was used as loading control. PARP
cleavage was normalized to glyceraldehyde 3-phosphate dehydrogenase and values are shown as n-fold expression at the bottom of the graph.
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daunorubicine, methotrexate, and etoposide), which are cur-
rently used in treatment protocols for children with ALL, were
tested at published LC50 concentrations (ref. 31; data not
shown). EPO (50 units/mL) reduced only prednisone-induced
apoptosis by 10% to 16% (Fig. 4A). This effect was Jak
dependent, because AG490, a Jak kinase inhibitor, completely
abolished the effects of EPO by blocking the direct downstream
signaling proteins of EPOR (data not shown). A survival
advantage by EPO was also reproduced in two other ETV6/
RUNX1-positive leukemic cell lines, AT-1 and AT-2, by 12% to
14% (Fig. 4B). AT cell lines are, similar to the majority of ETV6/
RUNX1-positive primary leukemias (32) but unlike REH cells,
sensitive to glucocorticoids. In the ETV6/RUNX1-negative BCP
cell lines Nalm6 and SEM, EPO had no effects on prednisone-
induced apoptosis (Fig. 4C). The alleviation of glucocorticoid-
induced apoptosis by EPO was also confirmed in primary ETV6/
RUNX1-positive leukemias. To exclude a possible effect of
normal EPO-responsive erythroid progenitor cells, which might
be present in density-gradient separated mononuclear cells,
highly purified (CD10+) primary leukemic blast cells were
prepared for these experiments. One of the two ETV6/RUNX1-
positive leukemias (patient ID 704) was responsive to gluco-
corticoid concentrations used for in vitro experiments and
displayed a reduced prednisone-induced apoptosis in the
presence of EPO (Fig. 4D), whereas the other (patient ID 685)
did not respond at all. There was no EPO-mediated influence on
ETV6/RUNX1 -negative leukemias (n = 3) detectable
(Fig. 4E). Of note, all leukemias used for these experiments
had a good prednisone response in vivo . It is therefore
concluded that EPOR signaling may lead to an increased
survival of ETV6/RUNX1-positive leukemia cells when exposed
to prednisone in vitro.
For glucocorticoid-induced apoptosis, the engagement of
caspases that cleave substrates at aspartate residues is required
(33). We consequently tested whether the EPO-mediated rescue
from glucocorticoid-induced apoptosis can be visualized by
cleavage of caspase-3 or its downstream target PARP. As shown
in Fig. 5, PARP cleavage was reduced by 30% to 50% in AT-2
and REH cells, but not in Nalm6 and SEM cell lines, when EPO
was added to the culture medium. We did, however, not detect
caspase-3 activation (data not shown), which suggests that
probably another effector caspase mediated apoptosis in these
cells, as has been reported recently (33).
EPO signals via the PI3K/Akt pathway in ETV6/RUNX1-
positive cell lines. In a next step, we set out to identify the
pathways that are involved in the EPOR-mediated survival
advantage. Despite the fact that extracellular signal-regulated
kinase 1/2 and STAT5 are commonly activated in erythroid
progenitor cells on stimulation with EPO but also in many
other cells (13), neither of the two pathways was activated in
REH cells (data not shown). Further, PI3K and nuclear factor-
nB signaling, implicated in glucocorticoid-mediated apoptosis
(33), were evaluated. On addition of EPO, the PI3K pathway
was activated in all three ETV6/RUNX1-positive cell lines
(Fig. 6), whereas a strong EPO-independent phosphorylation
of the p65 nuclear factor-nB subunit, a prerequisite for the
activation of the pathway, indicates that the nuclear factor-nB
pathway was constitutively activated (data not shown). These
results imply that activation of the PI3K/Akt pathway is most
likely involved in the proliferative and antiapoptotic effects
exerted by EPO.
Discussion
The overexpression of EPOR in ETV6/RUNX1 -positive
leukemias has become a well-recognized aspect of this
leukemia subtype since its description by Fine et al. (11). The
underlying mechanisms, however, as well as the biological
consequences for pathogenesis and implications for the
clinic have not been investigated thus far. In this study, we
provide first evidence that EPOR expression is up-regulated by
ETV6/RUNX1 . On engagement with EPO, signaling by the
receptor exerts a proliferative stimulus and evasion from
glucocorticoid-induced apoptosis in ETV6/RUNX1-positive
leukemias. Low Hb levels of children at the time of diagnosis
emerged as a new clinical feature for ETV6/RUNX1-positive
leukemia. It did not result from lack of EPO production, which
was appropriate for the degree of anemia. High EPO levels,
however, did not translate into higher EPOR mRNA expression
in leukemic cells.
The data presented here strongly suggest a fusion gene-
dependent up-regulation of EPOR expression in model systems.
Although a RUNX1 consensus binding site (TCTGGT) was
found 300 bp upstream of the EPOR promoter region, we
rather assume that EPOR up-regulation is an indirect effect of
the fusion protein based on its proposed repressor function on
RUNX1 target genes (34). Support for the EPOR overexpression
as a result of ETV6/RUNX1 in leukemias also results from
siRNA-mediated silencing of the fusion gene in REH cells,
which leads to down-regulation of the receptor.5 Such aFig. 6. EPO triggers signaling via PI3K/Akt pathway in ETV6/RUNX1-positive
leukemic cell lines. AT-1, AT-2, and REH cells were stimulatedwith 50 units/mLEPO
or a cytokine mix (Cyt.mix) for15 min.The PI3K inhibitor Ly294002 was used to
show specificity of signaling.Whole-cell extracts were analyzed byWestern blotting
and assessed for phosphorylation of AKT by a phospho-AKTantibody.Total AKT
was used as loading control. A vertical line has been inserted to indicate where the
membrane was cut.These membranes came from the same experiment. 5 C. Diakos and E.R. Panzer-Gru« mayer, unpublished data.
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scenario would be consistent with the distinct overexpression of
this receptor in the ETV6/RUNX1-positive subgroup of leuke-
mias, although it does not preclude other mechanisms being
operative as well.
We therefore considered the possibility that the cell in
which the ETV6/RUNX1 fusion gene occurs first might be a
progenitor cell with erythroid potential. Based on the
proposed existence of a lymphoid-primed multipotent
progenitor, which retains the potential for erythroid gene
expression (35), the overexpression of GATA2 and the
transferrin receptor together with EPOR in ETV6/RUNX1-
expressing leukemias would be compatible with such a
model.6 GATA2 is also highly expressed at the stem and
progenitor cell stage (36) and might thus, alternatively,
reflect the activation of a stem cell self-renewal program.
The issue of an erythroid component in ETV6/RUNX1-
positive leukemias has been addressed already before by
Andersson et al. comparing leukemia signatures with those
of normal hematopoietic cells (37). These authors did,
however, not detect overlapping gene expression with the
erythroid lineage. A possible explanation for missing the
erythroid lineage-associated genes that have emerged from
our analysis may lie in the selection of the top 200
differentially regulated genes from the ETV6/RUNX1-positive
leukemias for their analysis.
The finding of a significantly lower median Hb level in
children with an ETV6/RUNX1-positive leukemia compared
with other BCP ALL in this study is of particular interest for
two reasons. First, it may mean that the erythroid lineage is
affected by the fusion gene, as is the case for the structurally
and functionally related fusion gene, RUNX1/RUNX1T1 (also
known as AML1/ETO), resulting from the t(8;21) in acute
myeloid leukemias (38). In these leukemias, RUNX1/
RUNX1T1 leads to a differentiation arrest not only of
the myeloid lineage but also of erythroid precursor cells,
suggesting the transformation of a multipotent myeloid
progenitor cell. These fusion gene-dependent changes are
clinically apparent both in the fully leukemic and the
myelodysplastic stage in patients as well as in mouse models
(38). In contrast, similar alterations of normal hematopoiesis
may not be detectable in children with ETV6/RUNX1-positive
ALL because normal hematopoiesis is virtually completely
replaced by leukemic cells at the time of diagnosis. In mouse
and zebra fish models for ETV6/RUNX1-positive leukemia,
however, no evidence for a similar phenomenon has been
described (8–10, 39), implying that, even if in humans the
ETV6/RUNX1 fusion originated in a stem cell, differentiation
of the erythroid lineage may not be impaired. Second, a low
Hb in children with ETV6/RUNX1-positive leukemia might
also influence EPOR expression in leukemic cells, in keeping
with the up-regulation of the EPOR by its hormone (21).
As shown here, an increased serum EPO in children with low
Hb did not result in a higher EPOR expression in leukemic
cells compared with patients with normal Hb levels. These
data exclude a major effect of the actual EPO levels on the
expression of its receptor in these leukemias.
We further evaluated the influence of EPO on the fully
leukemic cells. Although EPO led to a dose-dependent
proliferation, cell growth and survival were not altered when
the EPO-binding site of the receptor was specifically blocked.
Constitutive activation of EPOR and its downstream kinase,
Jak2, seems an unlikely cause for abrogating these effects
because we and others did not detect mutations of these two
genes in ETV6/RUNX1-positive leukemias (40, 41). Instead,
the PI3K/Akt pathway is constitutively activated in these
leukemias, which could explain the lack of downstream effects
on EPOR blockage (37, 42). If the compensation for receptor
signaling by a downstream molecule was also a potential
scenario in vivo, the overexpression of EPOR may provide a
survival advantage during leukemia development before the
occurrence of this modification.
Recent developments in the treatment of cancer-related
anemia by recombinant erythropoietin and its consequences
have raised concerns about the safety and potential adverse
effects of the drug, such as the promotion of tumor growth
(12, 13). The data provided here suggest that, although
signaling via EPOR is not pivotal for the overt leukemia, as
exemplified in cell lines and a limited number of primary
leukemic cells, it may enhance proliferation and survival of
ETV6/RUNX1-positive leukemic cells. Of particular interest,
EPO mitigated the apoptosis rate induced by prednisone, an
essential drug in virtually all treatment protocols for
ALL (33), in ETV6/RUNX1-positive leukemias in vitro .
Importantly, this effect was not restricted to glucocorticoid-
resistant REH cells but was also reproduced in glucocorti-
coid-sensitive cell lines and leukemias. A potential limitation
of our findings lies in the concentrations of EPO used in
our experiments, which exceeds values reached under
physiologic conditions (43). These concerns may not be
relevant in situations when erythropoiesis-stimulating agents
are applied to the patients given the chance that EPO levels
might differ considerably from normal. Such analyses are
currently still missing.
Collectively, our data suggest that the EPOR is overex-
pressed as a function of ETV6/RUNX1 . It promotes survival
and evasion from prednisone-induced apoptosis in ETV6/
RUNX1-positive leukemias in vitro . Although we are tempted
to speculate that EPOR signaling may provide an evolutional
advantage during leukemia development, it is too early to
judge whether our findings are of clinical relevance. In
particular, we do not know whether EPO levels that may be
reached during treatment with erythropoiesis-stimulating
drugs would support the survival of the fully malignant clone
or the sustained growth of preleukemic cells.
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